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Emphysema is a complex inflammatory condition of the respiratory tract with an 
incompletely elucidated pathogenesis. Due to the complexity of the disease, treatment 
options are limited for patients and have poor efficacy. Therefore a greater understanding 
of disease pathogenesis is imperative to expand therapeutic strategies. Central to disease 
development is the activation of the innate and adaptive immune system, however, 
targeting blockade of only one side of the immune response, has shown little clinical 
benefit. The complement system, while regarded as an innate immune mechanism, can 
modulate both innate and adaptive immune responses. Given these dual modulatory 
effects, the complement system may be an ideal target for the management of 
emphysema. Complement activation has been reported in emphysema patients, 
demonstrated by increased plasma C3 concentrations, increased BAL complement 
cleavage fragments, and complement deposition within the emphysematous lungs. 
Therefore we hypothesize that by targeting the complement cascade we can modulate 
innate and adaptive immunity, and subsequently rescue lungs from the chronic 
inflammatory response that persists in emphysema. 
 
We demonstrate that deficiency in key complement components, C3, C5 and fB, provides 
protection from emphysema development. To test the therapeutic significance of these 
findings, we designed, established and characterized a novel rodent model of smoking 
	  
iv	  
cessation, and demonstrate that post smoking cessation modulation of the complement 
system, with CR2-fH or anti-C5 mAb, significantly reduced inflammation, lung  
 
destruction, and improved lung function. Together our multiple mouse models 
demonstrate that blocking complement protects against lung injury, inflammation, and    
T cell activation. Further we demonstrate reduced B cell infiltration and circulating 
autoantibody levels in our complement deficient active smoking models, but that 
autoantibody levels were unaltered in smoking cessation therapeutic studies. Whether 
these antibodies are biomarkers of disease or pathogenically contribute to disease 
development has yet to be elucidated. Using an elastin immunization model we show that 
increased anti-elastin autoantibodies are associated with exacerbated emphysema disease, 
thus demonstrating that these antibodies have pathogenic significance.  
 
In conclusion, these studies delineate a role for the complement system in the 
development, and persistence of emphysema, and further highlight the potential clinical 
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1.1 THE COMPLEMENT SYSTEM 
1.1.1 Overview 
The complement system is an essential component of the innate immune response, 
defending the host from invading pathogens (4, 5). There is growing evidence that the 
complement system plays diverse roles in not only the innate immune response, but also 
further steers, drives and activates both humoral and cellular adaptive immune responses 
(6-9). Once activated, complement cleavage fragments orchestrate the inflammatory 
response through interaction with both the innate and adaptive arms of the immune 
system, recruiting and activating immune cells, in addition to complement-mediated 
target cell lysis (10-12). Although the liver predominantly produces complement proteins, 
extra-hepatic sites generate their own complement repertoire, especially during 
inflammation in the local microenvironment or disease conditions (6, 7, 13, 14). Along 
with pro-inflammatory effector functions, the complement system also takes part in tissue 
homeostasis and regenerative mechanisms, further emphasizing the complexity and 
importance of this innate immune effector arm. 
 
Given the diverse and complex functions of complement proteins in an inflammatory 
setting, understanding how the complement cascade is involved in specific inflammatory 
conditions is critical to better define the complement-dependent mechanisms of disease 
promotion or protection. Clinical studies show complement is central to several diseases, 
including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic 
syndrome (aHUS) and hereditary angioedema (HAE), and further that specific targeting  
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of the complement system can be therapeutically beneficial for patients PNH (15-21). 
Currently there is limited literature addressing a role for the complement system in 
COPD, yet there are many parallels between the proposed hypotheses of its pathogenesis, 
and several key complement effector functions.  
 
1.1.2 Complement Activation and Effector Functions 
The complement system was classically known for its assisting role in antibody-mediated 
immunity, by “complementing” immunoglobulin for antigen recognition (4, 5). Today 
the complement cascade is known to have several roles in both the innate and adaptive 
immune response. The complement system is activated through one of three pathways, 
the classical, lectin and alternative (19, 20, 22, 23). Recognition proteins of each of these 
pathways serve to identify dangerous patterns in the host and help orchestrate an 
inflammatory response. The classical pathway is activated following association of its 
recognition protein C1q with immune complex (IC) formations. C1q binds to the Fc 
portion of the IC leading to a conformational change and proteolytic activity of C1r and 
C1s, cleaving C4 into C4a and C4b (24). After C4 cleavage, C2 is cleaved into C2a and 
C2b, resulting in the formation of the classical pathway C3 convertase (C4b2a) on the 
target cell surface (25). Formation of this enzymatic complex permits cleavage of the 
central complement component C3, as well as amplification of the complement system 






Figure 1-1: The Complement Cascade. As part of our innate immune response the complement 
system plays a role in several pro-inflammatory effector functions. Activation by one of the three 
activation pathways, complement proteins will recruit and activate cells of the innate and adaptive 
immune response to assist in amplification of the inflammatory response. 
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Similar to the classical pathway, the lectin pathway is activated by its recognition protein 
mannose-binding lectin (MBL) association with dangerous carbohydrate motifs on the 
foreign cell surface. Following MBL recognition, the lectin pathway proteases, MASP-1 
and MASP-2, similar to C1r and C1s, cleave C4 and then C2 into their a and b fragments 
to generate the classical C3 convertase via the lectin pathway (26).  
 
The third activation pathway, the alternative pathway, is activated through a spontaneous 
mechanism. C3 continuously undergoes cleavage, into C3a and C3b, and inactivation 
through binding of water molecules (C3bH2O). The continuous cleavage, referred to as a 
“tick-over” mechanism, allows for a constant alert state of the alternative pathway protein 
(27). If a sufficient amount of C3 is cleaved, C3b will initiate the alternative pathway 
convertase. The alternative pathway convertase (C3bBb) will be formed following factor 
B cleavage, into fragments Ba and Bb, by factor D. The alternative C3 convertase is 
further stabilized by the complement protein properdin (P), the only positive regulator of 
complement activation (10). The alternative pathway can also serve as an amplification 
loop, as all three activation pathways converge at C3 cleavage.   
 
Two potent effector proteins generated as a result of complement activation are the 
anaphylatoxins C3a and C5a. Once release from their parent proteins the anaphylatoxins 
can associate with their receptors, C3a receptor (C3aR) and C5a receptor (C5aR or 
C5aR2 (previously referred to as C5L2)), on both myeloid and non-myeloid derived 
cells(12, 28-32). Signaling through both C3aR and C5aR will lead to the activation of 
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immune cells, release of pro-inflammatory cytokines and amplification of the 
inflammatory response (33). Regardless of which activation pathway, continued C3 
convertase formation and subsequent deposition of C3b on the target cell surface 
generates a second enzymatic complex, the C5 convertase (classical and lectin C4b2a3b 
or alternative C3bBb3b). The C5 convertase cleaves complement protein C5 into its 
fragments C5a and C5b. Deposition of C5b on the target cell surface initiates the terminal 
complement pathway and formation of the membrane attack complement (MAC). MAC 
begins with the association of C6 with C5b, which then draws a sequential deposition of 
complement proteins C7, C8 and C9 on the cell surface. Once a sufficient number of C9 
molecules deposit on the target cell it creates a membrane pore and allows direct 
complement mediated lysis of the cell (34-36). Given the robust and potent complement 
activation and effector mechanisms, the host has developed tight regulation of the 
complement system to limit unnecessary activation and protect healthy tissue from non-
specific damage.  
 
1.1.3 Regulation of the Complement Cascade 
Host cells express soluble and membrane-bound complement regulatory proteins to 
protect self-tissue from untargeted complement attack. Soluble regulatory proteins for the 
classical and lectin pathways consist of C1 inhibitor (C1-INH), which inhibits C1s/C1r 
and MASPs protease activity, and also C4 binding protein (C4-BP), which prevents 
cleavage of the C4 component. Together these two soluble inhibitory proteins prevent 
classical/lectin C3 convertase formation (37-39). The alternative pathway has a specific 
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inhibitor, the soluble protein factor H (fH) (40-43). Factor H destabilizes the C3 
convertase and promotes degradation through the protease factor I, thereby preventing 
downstream complement activation and further complement cascade amplification (38, 
40-45).  
 
In addition to the soluble protein inhibitors, complement regulation is achieved with 
membrane bound proteins. Membrane cofactor protein (MCP/CD46) and decay 
accelerating factor (DAF/CD55) prevent assembly of the C3 convertase, thereby blocking 
all complement activation pathways (46). A mouse analog to MCP and DAF is 
complement regulatory proteins Crry (47). Membrane attack complex assembly is 
blocked/impaired by CD59. CD59 binds to C8 and/or C9 to inhibit membrane pore 
formation, thus protecting against cell lysis. Other terminal pathway inhibitors include, 
vitronectin and clusterin (48, 49). The last area of complement regulation is that of the 
two biologically active peptides generated from cleavage of C3 and C5, C3a and C5a 
respectively. The enzyme carboxypeptidase-N degrades C3a and C5a into C3adesarg and 
C5adesarg. These modifications alter the reactivity and the signaling pattern potential of 
the anaphylatoxins and thus changes their potency. The multitude of complement 
inhibitors highlights the importance of limiting complement-mediated activation, 





	  	    
Figure 1-2 Regulation of Complement Activation. Complement regulatory proteins target specific 
points along the complement cascade to modulate activity of specific arms. Soluble proteins C1INH and 
C4bp inhibit activation of the classical pathways, additionally C4bp blocks lectin pathway activation. 
Factor H inhibits alternative pathway activation along with amplification of all complement activation 
pathways. The C3 convertase is regulated by several proteins, including DAF, MCP, CR1 (mouse 
analog to MCP/DAF is Crry). Complement mediated lysis is inhibited on host tissue through MAC 
regulation via CD59. 
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1.2 Chronic Obstructive Pulmonary Disease 
1.2.1 Overview 
Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of 
mortality worldwide (50). COPD encompasses two main conditions, chronic bronchitis, 
characterized by enhanced inflammation of the upper airways, and emphysema, defined 
as irreversible destruction of the alveolar tissue (51, 52). Although COPD is a 
preventable disease, treatment options remain limited and progression into later stages of 
disease leads to irreversible lung tissue damage. Based on the Global Initiative for 
Chronic Obstructive Lung Disease (53) spirometric criteria, the stages of COPD range 
from mild, with a forced expiratory volume (FEV) ≥ 80% (GOLD stage I), to very severe 
(GOLD state IV), with a FEV < 30% (GOLD report 2010). With limited therapeutic 
options, those available are aimed to alleviate symptoms rather than target the disease 
itself. Behavioral modifications include smoking cessation, to limit ongoing lung tissue 
damage. Pharmacological treatments include corticosteroids to reduce inflammation, 
although prolonged use typically render treatment less effective due to the development 
of resistance (54-58). Additionally, long-acting bronchodilators, which include long-
acting β2-adrenergic receptor agonists (LABAs) and long-acting muscarinic 
acetylcholine receptor antagonists (59) that dilate the airways, especially during acute 
exacerbations and can improve systems (56-58). These treatments are temporal solutions 
and do not target a specific disease mechanisms. Therapeutic studies have attempted to 
target pro-inflammatory cytokines, such as Leukotriene B4 (LTB4), TNF-α and IL-8, and 
protease MMP-9, with monoclonal antibody biologics or receptor antagonists, yet the 
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results from these clinical trials have been disappointing and point towards complex 
COPD pathogenesis (60-66). Four hypotheses currently describe the onset and 
progression of COPD; however, targeting only one proves unsuccessful for a majority of 
patients. Understanding how these hypotheses may interact with each other, and finding a 
common pathway, which participates in multiple pathways may provide a solution for 
therapeutic strategies. Here we will discuss the potential impact that the complement 
system may have on the proposed mechanistic pathways in emphysema development, and 
aim to access the therapeutic potential for complement based therapies. 
 
1.2.2 Protease Anti-Protease Mechanism and Complement 
The protease anti-protease mechanism was first proposed in the mid-1960’s based on 
observations of patients whom developed panacinar emphysema as early as their third 
decade of life (67). These patients had a genetic deficiency in alpha-1 antitrypsin 
(A1AT). A1AT is a major serine protease inhibitor in the lung, which is predominantly 
synthesized in the liver. A1AT complexes with proteases, specifically neutrophil elastase, 
to inactivate and clear the enzyme once the immune response has subsided (68-75).  
A deficiency in A1AT leaves lungs more susceptible to proteolytic damage (76-79). 
Since the respiratory tract is continuously exposed to harmful material, such as noxious 
gases from air pollutants, the respiratory epithelium alert the innate immune response 
through the release of pro-inflammatory cytokines, such as IL-8 and monocyte 
chemotactic protein (MCP-1), to recruit neutrophils and macrophages, respectively (80-
82).  A1AT is an important protease inhibitor within the lung, which takes part in 
	  
11	  
controlling and resolving the inflammatory response. The importance of A1AT is 
illustrated in smokers that have a deficiency in the protease inhibitor.  These patients 
have accelerated lung tissue damage and an increase risk for development emphysema as 
early as their 3rd decade of life.  
 
This mechanism of a protease imbalance leading to emphysema development is also 
pertinent to chronic cigarette smokers that have normal levels of A1AT. Cigarette smoke 
contains over 7000 toxic chemicals and 1014-16 reactive oxygen species (78). The toxic 
microenvironment of a smoker’s lung amplifies the immune response and causes an 
influx of innate immune cells. The increased numbers of neutrophils and macrophages 
recruited to the lungs by the cigarette smoke produce proteases that overwhelm the anti-
protease defense and result in cleavage of the lungs extracellular matrix proteins, 
subsequently leading to emphysematous changes (83, 84). Furthermore, oxidative stress, 
either from the cigarette smoke itself or infiltrating immune cells, can oxidatively 
inactivate A1AT, causes a functional deficiency in A1AT in the lungs of COPD patients 
(85, 86). Analysis of patient samples find that the number of lung neutrophils and 
macrophages correlate to the degree of emphysema, indicating a central role for these 
immune cells in disease progression.  Even with smoking cessation, a continued 
inflammatory response within the lungs persists with continued invasion of neutrophils 
and macrophages as well as T cells and B cells, demonstrating an underlying and ongoing 




As a key aspect of the innate immune response, the complement cascade takes part in the 
immediate immune response. Toxins within cigarette smoke can prime and activate 
complement. Proteases within the lungs of smokers, such as neutrophil elastase and 
MMP-12, can cleave complement proteins into their active fragments (89, 90).  
Additionally, cigarette smoke can directly cleave C3 into its biologically activate 
fragments, activating the alternative pathway thus amplifying the complement cascade 
(91-96). Cigarette smoke cleaved complement proteins retain the ability to recruit and 
activate innate immune cells into the lungs, as well as continued activation of the 
remaining complement cascade (91-96). Neutrophils and macrophages express 
anaphylatoxin receptors, C3aR and C5aR, on their cell surface, and it remains feasible 
that the increased concentration of the anaphylatoxins will promote furthered recruitment, 
activation and pro-inflammatory cytokine release. Complement anaphylatoxins and the 
Toll-like receptor system (TLR) synergistically enhance the release of pro-inflammatory 
cytokines, including IL-6, IL-8, TNF-α and IL-1β, which remain elevated in emphysema 
patients (97). In vivo studies with complement deficient mice (C5-/-) demonstrate that in 
the absence of C5a generation, innate immune cell influx into the lung is reduced during 
acute cigarette smoke exposure (91-96). Furthermore, in clinical samples from COPD 
patients, there are reduced complement proteins in the serum along with increase 
complement cleavage fragments in the bronchoalveolar lavage fluid. Additionally, there 
is evidence of complement deposition fragments on lung tissue from COPD patients, 
demonstrating activation of the complement system within the respiratory tract, offering a 
potential system for a therapeutic target (98, 99). Targeting complement activation during 
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emphysema onset and progression could rescue the lungs from the ongoing complement-
mediated inflammation.  
 
1.2.3 Oxidant Anti-Oxidant Mechanism And Complement 
One of the leading risk factors for COPD development is cigarette smoke exposure. 
Similar to the protease anti-protease hypothesis, there is an increase in oxidative stress in 
the lungs of smokers that can overwhelm the anti-oxidant defense and damage lung 
tissues.  In smokers, oxidative stress can be sourced from the cigarette smoke itself, but 
can also be generated by the infiltrating inflammatory cells once activated within the 
lungs. ROS are volatile molecules, including superoxide anion (O2) and hydroxyl radicals 
(OH-), possessing an oxygen group that carries a highly reactive free radical(100). 
Phagocytic immune cells produce ROS to assist in microbial killing and ROS generation 
enhances the inflammatory response via induction of activator protein (AP-1) through 
NF-κB signaling (101). The anti-oxidant enzymes, superoxide dismutase (9), glutathione 
peroxidase and catalase, catalyze the detoxification of ROS and protect healthy tissue 
from ROS-mediated damage. SOD first converts ROS into hydrogen peroxide and water, 
and glutathione peroxidase or catalase breaks down hydrogen peroxide into water and 
oxygen, detoxifying the molecules and preventing oxidative damage (101). Mice 
deficient in the transcription factor for glutathione peroxidase, nuclear erythroid-related 
factor 2 (Nrf-2), developed accelerated and more severe emphysema following cigarette 
smoke exposure than Nrf-2 sufficient mice. These mice lack an essential anti-oxidant 





Even with an increase in SOD activity in the lungs of COPD patients, the overwhelming 
oxidative burden induces cellular apoptosis and modifies extracellular matrix proteins 
leading to emphysematous changes within the lungs (101). Anti-oxidant treatment 
strategies of COPD patients have been discouraging due to lack of effectiveness in 
treatments. The treatments of N-acetylcysteine (51) and carbocisteine are unstable and 
readily susceptible to inactivation by oxidative stress, making these a poor option in a 
highly oxidative environment. More potent and targeted therapies are needed since the 
oxidative burden is one component driving the inflammatory response, which remain 
elevated even after smoking cessation (55, 102, 103). 
 
Cigarette smoke has the capability to directly activate the complement cascade and 
generate its bioactive fragments C3a and C5a (91-96).  The anaphylatoxins can then 
recruit innate immune cells into the respiratory tract and initiate their activation, helping 
to orchestrate the increased oxidative burden within the lungs. Cigarette smoke and 
immune cell-derived ROS can then modify lung tissue through an oxidative process 
generating neo-epitopes. Modifications of self-proteins may allow for immune system 
recognition of self-tissues, promoting an autoreactive response and lung tissue damage. 
Liver ischemia reperfusion studies demonstrated that complement deficient mice had 
reduced levels of oxidative stress and were protected from tissue damage following 
reperfusion, indicating a role for the complement cascade in enhancing the oxidative 
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burden (104). Therapeutics that reduces complement activation can also lessen this 
oxidative burden, in addition to the direct effect on the immune system.   
 
1.2.4 Apoptosis And Regeneration Mechanism And Complement 
A third mechanism postulated to describe COPD onset and progression investigates the 
imbalance between cellular apoptosis and lung tissue regeneration following chronic 
smoke exposure. As highlighted previously, chronic exposure to cigarette smoke places 
the respiratory tract under continuous stress, stemming from increased proteases, oxidants 
and inflammatory cells. As a result, apoptosis within the lungs of COPD patients 
increases, and without sufficient regeneration of lung tissue, emphysematous changes 
will result. Increased apoptosis within the COPD lung was evidenced by an increase 
expression of several pro-apoptotic proteins, including Bax and Bad as well as an 
increase in caspase-3 activity, in lung tissue samples. Furthermore, COPD patients 
display a loss in epithelial and endothelial cells throughout the respiratory tract and a 
decrease in expression of vascular endothelial growth factor (VEGF), a growth factor 
needed for endothelial cell survival (105-108). In vitro work demonstrated that 
respiratory epithelial cells exposed to cigarette smoke down-regulated VEGF receptor 
(VEGF-R2) expression on the cell surface, with a corresponding reduction of VEGF in 
culture media (109). Moreover, in vivo mouse models reveal mice treated with a VEGF-
R2 antagonist have accelerated emphysema development following chronic cigarette 
smoke exposure, whereas mice infused with mesenchymal stem cells, which highly 
express VEGF, VEGF-R2 and TGF-β, were protected from emphysema development 
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(105-108).  These data reveal a critical need for VEGF to maintain lung integrity, which 
is lacking in COPD patients. An additional aspect of the apoptosis/regeneration 
hypothesis is the role of cellular senescence in COPD development. Tsuji et al. 
demonstrates an increase in cell senescent markers p16INK4a and p21CIP1/WAF1/Sdi1 in both 
epithelial and endothelial cells along with a reduction in telomere lengths in active 
smokers and patients with emphysema compared to nonsmoker controls (110).  
Furthermore, mice deficient in senescence marker protein–30 (SMP-30), a key protein 
involved in protecting lung tissue from aging, developed senile emphysema. Exposing 
SMP-30 deficient mice to cigarette smoke accelerated emphysema development, 
suggesting a role for cellular senescence in disease pathogenesis (111-113). 
 
Although characterized for pathogen recognition and clearance, the complement system 
also plays a critical function in host homeostasis. Apoptosis can cause shedding of 
complement regulatory proteins, which permits sufficient complement deposition for 
phagocytic clearance (114, 115). Apoptosis also promotes enhanced complement 
recognition of these apoptotic cells; during apoptosis, phospholipids flip from the inner 
membrane to become exposed on the cell surface. Exposed epitopes leads to the 
deposition of natural antibodies, IgMs, which can be recognized by complement to 
promote phagocytic cell clearance of these apoptotic bodies (116-121). Specifically, the 
classical pathway and C1q seem to be critical in apoptotic clearance. Classical pathway 
recognition proteins C1q associates with antibody coated apoptotic cells to tag the 
immune complex for clearance (117-121). Deficits in classical pathway-mediated 
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apoptotic clearance promote autoimmune disease experimentally and clinically, as 
patients with deficiencies in C1q are more susceptible to lupus, an autoimmune disease 
characterized by enhanced immune complex deposition on tissue leading to multi-tissue 
inflammation (122, 123). In COPD, complement recognition of the increased apoptotic 
cells within the respiratory tract could promote continuous activation, and ultimately 
overwhelm the adequate complement-mediated clearance. Without resolution of the 
ongoing inflammatory response, such as in the case of active smokers, healthy tissue 
becomes vulnerable to non-specific innate immune attack propagating the lungs for an 
autoimmune phenotype to develop.  
 
An emerging function of complement activation is that of tissue regeneration, specifically 
via signaling through the anaphylatoxins, C3a and C5a, with their receptors (12, 124). In 
a murine model of CCl4-induced liver injury, C5 deficient mice had impaired tissue 
regeneration that was restored with C5 or C5a reconstitution. Furthermore, administration 
of a C5a receptor antagonist impaired hepatocytes proliferation in response to injury, 
demonstrating a critical role of anaphylatoxin receptor signaling for regeneration (31, 
125). The anaphylatoxins are chemoattractants for human bone marrow-derived 
mesenchymal stem cells (MSCs), indicating a potential role in tissue regeneration 
following injury (126, 127). In COPD patients, enhanced complement activation from 
chronic cigarette smoke may reduce the regenerative properties and/or recruitment of 
stem cells to the highly inflamed tissue, which may predispose the lungs to a pre-
cancerous state.  
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1.2.5 Autoimmunity and Complement 
While the first three mechanisms focus predominantly on cells of the innate immune 
response during COPD progression, the fourth COPD hypothesis that describes the 
pathogenesis of COPD centers on why the disease progresses even after smoking 
cessation (128). Growing evidence supports a role of the adaptive immune response in 
COPD pathogenesis; such there is an ongoing inflammation response within the lungs, 
even after smoking cessation (129-133). An increase in T and B cells, the presence of 
follicular formations within the lung and lung-specific autoantibodies in late stage COPD 
patients led investigators to ask the questions: Is emphysema an autoimmune disease and 
what antigens are driving the underlying adaptive immune response within the lungs 
(133, 134)? 
 
The first animal model investigating a potential autoimmune phenotype during 
emphysema progression comes from rats immunized with human umbilical vein 
endothelial cells (HUVECs). As early as 11 weeks, treated rats developed airspace 
enlargement in their lungs compared to mice receiving only adjuvant. Interestingly, naive 
mice progressed into a disease state following adoptive transfer of serum or isolated T 
cells from disease rats (135, 136). These data highlight a role for the adaptive immune 
response in COPD progression. 
 
Exposure to cigarette smoke increases respiratory cell death, extracellular matrix 
degradation and oxidative stress. These processes increase the concentration of either self 
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and/or modified-self proteins within the lung, which may initiate an adaptive immune 
response against self. Increases in epithelial and endothelial cell- reactive autoantibodies 
have been reported in sera of COPD patients (137, 138). Additionally, Lee et al 
demonstrated both in mice with chronic cigarette smoke exposure and COPD patients 
samples, increases in IFN‐γ production by local and systemic T cells and autoantibody 
responses targeted against elastin peptides (139, 140). Other antigens that have been 
identified as potential primers of an autoimmune response include extracellular matrix 
proteins collagen‐IV, collagen‐V and decorin (138). Moreover, Rag‐/‐ mice adoptively 
transferred with CD3+ T cells from chronically smoke exposed mice develop an 
exaggerated inflammatory response and display accelerated emphysema in comparison to 
mice given naïve T cells, indicating a cell-mediated autoimmune response (129). Other 
studies show that inhibition of CD4+ and/or CD8+ T cells protects mice from cigarette 
smoke induced emphysema development. These data establish a lung tissue specific 
immune response and emphasize the importance of identifying a panel of reactive self-
antigens propagating inflammation in COPD patients. Although a requirement for cell-
mediated signaling has been clearly defined, the pathogenic significance of 
autoantibodies is less clearly defined. Whether these autoantibodies contribute to disease 
development or are merely biomarkers of disease is yet to be completely elucidated. 
 
The role of the complement system in autoimmune diseases is complex.  Increased 
complement activation is evidenced in several autoimmune diseases, including systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SS) (141-
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145). Conversely, patients deficient in key complement components, such as C1q, 
C1s/C1r or C4, display an increased risk of autoimmune disease development. A main 
effector mechanism is recognition and assistance in immune complex (IC) clearance 
(146-148). Without sufficient clearance of immune complexes via complement-mediated 
IC recognition, it leads to IC deposition on healthy tissue and persistent inflammation. 
However, in those complement sufficient individuals, complement activation from IC 
deposition promotes a continuing inflammatory state, leaving healthy tissue susceptible 
to non-specific attack. The multifaceted role of the complement system in autoimmune 
development demonstrates that disease state and complement targeting strategies need to 
be considered for future treatments options (149-152). 
 
In addition to “complementing” antibody-mediate recognition, complement proteins can 
promote T cell activation and proliferation during an immune response.  Following an 
interaction between the antigen presenting cell and T cell, alternative pathway proteins 
are released, amplify cleavage of anaphylatoxins, C3a and C5a and signal via respective 
receptors, C3aR and C5aR, to stimulate T cell activation and proliferation (8, 153).  
Furthermore, T cell specific C3aR and C5aR blockade enhances the production of 
Foxp3+ T regulatory cells, leading to a more tolerogenic microenvironment (153). Mice 
deficient in key complement proteins, such as C3, C3aR and/or C5aR, have a suppressed 
T cell response, which could lead to a potential T cell mediated autoimmune disease.  
Due to the diverse role of the complement cascade in the adaptive immune response it 
offers an ideal target for therapeutic intervention during an autoimmune inflammatory 
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conditions, which could be the underlying inflammatory phenotype in COPD patients. 
 
11.3 Conclusion 
The pathogenesis of emphysema is complex. It involves the initiation of inflammation 
that results in tissue injury. Several pathways to inflammation have been proposed, 
specific inhibition of these distinct pathways have not proved effective therapeutically. 
Here we discussed how the complement system might play a role in each of the complex 
pathways and demonstrate, through review, the many points of each proposed hypothesis 
where complement components may intersect. In Figure 1-2 we provide a schematic 
overview of how complement activation may interact with the various cells of both the 
innate and adaptive immune response and how the complement system could be activated 
by key initiators, including cigarette smoke, neutrophil elastase, metalloproteases, of 
disease (153).  
 
As a common denominator function and potentially linking each hypothesis, the 
complement system may be an ideal target for future therapies for emphysema patients. 
Since the complement system takes part in many pro-inflammatory mechanisms and can 
influence both the innate and adaptive immune responses modulating the complement 
cascade could offer protection from the ongoing inflammation seen in the lungs of 
emphysema patients following chronic cigarette smoke exposure. Additionally, since the 
complement cascade can be activation through several different pathways, targeting only 
one pathway therapeutically may allow the remaining pathways to continue to function, 
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thus pathway protecting other host homeostatic mechanisms to persist.   
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Figure 1-3 Potential Mechanisms of Complement Mediated Inflammation in Emphysema 
Development and Progression. Several different inflammatory mechanisms have been 
postulated to describe emphysema development. The above image depicts potential axis for 
complement effector molecules to influence these proposed mechanisms. 
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1.4 Rational and Description of Research Project  
Chronic obstructive pulmonary disease is currently the third leading cause of mortality 
worldwide (50). The leading risk factor for COPD development is cigarette smoke 
exposure, yet its pathogenesis remains unclear (134, 154-157). Current treatment options 
for patients are limited and offer temporary symptomatic relief rather than target disease 
pathogenesis itself, which is due to the complex inflammatory response within the lungs. 
There are several postulated inflammatory mechanisms describing emphysema 
progression, including increased protease burden and oxidative stress without regulation, 
enhanced apoptosis without regeneration and lastly, autoimmune development, all of 
which lead to lung tissue destruction (53, 84, 100, 134, 155, 158, 159). Although each 
hypothesis addresses a certain aspect of emphysema development, targeting only one 
offers little clinical benefit 
 
The complement system is a major component of the innate immune response but also 
takes part in priming the adaptive immune response (160-162). Complement can be 
activated by one of three activation pathways, the classical, lectin and alternative (163). 
Effector mechanisms and molecules generated following activation assist in immune cell 
recruitment and activation, pro-inflammatory cytokine release and complement-mediated 
cell lysis (10, 11, 164, 165). Similar to all other inflammatory systems in the host, there 
are several different molecules that take part in regulating the system. However, during 
an inflammatory condition, such as cigarette smoke induced emphysema, we propose that 
there is an increase in complement activation without sufficient regulation. There is 
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evidence of complement activation in emphysema patients, with increased complement 
serum protein levels, increased complement anaphylatoxin in the bronchoalveolar lavage 
fluid, and complement deposition fragments present within lung tissue (98, 166). All 
these data taken together highlight a potential role for the complement system in 
emphysema development and progression, but how complement proteins are taking part, 
in the pathogenesis of emphysema remains unknown.  
 
Investigation into the role of the complement system in emphysema development is 
needed and should we find that it plays a significant role in disease pathology, it may 
identify a novel pathway for therapeutic intervention. From all the aforementioned data, 
we hypothesize that the complement system plays a role in emphysema progression, 
targeted inhibition of which will modulate both the ongoing innate and adaptive immune 
response within the lungs, thereby protecting the lungs from tissue destruction and 
disease development. To address this hypothesis we first investigated which complement 
effector mechanisms and molecules play a role in emphysema development by exposing 
several different complement deficient mouse strains (C1q/MBL-/-, C3-/-, factor B-/-, C6-/- 
and anti-C5mAb treated) to 6 months of cigarette smoke exposure. We also addressed the 
potential of complement therapeutics in a novel cigarette smoke cessation model to 
investigate the clinical benefits of targeting the complement system. Lastly, we addressed 
the autoimmune component to disease progression, and investigated whether 




MATERIALS AND METHODS 
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2.1 Murine Models 
2.1.1 Chronic Cigarette Smoke Model 
i. The Teague Machine  
A TE-10 Smoking Machine (Teague Enterprises) was utilized for all chronic smoke 
exposure studies to generate emphysema in our mouse models. Eight week old C57BL/6 
male mice were exposed to cigarette smoke within a smoking chamber produced from 
3R4F cigarettes at a concentration of 150ppm for 5 hours a day, 5 days a week for 6 
months. To evaluate the contribution of each complement pathway to disease 
development complement deficient mice were utilized. The different complement 
deficient mouse strains utilized were C1q/MBL, blocking activation of the classical and 
lectin pathways, C3, blocking all complement activation pathways, factor B, blocking the 
alternative pathway and amplification loop, C6, blocking assembly of the membrane 
attack complex (MAC). All complement deficient mice were backcrossed on a C57BL/6 
background.  
 
Since C5 deficient mice were not accessible on a C57BL/6 background we utilized wild 
type mice treated a monoclonal antibody against complement component C5 to address 
the role of C5 in emphysema development. By blocking C5 mice were protected from 
C5a generation and membrane attack complex (MAC) formation. For anti-C5 studies 
mice were given anti-C5 before cigarette smoke exposure and throughout the exposure to 
block activity C5 functions prior to the cigarette smoke induced inflammation. Following 
the 6-month exposure, lung tissue, serum, spleen and bronchoalveolar lavage fluid were 
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collected for analysis of the inflammatory response and emphysema development (75). 
 
2.1.2 Cigarette Smoke Cessation Model 
To address the clinical significance of the complement therapeutics in emphysema 
progression we developed and characterized a cigarette smoke cessation mouse model. 
To warrant emphysema development, cigarette smoke exposure was done as described 
above.  For our therapeutic model, following six months of smoke exposure, mice 
underwent three months of smoking cessation along with complement inhibition 
treatment. Complement therapies including targeted inhibitor CR2-fH, blocking the 
alternative pathway, systemic inhibitor anti-C5, blocking the generation of C5a and MAC 
formation, or vehicle control (PBS). Experimental layout is depicted in chart below 
(Figure 2-1) Targeted inhibition was administered via i.p. injections, three times a week 
at a dosage of 0.25mg per mouse, anti-C5 treatment was given twice a week at a dosage 
of 800ug per mouse.  Lung tissue and bronchoalveolar lavage fluid were taken to 
investigate emphysema development.  Serum and splenocytes were taken to determine 






Figure 2-1 Targeted Complement Treatment. Mice were exposed to cigarette smoke for six months 
to ensure emphysema development. Following the chronic smoke exposure mice were given 
complement therapeutics via intraperitoneal injections to block complement activation. Following the 




2.1.3 Combined Elastase and Cigarette Smoke Immunization Model 
Currently, there are two well-characterized mouse models utilized to investigate 
emphysema development and progression, 1. Porcine pancreas elastase delivered directly 
into the lungs, or 2. Chronic cigarette smoke exposure (53, 167). For our immunization 
model studies we combined both models by giving C57BL/6 mice a low dose (0.4U) 
porcine pancreas elastase (Sigma-Aldrich) intratracheal to begin elastase induced lung 
tissue damage. Additionally, mice were exposed to cigarette smoke for 12 weeks to 
create a highly oxidative microenvironment in the lungs, as seen in active smokers (51).  
 
Experimental timeline is depicted in schematic below (Figure 2-2). In brief, to investigate 
the role of autoantibodies in cigarette smoke induced emphysema development mice 
were immunized intraperitoneally with 100uL of Sigma Adjuvant (Sigma-Aldrich) along 
with 10ug of moues lung elastin peptides (Elastin Product Company) or cigarette smoke 
modified mouse lung elastin peptides (modification process described in detail in 
carbonyl-modified ELISA method). Three weeks later mice were given a booster (168). 
Seven days after the elastase surgery mice began the 12-week cigarette smoke exposure. 
Throughout the experiment, mice were monitored via lung function analysis. 16 hours 
after the last cigarette smoke exposure lung tissue and bronchoalveolar lavage fluid were 
taken to investigate emphysema development.  Serum and splenocytes were taken to 






Figure 2-2: Representative Timeline for Immunization Experiment. In the immunization model 
mice were give a low dose of elastase in combination with cigarette smoke exposure to allow for 
emphysema to develop in the lungs. Mice were also immunized with either elastin peptides or elastin 




2.2 Lung Function Analysis 
2.2.1 Plethysmograph System 
Lung function was measured utilizing a Mouse Double Chamber Plethysmograph System 
(EMKA). Mice were placed in the nose out retainer and allowed to acclimating to the 
chamber for 2-3 minutes. Following the acclimation period, EMKA software began to 
collect readings of multiple parameters based off the airflow changes in the nose and 
body chambers, as well as the breathing rate (frequency of breathes) of the mouse. Each 
mouse was analyzed for approximately 10-15 minutes. The parameters that were 
calculated included time of inspiration (Ti), time of expiration (Te), peak inspiratory 
pause (PIP), peak expiratory pause (169), tidal volume (TV), expiration volume (EV), 
minute volume (MV), relax time (RT), end inspiratory pause (170), end expiratory pause 
(EEP) and enhanced pause (2). For each parameter analyzed an average was taken, 
calculating values 3 minutes into the data read and averaging 10 minutes worth of a data, 





2.3 Morphological Characteristics of Emphysema 
To address the effect of the complement system in emphysema development we 
evaluated airspace enlargement, which is done through mean linear intercept analysis, in 
the lung following 6 months of cigarette smoke exposure. Complement deficient strains 
were compared to our complement sufficient mice to address complement-mediated 
destruction. 
 
2.3.1 Mean Linear Intercept 
Mice were euthanized, and lungs inflated through the trachea to 25cm water pressure 
with 10% buffered formalin (Surgipath, USA) and lungs removed en bloc, and formalin 
fixed for a further 24 hrs. Lungs were then processed to paraffin, sectioned at 4mm and 
stained with hematoxylin and eosin stain.  To assess the different morphological 
parameters of emphysema, an Olympus BX61 Microscope equipped with digital camera 
linked to VisioPharm image capture software was employed to capture 10 random fields 
from H&E stained lung tissue sections. All morphological determinates were assessed in 
line with the American Thoracic Society criteria (172). Mean linear intercept values were 
calculated as previously described.  In brief, the number of intra alveolar walls that are 
intersected a 10 by 11 grid placed over the section was counted and expressed as number 





2.4 Inflammatory Response 
The complement cascade not only recruits and activates innate immune cells but also 
primes adaptive immune cells during antigen presentation. To determine the mechanistic 
contribution of the complement system during emphysema development we evaluated 
both the innate and adaptive immune response in the respiratory tract in all experimental 
mice from bronchoalveolar lavage samples and immunohistochemistry stained tissue 
sections.  
 
2.4.1 Bronchoalveolar lavage Fluid 
Bronchoalveolar lavage fluid was collected using the method our laboratory has 
previously described (75). In brief, BAL samples were centrifuged and the supernatant 
treated with protease inhibitor and stored at -80C for future analysis. The cell pellet was 
re-suspended in PBS.  Red blood cells were lysed and the total number of cells quantified 
by the mean of two hemocytometer counts.  Subsequently, cytospins were prepared and 
stained with Hema 3 for differential counts. 
 
2.4.2 Immunohistochemistry and Immunofluorescence 
To evaluate the innate immune response in the lungs, neutrophil (Gr-1 1:20, BD), 
macrophage (Mac-3 1:20, BD), and complement deposition fragment, C3d (1:30, R&D) 
staining was performed on paraffin slides following antigen retrieval optimized for each 
antibody.  ImPRESS Reagent Kit (Vector Laboratory) was utilized for secondary 




For co-localization studies, immunofluorescence stains were utilized. C3d (1:30, R&D) 
deposition was fluorescently visualized by using an Alexa 555 anti-goat secondary 
antibody (1:100, Life Technologies) followed by a directly conjugated anti-mouse IgM 
FITC (1:100) or anti-mouse IgG FITC (1:25). All antibodies have been optimized in our 
laboratory for use on mouse paraffin tissues.  
 
2.4.3 Complement Protein ELISAs 
Complement proteins C3, C3a, C5 and C3a were measured in the bronchoalveolar lavage 
fluid and serum by commercially available kits (BD and R&D) to investigate 
complement activation in the lungs following cigarette smoke cessation.   
 
Association of complement anaphylatoxins, C3a and C5a, with their receptors, C3aR and 
C5aR, expressed on myeloid and non-myeloid cells leads to the release of pro-
inflammatory cytokines, including IL-6, KC, MCP-1 and TNF-α (29, 174, 175). Our 
studies investigated the effect of cigarette smoke on complement protein production as 
well as pro-inflammatory cytokines production. Cytokines that are reported to be 
involved in cigarette smoke related inflammation, including KC, MCP-1 IL-6, TNF-α, 
IL-1β (176). Additional cytokine analyzed include those essential in the adaptive immune 
response, such as Th1 cytokine  (IL-2, IL-12 IFN-Υ), Th2 cytokines (IL-4, IL-13), Th17 
cytokines (IL-17, IL-23) and Treg (IL-10, TGF-β). Analysis included semi-quantitative 
real time PCR or ELISAs of lung tissue and BAL samples, investigating complement 
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deficiency on the immune communication network in the lungs. 
 
2.5.1 Semi-Quantitative RT-PCR 
Tissues for RNA extraction were placed immediately into RNAlater (Qiagen).  Total 
RNA was isolated from lungs using Qiagen RNeasy Plus Mini RNA extraction kit 
(Qiagen).  cDNA was made from 1 µg total RNA using the iScript cDNA synthesis kit 
(Bio-Rad) and real-time RT-PCR analysis was performed using the QuantiTect SYBR 
Green PCR Kit (Qiagen) following the manufacturer’s protocols. Analysis was 




Figure 2-3: List of RT-PCR Primers 
Gene Sequence (LP, RP) 
C3 5’GCTCTATCTGTGGATGTATCT3’ 
5’ TCTATTATGGTTGTCTGTAGTGA3’  
C3a receptor 5’ CCAGACACATCCACAGATGG 3’ 
5’ TGTTTGCCAGTGTCTTCCT 3’ 
C5 5’ CAG GGT ACT TTG CCT GCT GA 3’ 
5’ TGG ATT TTC ATG GTG GGG CA 3’ 
C5a receptor 5’ ACCTTCGATCCTCGGGGAGC 3’ 
5’ GCGTACATGTTGAGCAGGAT 3’ 
Factor B 5’ AGAAGGTGGCTCATGGAGTG 3’ 
5’ TGGTCTCTGTCAGGGAGG 3’ 
C9 5’ CCGAGTAGCGGAAGAATCAG 3’ 
5’ CGGTCACAGAGTCCGTTGTA 3’ 
KC 5’ GCACCCAAACCGAAGTCATA 3’ 
5’ TGGGGACACCTTTTAGCATC 3’ 
MCP-1 5’ AGGTCCCTGTCATGCTTCTG 3’  
5’ CGTTAACTGCATCTGGCTGA 3’ 
MIP-2 5’ TCCAGAGCTTGAGTGTGACG 3’ 
5’ TTCAGGGTCAAGGCAAACTT 3’ 
IL-1β 5’ CAGGCAGGCAGTATCACTCA 3’ 
5’ TGTCCTCATCCTGGAAGGTC 3’ 
IL-6 5’ CCGGAGAGGAGACTTCACAG 3’ 
5’ TCCACGATTTCCCAGAGAAC 3’ 
TNF-α 5’ ACGGCATGGATCTCAAAGAC 3’ 
5’ GTGGGTGAGGAGCACGTAGT 3’ 
IFN-γ 5’ ACTGGCAAAAGGATGGTGAC 3’ 
5’ GCTGATGGCCTGATTGTCTT 3’ 
IL-4 5’ CCAAGGTGCTTCGCATATTT3’  
5’ ATCGAAAAGCCCGAAAGAGT 3’ 
IL-17 5’ TCTCTGATGCTGTTGCTGCT 3’ 
5’ AGGAAGTCCTTGGCCTCAGT 3’ 
IL-2 5’ TTTGAGTGCCAATTCGATGA 3’ 
5’ AGGGCTTGTTGAGATGATGC 3’ 
IL-12 5’ CTCCTGTGGGAGAAGCAGAC 3’ 
5’ CAGATAGCCCATCACCCTGT 3’ 
TGF-β 5’ CACCTGCAAGACCATCGACA 3’ 
5’ CACGCGGGTGACCTCTTTAG 3’ 
IL-10 5’ CCAAGCCTTATCGGAAATGA 3’ 
5’ TCTCACCCAGGGAATTCAAA 3’ 
APRIL 5’ GGACAAGGAACGGTCAAGAA 3’ 
5’ CATGGAGTCAAAGCCCAGAT 3’ 
BAFF 5’ TTGTCCAGCAGTTTCACAGC 3’ 
5’ CTGAACCTCGGTAGCTCTGC 3’ 
SDF-1 5’ AGGCAGGTGAGAGGGGTAGT 3’ 
5’ AGAGGTCTTGGTGCTCAGGA 3’ 
CXCR5 5’ ATCTCTCTGTGGCCATCACC 3’ 
5’ GAGAGAGGTCACTGCGGAAC 3’ 
CXCL13 5’ AGCTGAGAGGGAATGCTCAA 3’ 
5’ CATGCATCTGAAGTGGGTTG 3’ 
β-Actin 5’ TACGTAGCCATCCAGGCTGT 3’ 
5’ GGAGAGCATAGCCCTCGTAG 3’ 
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2.5.2 Lung Tissue Homogenizing 
Lung tissue was collected and snap frozen in liquid nitrogen at time of tissue harvest.  To 
homogenize tissue, frozen lung samples were placed in glass tubes containing protease 
inhibitor lysis buffer. Homogenized samples were then centrifuge at 1500prm for 8mins 
at 4 °C. Samples were then frozen down at -80 degrees until cytokine analysis 
 
2.5.3 Cytokine ELISAs 
Pro-inflammatory cytokines were measured in the BAL and lung tissue by a 
commercialized available kit (BD and R&D) to investigate the inflammatory response in 
the respiratory tract.  
 
2.5.4 Flow Cytometry 
Frozen splenocytes or bronchoalveolar lavage cells were incubated in RMPI-10 media 
(Invitrogen) overnight. Cells were stimulated with PMA/Ionomycin (Sigma-Aldrich) for 
1 hour, followed by a 4 hour Monensin (Biolegend) treatment. Splenocytes and lavage 
cells were stained for extracellular surface markers CD4-APC/Cy7, CD8-FITC (BD 
Bioscience) following by fixation then permeablized (BD Bioscience) to evaluate IFN-γ-
PE/Cy7 and IL-17-PE (BD Bioscience) and determine the Th1/Th17 response during 







2.6.1 Elastin Stimulated Flow Cytometry 
To investigate the potential auto-reactive T cell response in the mice following chronic 
cigarette smoke exposure and smoking cessation, splenocytes were stimulated with 
mouse lung elastin peptides or cigarette smoke modified elastin peptides (30ug/mL), 
peptides utilized in immunization model, for 36hrs along with recombinant IL-2 (R&D). 
Following the stimulation period splenocytes were activated and analyzed following the 
aforementioned flow cytometry protocol, investigating the potential autoreactive T cell 
response as previously described (168, 177). 
 
2.6.2 Follicular Formations 
Late stage COPD patients present with ectopic follicular formations in their small 
airways.  Studies debate on whether these formations are beneficial for protection against 
bacterial infections or are harmful and promote an autoimmune disease (159, 178). In our 
in vivo model, we evaluate follicular formation and investigate the effect that the 
complement system has on these T cell and B cell aggregates.  Follicular formation 
counts were done on H&E stain lung tissue. Aggregates containing 50 or more immune 
cells were considered a positive follicle (179).  
 
2.6.3 Anti-Extracellular Matrix Protein ELISAs 
Extracellular matrix autoantibody levels were measured via ELISA methods as 
previously described by Brandsma et al. (168) In brief, 96-well plates (Nunc, Fisher) 
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were coated in PBS with ECM proteins collagen (10ug/mL), decorin (10ug/mL) or 
elastin peptides (25ug/mL) (Elastin Products Company) overnight at 4°C. Plates were 
blocked for 1.5 hours at 37°C in 0.2% milk in PBS, then washed three times in PBST 
(0.05% Tween). Wells were filled with 50uL of diluted serum (1:40) and incubated for 2 
hours at 37°C followed by 2 hours incubation of the secondary biotin labeled anti-mouse 
IgM or IgG (1:4000, Sigma (1:1000 for IgG isotypes) at 37°C. After three washes plates 
were then incubated for 30 minutes with ABC complex (Vector) and then TMB substrate 
(eBioscience) was added for 15 minutes.  Plates were analyzed by (BioTek Synergy H1 
hybrid) at a 450 wavelength. 
 
2.6.4 Carbonyl-Modified Protein ELISAs 
Antibodies against carbonyl-modified proteins were also measured by ELISA methods, 
as previously described (180). Carbonyl-modified epitopes were generated in a multistep 
processes, beginning with a 24-hour incubation at 37°C containing either mouse serum 
albumin (MSA Sigma) or mouse lung elastin peptides (Elastin Products Company) and a 
oxidizing reagent, such as 10% cigarette smoke extract or Malonyldialdehyde (1) at a 
starting concentration of 1mg/mL diluted in PBS (pH 6.4). Following oxidative 
modification, samples were dialyzed for 24 hours in PBS at 4°C. BCA measured stock 
protein concentration, which was diluted to the working concentration of 1ug/mL. 96-
well plates (Nunc, Fisher) were coated 1ug/mL of carbonyl-modified MSA or elastin 
peptides in coating buffer (pH 9.5) and incubated for three house at 4°C. Plates were 
blocked for two hours at 37°C with 100ul of 1%BSA in PBST, then washed.  Wells were 
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filled with 50uL of diluted serum (1:40) and incubated for 16 hours at 4°C followed by 
detection with anti-mouse HRP-IgM/IgG (1:4000, Sigma (1:1000 for IgG isotypes)). 
Autoantibodies were detected by TMB substrate (eBioscience) and plates were analyzed 
by (BioTek Synergy H1 hybrid) at a 450 wavelength. 
 
2.7 Statistics 
Statistical analyses were performed utilizing Prism 5 software (GraphPad, La Jolla, CA). 
For parametric data, the means ± the standard deviation were calculated and analyzed for 
statistical significant by one-way ANOVA comparison between groups by Tukey for 
post-hoc analysis. For non-parametric data, the means ± the standard error mean were 
calculated for statistical significant (paired or unpaired) performed by using Student’s t-
test or Mann-Whitney U-test, when appropriate. Statistical significance was attained 









Chronic obstructive pulmonary disease (COPD) is an abnormal inflammatory condition 
of the respiratory tract that is currently the third leading cause of mortality. COPD 
encompasses two main conditions, chronic bronchitis and emphysema (50, 58). One of 
the leading risk factors for emphysema development is cigarette smoke exposure, yet 
disease pathogenesis remains unknown (58, 181-183). There are several hypotheses 
attempting to explain emphysema development, including imbalances in the 
protease/anti-protease, oxidative/anti-oxidant defenses and/or an increase in apoptosis 
without sufficient regeneration of the lung tissues (57, 75, 86, 106, 109, 140, 156, 170, 
184-186). Each of these hypotheses addresses a specific aspect of emphysema; yet the 
complexity of disease onset, and sustained progression leaves its mechanisms 
incompletely elucidated.  
  
Investigation into emphysema development has previously focused primarily on cells of 
the innate immune system, specifically neutrophils and macrophages. However, recent 
studies have begun to consider the role of the adaptive immune response, with 
investigations focusing on the contribution of T cells and B cells in emphysema 
progression. Mice deficient in CD8 T cells were protected from lung damage, 
macrophage infiltration, and emphysema development. Further, treatment with anti-CD4, 
and/or anti-CD8 antibodies, the T cell immunosuppressive agent cyclosporin A were 
protected from the characteristic macrophage infiltration and the development of 
emphysema development (187). In novel studies Rag1-/- mice were adoptively transferred 
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with CD3+ T cells isolated from the lungs of mice that were chronically exposed to 
cigarette smoke. T cell transfer induced emphysematous like changes in naïve recipient 
mice; independently of whether the recipient mouse was pre-exposed to cigarette smoke 
(129). Taken together these data support a role for T cell adaptive immunity in 
emphysema, and demonstrate autoimmune characteristics that are thought to explain the 
persistence of lung function decline even following smoking cessation (129).  
 
An immune component that is involved in both arms of the immune response is the 
complement system. The complement system can be initiated by one of three activation 
pathways, the classical, lectin or alternative. All three pathways converge at the C3 
protein generating the opsonization fragments (C3b, iC3b, C3d, C3dg), which coat target 
cells to enhance phagocytic uptake. Opsonin-coated antigens can also interact with 
complement receptors (CR2) present on B cells and lower the threshold for antigen 
processing, thereby bridging the innate and adaptive immune response (188-192). 
Additionally, the anaphylatoxins (C3a and C5a) associate with their receptors on both 
myeloid and non-myeloid derived cells to activate immune cells as well as enhance the 
release of pro-inflammatory cytokines (30). In addition to these humoral and 
inflammatory cytokine roles, recent data has begun to delineate a role for complement 
anaphylatoxins, C3a and C5a, in T cell priming, T effector/memory/regulatory cell 
skewing, and proliferation; once again linking the innate and adaptive immune responses 




Previous work from Kew et al demonstrates that components in cigarette smoke have the 
capability to activate the complement system through cleavage of the central complement 
component C3 via an alternative pathway mediated mechanism (94-96). Moreover, the 
cigarette smoke cleaved complement proteins retain their chemotactic ability to recruit 
and activate immune cells (93, 94). Evidence of complement activity in emphysema 
patients is shown through decrease complement serum proteins levels, increase C4a, C3a 
and C5a in the bronchoalveolar lavage fluids, and deposition of C3 in lung sections from 
emphysema patients, signifying complement activation in the respiratory tract (98, 99, 
197). The major etiological risk factor for emphysema is cigarette smoke exposure (50). 
Smoke exposure leads to oxidative stress and increased proteolytic enzyme production 
within the lung. In addition to direct cleavage of complement proteins by cigarette 
smoke, oxidative stress, and proteolytic enzymes, such as neutrophil elastase (NE) and 
matrix metalloproteinase 12 (MMP12) have also been shown to activate and directly 
cleave C3 and C5 (90, 93-95). Therefore, the working hypothesis presented here in 
specific aim 1 is that the complement system is a major contributor to the pathogenesis of 
emphysema, and by blocking complement activation we can protect lung tissue from 
chronic cigarette smoke mediated lung injury. 
 
Previous work in our laboratory has shown that mice deficient in key complement 
components, C3 and factor B, are protected from acute cigarette smoke exposure, 
suggesting a role of the complement cascade in cigarette smoke mediated pathologies. 
Further, specific C3a and C5a receptor therapeutic blockade similarly protects against 
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smoke induced acute lung injury (Manuscript submitted for Publication PLosOne). Taken 
together these studies support a role for complement activation in sterile lung 
inflammation; and that alternative pathway generation of C3a and C5a drives injury. In 
support of these findings a recent study has demonstrated that C3 and C3a receptor 
deficiency protects against emphysema development in a chronic model of emphysema 
(90). Here the authors postulate that C3a drives C3aR expression resulting in monocyte 
dendritic cell (moDCs) induced T cell priming, which results in reduced lung injury (90).  
 
Given these clinical and experimental data, we sought to investigate the complement 
effector mechanisms involved in the development of emphysema. To address the role of 
the complement system in disease development we utilized a 6 month cigarette smoke 
exposure mouse model that models emphysema. Several complement deficient strains 
were employed to dissect the complement effector mechanisms that contribute to disease 
development. Mice deficient in C1q/MBL (blocking activation of the classical and lectin 
pathways), C3 (blocking all complement activation pathways), factor B (blocking the 
alternative pathway and amplification loop) and lastly, C6 (blocking assembly of the 
membrane attack complex (MAC)). Since C5 deficient mice were unavailable on a 
C57BL/6 background, we addressed the role of C5 in emphysema development by 
treating mice with anti-C5 monoclonal antibody throughout the cigarette smoke 
exposure. Following 6 months of cigarette smoke exposure, lung histology and the 
inflammatory profiles of the mice were evaluated to determine the role of complement 
proteins in the pathogenesis of emphysema. 
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3.2 RESULTS  
3.2.1 Complement Protein Expression and Activation in the Lungs Following Chronic 
Cigarette Smoke Exposure 
Previous work from our laboratory, and others, has shown an increase in complement 
protein production in the lungs following acute smoke exposure (91-96).  Cigarette 
smoke exposure leads to oxidative stress, neutrophil elastase, MMP12 release that have 
all been shown to cleave and activate complement (90). Here we investigate the degree of 
complement activation and complement protein expression levels in the lungs following 
6 months of smoke exposure. Immunohistochemistry studies demonstrate an increase in 
C3d deposition on the vasculature and epithelial cells in a similar pattern to that seen in 
human studies, demonstrating cigarette smoke mediated activation within the lungs that is 
specifically targeting respiratory tissue (Figure 3-1a). Analysis of lavage fluid shows an 
increase in C3 and C5 as quantified by western blot analysis (Figure 3-1b) in smoked 
animals as compared to non-smoked controls. The liver is the major source of 
complement proteins, however, extra-hepatic sites, such as the lungs are known to 
generate their own complement proteins (7, 198). To assess whether smoking induces 
increase complement production in-situ in the lung we performed RT-PCR analysis of 
C3, C5, fB, C9, C3aR and C5aR (Figure 3-1c). We show that chronic smoke exposure 
leads to elevated complement gene transcription. We see no C9 expression, which is 
consistent with previous findings in lung tissues (199). While complement can be made 
by a number of cell types, infiltrating immune cells, endothelial cells, and respiratory 
epithelial cells, it is thought that the terminal complement proteins are not produced in 
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large quantities in these extra hepatic sites (7, 198). C3aR and C5aR expression were 
significantly elevated by smoke exposure, which is in keeping with our acute exposure 
studies and in-vitro culture model. These data present here build on our acute exposure 
studies that demonstrated that complement deficiency, specifically C3 and fB, and 
complement receptor blockade leads to reduced inflammation and lung injury. The 
presence of complement proteins, complement activation, and increased complement 
gene expression, together with our acute exposure data, and clinical studies showing 
complement activation in human plasma and tissues, provides evidence that complement 
may play a role in the pathogenesis of emphysema. To explore this we next utilized 
several complement deficient mouse strains to determine the key complement effector 
mechanisms and pathways involved in the development of emphysema.  
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Figure 3-1 Complement Protein Transcription and Deposition in the Lungs Following Chronic 
Cigarette Smoke Exposure. Following 6 months of smoke exposure mouse lung tissue was analyzed 
for complement activation and transcription. (A) Representative images of C3d staining indicates 
increased complement deposition in lungs of mice that were exposed to cigarette smoke for 6 months 
compared to their non-smoke controls, demonstrating localized complement activation. Original 
magnification 40x, scale bar 20µM. (B) Western blot quantification of C3 and C5 proteins in lung 
bronchiolar lavage fluid samples from smoke exposed and non-smoked control mice. n=4-6, data 
represented as mean ± SD *p<0.05, **p<0.01. (C) Real time-PCR analysis of complement protein gene 










3.2.2 Complement Deficiency Protects Against Emphysema Development During Chronic 
Cigarette Smoke Exposure 
Following six months of cigarette smoke exposure the lungs were inflated with formalin 
and analyzed by histological assays to determine the degree of lung injury. Hematoxylin 
and eosin staining of lung sections demonstrated the characteristic pathological changes 
associated with chronic smoke exposure, increased parenchymal tissue damage, mucus 
hyperplasia of the airway epithelial cells, and increases in macrophage and sub-epithelial 
neutrophil infiltration (Figure 3-2a). For non-bias stereological histomorphometry 
sections from each of the 7 study groups where assessed for the degree of lung damage 
by calculating the mean linear intercept (MLI) values as previously described (139, 200). 
MLI data demonstrate an increase in tissue destruction in wild type mice following 6 
months of cigarette smoke exposure. Similar to our findings in the acute exposure model, 
and recently published data, C3-/-, fB-/-, anti-C5 monoclonal antibody blockade and C6-/- 
resulted in a significant reduction in lung injury as compared to wild type controls 
(Figure 3-3b) (90). While not significant when compared across all groups the greatest 
protection was seen in fB-/- mice, with fB-/- associated with significantly less damage than 
wild type and anti-C5 depleted smoked exposed mice.  
 
Although several different deficiencies could be utilized to further investigate the 
mechanism of how complement deficiencies were protective, we choose to focus on the 
role of the alternative pathway following chronic smoke exposure. The rationale for 
focusing on the alternative pathway is two fold: 1. Clinically, it would be ideal to block 
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alternative pathway amplification of the complement pathway, thus keeping the 
remaining pathways intact, allowing for pathogen and apoptotic cell opsonization and 
clearance. 2. Previous studies have highlighted the pivotal role that the alternative 
pathway, specifically fB, has in direct cigarette smoke mediated complement activation 
(92-96, 201). Therefore, for the remaining studies factor B deficient mice were utilized to 
investigate the role of the alternative pathway in cigarette smoke induced inflammation 
and to investigate the mechanisms by which fB-/- provides protection from emphysema 





Figure 3-2: Complement Deficiency Protects Against The Development of Cigarette Smoke 
Induced Emphysema. After 6 months of cigarette smoke exposure the degree of emphysema in the 
lungs was quantified by morphological analysis measurement (A) mean linear intercept (MLI). Data 
indicated increased airspaces in wild type mice following 6 months of cigarette smoke exposure when 
compared to non-smoke controls. Complement deficient strains were utilized to delineate the role of the 
complement system is disease development. Note several deficiencies were protected from disease 
development. n=11-15 data represented as mean ± SEM p-values noted on graphs. (B) Representative 
hematoxylin and eosin stained section. Original magnification x20.  
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3.2.3 Complement Deficiency Reduces Complement Activation Within the Lungs 
Following Chronic Smoke Exposure 
To investigate the effects of complement deficiency on complement activity within the 
lungs we first looked at the gene expression of several complement proteins through RT-
PCR analysis. Blocking one arm of the complement cascade, the alternative pathway (fB-
/- mice), results in decreased expression of several key complement proteins, including 
C3, C5 and C3a receptor (Figure 3-3a). Furthermore, there is a significant reduction in 
C3d deposited on the lung tissue in fB-/- mice when compared to wild type (Figure 3-3b) 
demonstrating a reduction in complement activation. These data show that when blocking 
the alternative pathway mice are protected from enhanced complement activation, 










































































Figure 3-3 Complement Protein Transcription in the Lungs Following Chronic Cigarette Smoke 
Exposure. Complement protein expression and activation were evaluated in the lungs by real time-PCR 
analysis and immunohistochemistry. (A) Gene transcription demonstrates reduced expression of 
complement proteins within the lungs of factor B deficient mice when compared to wild type following 
6 months of cigarette smoke exposure. β-actin was utilized as the housekeeping gene and data was 
normalized to strain matched non-smoke controls. (B) Immunohistochemistry staining for C3d 
deposition indicates reduced complement protein deposition on lung tissue in complement deficient 
mice when compared to wild type controls following 6 months of cigarette smoke exposure. Original 





3.2.4 Complement Deficiency Dampens the Innate Immune Response During Emphysema 
Development 
Following complement activation, complement cleavage fragments assist in the 
activation and recruitment of innate immune cells. Neutrophils and macrophages express 
anaphylatoxin receptors (C3aR and C5aR) on their cell surface. Following association of 
complement anaphylatoxins with their receptors, innate immune cells will migrate to the 
site of injury and activate to amplify the pro-inflammatory response (4, 5, 126, 202, 203). 
Differential counts of cellular infiltrates in bronchoalveolar lavage (BAL) of wild type 
and fB-/- deficient mice show a significant reduction following chronic smoke exposure in 
complement deficient mice when compared to wild type (Figure 3-2a). Specifically, there 
is a reduction in neutrophils and macrophages; innate immune cells that are known to 
play a significant role in emphysema development, indicating protection from the 
cigarette smoke mediated inflammatory response within the lungs (Figure 3-2b-d) (53, 





Figure 3-4: The Effect of Complement Deficiency on Infiltrating Immune Cells Following Chronic 
Cigarette Smokes Exposure. Bronchoalveolar lavage fluid (BAL) was collected from wild type and 
complement deficient mice following 6 months of smoke exposure to evaluate infiltrating immune cells 
in the lungs. (A) Factor B deficient mice had a reduction in the total number of cell. Specifically, fB-/- 
had a reduction in infiltrating neutrophils (B), macrophages (C) and lymphocytes (D), key immune cells 
that are known to play a significant role in emphysema development. Data demonstrates a protection 
from the enhanced innate immune response in the lung in complement deficient mice. n=4-8, data 



























3.2.5 Factor B Deficient Mice Have Reduced Pro-inflammatory Cytokine Levels in the 
Lungs Following Chronic Cigarette Smoke Exposure 
The development and progression of emphysema is complex pathogenesis with 
contributing roles from both the innate and adaptive immune response. Pro-inflammatory 
cytokines production from both arms of the immune response show increased levels of 
several key cytokines, including KC, MIP-2, IL-6, IL-1β, IFN-γ, within the lungs during 
chronic cigarette smoke exposure (52, 102, 207). In fB-/- deficient mice there is a 
significant reduction in several pro-inflammatory cytokines, suggesting protection from 
an overwhelming inflammatory response within the lungs (Figure 3-5). Furthermore, RT-
PCR analysis from lung tissue demonstrates increase gene transcription from cytokines of 
the Th1 and Th17 immune response in wild type mice following 6 months of cigarette 
smoke exposure that were decreased in our fB-/- mice, demonstrating modulation of the 
adaptive immune response as well (Figure 3-6a).  Interestingly there was decreased 
expression in cytokines associated with a regulatory T cell response, TGF-β and IL-10 
(Figure 3-6b), in factor B deficient mice. The lack of regulatory cytokine production 
could be due the reduced levels of inflammation within the lungs of the complement 
deficient mice when compared to the overwhelming inflammatory response in the lungs 
of wild type. Previous publications demonstrate an increase in IFN-γ and IL-17 
producing T cells in COPD patients and mouse models following chronic smoke 
exposure (208, 209).  Flow cytometry analysis from splenocytes shows a significant 
increase in IL-17 CD4+ and CD8+ T cells in wild type mice following chronic smoke 
exposure, however no difference in IFN-γ, although CD8+ IFN-γ levels were evaluated 
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when compared to non-smoke controls (Figure 3-6c).  Interestingly, there was not 
significant difference in factor B deficient mice following chronic cigarette smoke 
exposure and there was a significant decrease when comparing to wild type mice. These 
data demonstrate protection of the potential IL-17 driven adaptive immune response in 
our complement deficient mice, which could protect these mice from the potential 


































































































































































































Figure 3-5: The Effect of Complement Deficiency on Pro-inflammatory Cytokine Levels. 
Following 6 months of cigarette smoke exposure pro-inflammatory cytokine levels from lung tissue 
homogenates were assessed via ELISA analysis. Note that factor B deficient mice were protected from 
the increased levels of many of the pro-inflammatory cytokines following chronic smoke exposure. All 
cytokine levels were normalized to total protein from homogenate preparation. n=11-15 all statistical 





Figure 3-6: The Effect of Complement Deficiency on the Adaptive Immune Response. Real time 
PCR analysis of Th1, Th17 (A) and Treg (B) cytokines from lung tissue samples demonstrates reduced 
transcription of all evaluated T cell cytokines in factor B deficient mice compared to wild type 
following chronic cigarette smoke exposure, suggesting modulation of the T cell response in the lungs 
of complement deficient mice. (C) Flow cytometry analysis from splenocytes further support 
modulation of the T cell response in complement deficient mice, as indicated by a reduction in 
circulating IFNγ and IL-17 producing CD4+ and CD8+ T cells in fB-/- mice when compared to wild type 
















































































































































































































3.2.6 Reduction in Tertiary Follicular Formations within the lung of Complement 
Deficient Mice During Emphysema Development 
Following chronic cigarette smoke exposure there is an increase in infiltrating adaptive 
immune cells into the lungs of mice. The antigen that is driving the adaptive immune 
response remains unknown. In patients with late stage COPD adaptive immune cell 
infiltrates can form ectopic follicular formations within the lungs and whether these 
structures are beneficial or pathogenic remain under debate (210, 211). Complement 
cleavage fragments, such as C3a and C5a, can prime the adaptive immune response by 
lowering the threshold for antigen uptake in B cells and enhancing proliferation and 
survival of T cells (7, 8, 212). APRIL and BAFF are two B cell ligands that have been 
reported in B cell hyper-reactive conditions, such as transplant rejection and 
autoimmunity. Furthermore, the ligand CXCL13 and its receptor CXCR5 are associated 
with lymphoid tissue generation and groups have demonstrated blocking their interaction 
prevents tertiary structure formation (213). RT-PCR analysis from lung tissue of wild 
type mice shows an increase in transcription in all these B cell associated genes, which 
was not seen in the fB-/- mice following chronic cigarette smoke exposure (Figure 3-7). 
Interestingly, when looking histologically at the lung tissue of the mice, fB-/- mice show a 
significant reduction in the number of cellular aggregates within the lungs as well as the 
number of follicular formation (Figure 3-8a, b, d), demonstrating protection from 
potential pathogenic lymphoid structures. Surprisingly there were no significant 
differences in the perivascular follicular formations, suggesting that factor B deficient 
mice were protected from the seeding of the lymphocytes within the lungs, resulting in 
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protection from the tertiary lymphoid structures (Figure 3-8c). Moreover, RT-PCR data 
show comparable levels of CXCL13 expression within the lung tissue and reduced 
expression of its receptor CXCR5, further supporting a possible protective mechanism 
preventing lymphocyte seeding within the lungs, thereby reducing follicle formation 







Figure 3-7 Reduction in B Cell Ligand Transcription in the Lung of Complement Deficient Mice. 
B cell ligands associated with lymphoid tissue development were evaluated from lung tissue samples 
from mice following chronic cigarette smoke exposure. Data demonstrates a reduction in transcription 
for several of the B cell ligand genes in factor B deficient mice when compared to wild type smoke 
exposure, demonstrating a potential protective mechanism from potential pathogenic lymphoid 
follicular formation. n=4. APRIL: a proliferation inducing factor, BAFF: B cell Activating Factor, SDF-






































































Figure 3-8 Follicular Formation Quantification Following Chronic Cigarette Smoke Exposure. 
(A-D) Cellular aggregates and lymphoid follicles were quantified in the lungs of wild type and factor B 
deficient mice. Note the significant reduction in cellular aggregates and follicles around the bronchi in 
complement deficient mice. n=11-15 data represented as mean ± SEM, all p-values are noted on graphs. 
Original magnification x1.25 (top panel images) and x20 (bottom panel imaged) bottom panel scale 
bars, left image 50µM, right image 20µM. 
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3.2.7 Reduced Serum Autoantibody Levels in Factor B Deficient Mice Following Chronic 
Cigarette Smoke Exposure 
Histological data demonstrates the presences of tertiary lymphoid structures within lung 
of wild type mice following chronic smoke exposure, which are absent in our 
complement deficient animals. To investigate the potential pathogenic role of these 
lymphoid structures we measured autoantibody levels from serum samples from each 
group. Recent publications have found an increase in autoantibodies levels specific to the 
respiratory extracellular matrix proteins in patients during late stages of COPD (134, 138, 
211). Furthermore, in a publication from Lee et al, the group demonstrates increase anti-
elastin antibodies in the plasma of COPD patients and enhanced production of IFN-γ 
from T cells of COPD patients following elastin stimulation, suggesting an autoimmune 
component to the disease (177). When analyzing extracellular matrix autoantibodies 
levels within our mice, we found a significant increase in anti-collagen IgM and IgG 
(Figure 3-8a) as well as anti-elastin IgM (Figure 3-9a) levels in wild type mice following 
6 months of cigarette smoke exposure.  There was no significant difference in anti-
decorin IgM or IgG (Figure 3-10). Interestingly there was no significant change in any of 
the autoantibody levels in the fB-/- mice, demonstrating that by blocking the alternative 
pathway mice are protected from a potentially autoimmune component to emphysema 
development. Evaluating the different IgG subclasses, data shows a significant increase 
in anti-elastin IgG2b and anti-elastin IgG3 in wild type mice following chronic smoke 
exposure, which once again was absent in our fB-/- mice (Figure 3-9b). Importantly, 
IgG2b is one of the isotypes that can activate the complement cascade, suggesting a 
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possible mechanism of disease propagation. Following chronic cigarette smoke exposure 
there is an increase in complement activating antibodies, therefore blocking activation of 

























































































































































































































































































































































































































































Figure 3-9: Complement Deficiency Reduced Anti-Collagen Autoantibody Production During 
Emphysema Development. Anti-collagen (A) IgM and IgG levels were measured in the serum by 
ELISA method of mice following chronic cigarette smoke exposure. ELISA data shows a significant 
increase anti-collagen IgM and IgG (a) in the serum of wild type mice when compared to non-smoke 
controls following chronic smoke exposure, however with no significant difference in any of the IgG 
isotypes (B). Note that were was no significant difference in any anti-collagen autoantibody levels in 
factor B deficient mice when compared to their non-smoke controls following chronic cigarette smoke 









Figure 3-10: Complement Deficiency Reduced Anti-Elastin Autoantibody Production During 
Emphysema Development. Serum anti-elastin (A) IgM and IgG levels were measured by ELISA 
method of mice following chronic cigarette smoke exposure. ELISA data shows a significant increase 
anti-elastin IgM (a) and also a significant increase in anti-elastin IgG2b and IgG3 (B), similar to anti-
collagen data there were was no significant difference in autoantibody levels in factor B deficient mice 
when compared to their non-smoke controls. n=5-14 data represented as mean ± SD p-values noted on 
graphs. 
 































































































































































































































































































































































































































































































































Figure 3-11: Complement Deficiency Reduced Autoantibody Production During Emphysema 
Development. Serum anti-decorin IgM and IgG antibodies were also measure via an ELISA. Data 
demonstrates no significant difference in anti-decorin IgM or IgG levels in the serum of mice following 




3.2.8 Factor B Deficient Mice Are Protected From Autoantibodies Generation Against 
Oxidatively Modified Proteins 
Although there are elevated levels of anti-elastin and anti-collagen antibody levels in the 
serum of mice following chronic smoke exposure, it has been debated whether or not 
these autoantibodies are truly pathogenic or just biomarkers of disease. A recent 
publication from Kirkham et al. investigates a potential modification process in the lungs 
that could generate neo-epitopes that drive disease progression in the lung during 
emphysema progression (214). Carbonyl-modified proteins are generated to evaluate the 
potential role of oxidative stress in disease development. We generated carbonyl-
modified antigens from mouse albumin (215). MSA was incubated with whole cigarette 
smoke extract (3) or malondialdehyde (1), an oxidizing component of cigarette smoke. 
Serum autoantibody levels in wild type mice for anti-CSE modified MSA IgM and IgG 
as well as anti-MDA modified MSA IgG were increased, however this was not seen in 
the fB-/- mice (Figure 3-11a and Figure 3-12a).  Interestingly there was a significant 
increase in the level of anti-CSE modified MSA and anti-MDA modified MSA IgG2a, 
which is a complement activating IgG subtype (Figure 3-11b and Figure 3-12b).  Once 
again, there was no significant difference in isotype levels in the fB-/- CS exposed mice 
when compared to their non-smoke controls.  These data demonstrate a possible 
complement activating mechanism following long term cigarette smoke exposure through 
antibody mediated activation and by blocking amplification of the complement cascade 











































































































































































































































































































































































































































































































































































































Figure 3-12: Autoantibody Levels Against Cigarette Smoke-Modified Proteins in Serum 
Following Chronic Smoke Exposure. Mouse serum albumin was oxidatively modified with 
cigarette smoke extract (3) to generate neo-epitopes. ELISAs measured the IgM and IgG antibody 
response in the serum against the CSE-modified neo-epitopes. Note the significant increase in anti-
CSE modified MSA IgM and IgG (A) which was not seen in factor B deficient mice.  Interestingly, 
there was significant increase in anti-CSE MSA IgG2a levels (B), which is a complement activating 














































































































Figure 3-13: Autoantibody Levels 
Against Cigarette Smoke-Modified 
Proteins in Serum Following Chronic 
Smoke Exposure. A second component 
of cigarette smoke, malondialdehyde (1), 
was utilized to oxidatively modify 
albumin.  There was a significant 
increase in anti-MDA modified IgG (A) 
and IgG2a levels (B), similar to the CSE-
MSA data, supporting the hypothesis 
that a modification of lung proteins 
could be driving autoantibody 
production. n=5-14 data represented as 
mean ± SD p-values noted on graphs. 
 
































































































































































































































































































































































































































































3.2.9 Complement Deficiency Protects against Lung Function Decline Following 
Chronic Smoke Exposure 
Chronic cigarette smoke exposure can lead to irreversible lung tissue destruction, which 
results in decline in lung function. By utilizing a whole body plethysmograph lung 
function was measured following 6 months of cigarette smoke exposure. Data 
demonstrated in our wild type mice a significant increase in enhanced pause (2) and time 
of expiration (Te), signifying a disruption in normal respiration. Interestingly, factor B 
deficient mice did not have a significant difference in lung function levels following 6 
months of cigarette smoke, demonstrating protection from breathing obstruction. These 
data suggest that complement based therapy will protect in modulating the inflammatory 
response within the lung during emphysema development to protect from lung tissue 































































Figure 3-14: Protection of Complement Deficient Mice from Lung Function Decline Following 
Chronic Smoke Exposure. Lung function analysis demonstrates that factor B deficient mice were 
protected from airway hyporesponsiveness (PenH) and a delay in their time of inspiration, 
demonstrating protection from respiratory destruction. Data represented as mean ± SEM, n=3-4, p-




Chronic inflammation can lead to uncontrolled complement activation resulting in, direct 
and indirect complement-mediated tissue damage, as has been described in conditions, 
such as sepsis, systemic lupus erythematosus (SLE), rheumatoid arthritis and asthma 
(122, 152, 216-223). In these conditions, and inflammation in general, excessive 
complement activation can overwhelm the hosts complement regulatory mechanisms, 
which can result in enhanced recruitment and activation of immune cells, cytokine 
release and complement-mediated lysis. Given complements important roles in chronic 
inflammatory diseases and the available clinical data demonstrating increased 
complement activation in emphysema patients, here we analyzed the role of complement 
in emphysema using a mouse model of total body cigarette smoke exposure (98, 99, 197). 
 
One of the leading risk factors for emphysema development is cigarette smoke exposure, 
which has been shown to directly cleave complement proteins into their biologically 
active fragments, specifically, C3a, C3b, Ba, Bb, C5a (91-96). In this aim, we sought to 
investigate whether complement activation contributes to emphysema and further define 
which complement effector mechanisms/effector molecules play a role in pathogenesis of 
emphysema. Our protein and RNA studies demonstrate that 6 months of cigarette smoke 
exposure in our mouse model results in an increase of lung complement protein 
production, which included significant increases in C3, C5, and anaphylatoxin receptors, 
C3aR and C5aR.  In keeping with previous reports we did not demonstrate C9 gene 
expression in the lung, as it is thought that the local production of terminal pathway 
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proteins are restricted as a in-situ control mechanism to protect against non-specific lysis 
(199). Further, in keeping with human data, we showed that cigarette smoke exposure 
results in complement deposition, C3d, in the lung microvasculature and on epithelial 
cells of the large and small airway in a similar pattern to that seen in human samples (99). 
Taken together, the increased complement gene expression, receptor expression, protein 
deposition and clinical correlative studies lead us to analyze the impact of complement 
deficiency on the development of emphysema (197).  
 
Having determined that the mouse model contains many of the complement deposition 
and activation features seen in human clinical studies, we next looked to determine 
whether complement activation and deposition were associated with disease development 
(98, 99, 197). Using a panel of complement deficient, or inhibited mice, we sought to 
investigate whether complement deficiency provided protection from emphysema, and 
further to determine which specific complement components were involved. We used 
histopathological measurements for our end-point analysis of protection from 
emphysema. Our computerized non-bias random field acquisition, mean linear intercept 
(MLI) measurements, demonstrated that C3-/-, fB-/-, anti C5mAb treated, and C6 deficient 
mice were protected from emphysema developed, but not C1q/MBL deficient. These data 
support roles for C3, the alternative pathway, C5a, and the membrane attack complex, 
and infer that antibody and Lectin binding are not key to the development of emphysema.  
 
Our findings with C3 deficient mice which lack the central complement component C3, 
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are in keeping with a recent paper that similarly shows that C3-/- protects against 
emphysema development. In these new studies the authors propose a novel mechanism 
whereby C3a interacts with C3aR on lung resident dendritic cells to promote T cell 
activation and lung destruction. Their conclusions are supported with studies in C3aR-/- 
mice, which show a similar level of protection (90). While the studies focus on T cell 
responses little attention is paid to the innate immune cell response, or the B cell antibody 
responses that are characteristic of the disease. C3 is the convergence point for all 
activation pathways and cleavage leads to the generation of C3a and C3b (163, 165). The 
anaphylatoxin C3a is largely responsible for recruiting and activating immune cells, 
enhancement of pro-inflammatory cytokine release, and as demonstrated by Heeger et al 
priming and proliferation of T cells. C3 deficient mice also lack C3b, a key component in 
the C5 convertase complex, inhibiting mice from C5 convertase assembly thus blocking 
terminal pathway initiation, thereby impeding complement-mediated lysis (6, 203, 224, 
225). C3b is also a parent protein to opsonization fragments, iC3b, C3d and C3dg, all of 
which are recognized by complement receptor 2 (CR2), which is highly expressed on B 
cells, fragments that act as natural adjuvants to enhance antigen recognition and uptake 
(160, 188, 189). We show following 6 months of cigarette smoke exposure there is 
increase complement deposition within the lungs, therefore mice lacking C3 deposition 
fragments are also potentially protected from opsonin-mediated inflammation and 
complement induced cell death (225, 226). While C3 is central in the conically described 
complement activation pathways, other mechanisms independent of Classical, Lectin and 
Alternative pathways may also activate complement. Neutrophil elastase, cigarette 
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smoke, matrix metalloproteinase 12, and thrombin have all been shown to activate C3, 
and to a lesser extent C5 independently of conical complement activation pathways, and 
are present at high levels in smoke injury models (90, 94, 95, 227-230). Therefore, while 
C3-/- are protected from emphysema, it is likely that C5 activation may still persist in 
these animals, and induce cell lysis and inflammation explaining the lack of complete 
protection seen here.   
 
Factor B deficient mice have impaired alternative pathway activation due to the proteins 
role in stabilizing assembly of the C3 convertase. By targeting the alternative pathway, 
factor B deficient mice are also protected from amplification of the complement cascade, 
and as our data shows, blocks the development of emphysema. Several inflammatory 
conditions have demonstrated the protective benefits of targeting only the alternative 
pathway, such as ischemic stroke, transplantation, systemic lupus erythematosus, age-
related macular degeneration (1), and further demonstrate benefits over complete C3 
inhibition (116, 231-236). Analysis of MLI between C3-/- and fB-/- were not significantly 
different, indicating the alternative pathway is required for amplification of complement 
activation in emphysema development. The potential mechanisms for protection are 
likely to be the same as in C3-/- mice. Complement opsonins are important for the 
clearance of apoptotic bodies and impairment of this process is associated with 
autoimmunity. It is therefore possible that by inhibiting the alternative pathway 
selectively that apoptotic cell clearance will be largely unaffected and the development of 
autoantibodies and autoimmunity reduced in fB deficiency as compared to C3 deficiency. 
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This would be an interesting area to follow in more detail in future studies. 
 
C6 deficient mice and mice given anti-C5 therapy throughout the course of cigarette 
smoke exposure were also protected from emphysema development, implying important 
roles for C5 and the membrane attack complex. C6 deficient mice lack the ability to 
assemble the membrane attack complex and therefore are protected from complement-
mediated lysis (225, 226). In addition to lysis, sublytic concentrations of the MAC have 
been shown to promote pro-inflammatory signaling mechanisms, including protein 
kinases, pro-inflammatory gene transcription, reactive oxygen generation and 
endoplasmic reticulum stress (225). Therefore the lack of C6 hypothetically impairs 
emphysema development through reduction in antibody-mediated injury and a reduction 
of inflammation. 
 
Similar to C6 deficient mice, anti-C5 treated mice have impaired MAC assembly. In 
addition, anti-C5 treatment prevents the cleavage of C5, thereby blocking generation of 
the anaphylatoxin C5a. C5a, which is often referred to as the more potent anaphylatoxin, 
assists in immune cell recruitment, pro-inflammatory cytokine release, vasoconstriction 
and vessel permeability, and like C3a, helps orchestrate a rapid innate and adaptive 
immune response (27, 161, 202, 221, 237). By blocking C5a production these mice are 
potentially protected from all aforementioned inflammatory mechanisms, resulting in 
protection from lung tissue destruction. While anti C5mAb therapy provided protection 
from emphysema development, as indicated by mean linear intercept measures, the level 
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of protection seen in C3 and fB-/- was significantly better. This observation may suggest 
that components of the complement pathway downstream of C5 are important disease 
modulators, or may point towards incomplete C5 blockade by anti-C5 mAb, given the 
data in C6-/- mice. We administered the antibody at a dose previously described (238) to 
provide effective serum inhibition of C5. Further, we confirmed serum inhibition of C5 
using the chicken red blood cell assay as previously described, and demonstrated 
systemic inhibition as compared to wild type smoke exposed animals (239). We did not 
however directly determine the effect of C5 mAb on local pulmonary expression and 
function of C5. Our PCR data demonstrated that C5 is produced locally in the lung and is 
exacerbated by smoke exposure. Therefore, whether systemic inhibition translates to a 
significant decrease of C5 of pulmonary origin (C5-po) has not been determined. It is 
possible that local production of C5 by epithelial cells (we have demonstrated this in a 
recently submitted paper) in response to smoke exposure may contribute to the local 
complement mediated inflammation. We further explore this question in the next chapter 
that focuses on the application of complement therapeutics for the treatment of pre-
existing emphysema.   
 
Interestingly, C1q/MBL deficient mice were not protected from emphysema 
development, even though one of the proposed mechanisms of emphysema disease 
development and progression is autoantibody induced inflammation (138). Since 
C1q/MBL-/- mice lack immune complex (IC) recognition, which is an important 
mechanism for apoptotic cell clearance, these mice are more susceptible to developing 
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autoimmune diseases, such as SLE (122, 217, 218, 231, 236). In cigarette smoke induced 
inflammation one of the postulated mechanisms for disease progression addresses the 
imbalance of increased apoptosis without sufficient regeneration of lung tissue (107, 
108). A key homeostatic mechanism of the classical complement pathway is recognition 
and clearance of apoptotic cells (117-120). Therefore, without sufficient clearance of 
apoptotic cells resulting from cigarette smoke induced inflammation, C1q/MBL-/- mice 
could have a secondary inflammatory response within the lungs, an avenue that falls 
beyond the scope of this study, but that should be explored in the future. 
 
Taken together these chronic smoke exposure studies clearly demonstrate a role for the 
complement system in the pathogenesis of emphysema. The results demonstrate that the 
alternative pathways and terminal pathways are key in disease development, and that 
C1q/MBL recognition/pathways are not specifically required. While these results provide 
promise for future therapeutic studies, they also provide caution regarding the limitations 
of the chronic smoke exposure model. Autoantibodies have been suggested to play 
important roles in the propagation of autoimmune diseases and have further been 
implicated in the pathogenesis of emphysema (158, 159, 168, 177, 211, 240-243),. It was 
therefore an unanticipated finding that C1q-/-, a key component of antibody recognition 
and complement cascade activation, that these mice were unprotected. The chronic 
smoke exposure model has been shown to have a biphasic immunological response. 
Initially, smoke exposure promotes an intense innate immune cell driven (neutrophil and 
macrophage) protease induced injury, which due to chronicity of the inflammation and 
	  
82	  
smoke exposure, eventually swings towards adaptive immune response characterized by 
anti-extracellular matrix specific T and B cell responses, with neutrophil and macrophage 
involvement subsiding with time (159, 178, 244-247)). This pattern has been described 
clinically, and explains some of the early confusion from studies with T cell genetic 
deficient animals. The role of T cells in emphysema development initially was largely 
ignored, due in the most part to the lack of protection afforded to Rag1-/- and SCID mice 
that were chronically exposed to cigarette smoke (248, 249). It was not until the 
application of specific T cell depletion studies (187), and T cell adoptive transfer 
experiments that the important role of T cells in disease development and progression 
were accepted (248). The same could be true here with our data. For instance, given that 
autoantibodies do not start to appear in significant quantities until 4-6 months following 
smoke exposure, after prolonged inflammation breaks tolerance to neo-antigens, the lack 
of protection seen in C1q/MBL-/- mice may be more related to the late exposure of the 
lung autoantibodies then to C1q/MBL not being important in emphysema pathogenesis 
(168). Whereas C3-/- and fB-/- deficiencies likely inhibit innate immune responses from 
the initiation of smoke exposure, which may provide protection from protease induced 
lung injury, thus directly delaying adaptive responses, and/or inhibiting adaptive immune 
responses directly.  
 
As described above, and previously published studies (90), deficiency in C3 is likely to 
lead to protection from emphysema developed via multiple effector systems, yet blocking 
all complement activation pathways systemically is probably not ideal for therapeutic 
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intervention in emphysema patients, as these patients are at increased risk of respiratory 
infections (88, 250). Mean linear intercept analysis identified several different points 
along the complement cascade to target therapeutically. Complement proteins take part in 
homeostatic mechanisms, control of infectious agents, and apoptotic cell clearance. 
Therefore, choosing a target for intervention is complex and is likely to impair host 
immune functions (224). Targeting the alternative pathway of complement activation will 
leave the remaining activation pathways intact, while reducing the amplification and 
spontaneous activation of the complement cascade; thereby its inhibition may be an ideal 
target for the therapy of emphysema. Therefore, given our results we sought to more 
thoroughly characterize the protective phenotype seen in factor B deficient mice by 
dissected the impact of alternative pathway deficiency on both the innate and adaptive 
immune responses seen in chronic smoke induced emphysema.  
 
We found that deficiency in factor B lead to reduce innate immune cell infiltration and 
reduced innate immune cytokine profiles (MCP-1 KC, IL-1β, TNF-α) as compared to 
wild type controls. Complement activation fragments are important mediators of 
inflammation by their direct chemotactic properties and ability to promote pro-
inflammatory cytokine release by innate immune cells, respiratory epithelial cells, and 
endothelial cells (28, 29, 80, 161, 251, 252). Here we demonstrated that lung complement 
deposition and anaphylatoxin levels were significantly reduced in fB-/- as compared to 
wild type controls, which correlated with reduce innate immune cell infiltration and 
cytokine release. These findings are in keeping with data in acute lung injury models, 
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such as acute cigarette smoke exposure, paraquat injury and lung injury secondary to 
remote organ ischemia, were alternative pathway deficiency, inhibition or C3aR/C5aR 
antagonism reduced lung inflammation, pro-inflammatory cytokine release and injury 
(253, 254). Here in our chronic cigarette smoke induced lung injury model we similarly 
demonstrate that sustained inhibition of innate immune mechanisms, reduced neutrophil 
and macrophage infiltration as a consequence of fB deficiency. 
  
It has been recently postulated that lung injury in emphysema patients progresses even 
upon smoking cessation, a feature that has lead many to suggest that emphysema has an 
autoimmune component (159, 178, 211, 244, 245). Initial evidence for this assumption 
came from human correlative studies, which demonstrate that lung immune cell infiltrates 
persist at supra-normal levels following smoking cessation. Further, studies by Hogg et 
al., and others, identified the presence of ectopic follicular formations in COPD patients 
that appeared to increase concomitantly with disease severity (178, 211, 213, 255, 256).  
These follicles were shown to be composed of B and T cells, and follicular dendritic cells 
(133). Development of tertiary lymphoid organs (TLO), and specifically B cell follicles, 
is a key feature associated with autoimmunity and is controlled by the expression of key 
chemokines, such as CXCL13. In a recent study blockade of CXCL13 in a mouse 
cigarette smoke exposure model lead to reduced B cell follicles; however, blockade alone 
did not significantly impair emphysema development (213). Again the absence of a 
disease modifying effect in these studies could again be related to the choice of model, 
where an intact innate and T cell response in these experiments provided sufficient injury 
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to promote emphysema development. However, as these features are key pathological 
and phenotypic phenomenon associated with emphysema we explored the presence of B 
cell follicles and aggregates in our model system. Overall fB-/- was associated with a 
reduction in T and B cell infiltration. In fB-/- airway lymphocyte follicles were 
significantly reduced as compared to wild type mice. Airway and vascular lymphocyte 
aggregates were not significantly different between groups, but parenchymal aggregates 
were different reduced in fB-/- mice. Given that there was an overall reduction in B cell 
numbers and follicular formation in fB-/- we investigated the presence of key B cell 
migratory, maintenance and follicle formation factors by qRT-PCR.  
 
APRIL (a proliferation including ligand), BAFF (B cell activating factor), SDF-1 
(Stromal cell-derived factor 1) are key B cell ligands that assist in B cell growth, survival 
and migration, respectively. Pathologically, elevated serum levels APRIL and BAFF 
have been identified in autoimmune conditions, such as SLE and arthritis. Blocking 
associated of APRIL and BAFF with their receptors reduced symptoms in experimental 
mouse models, demonstrating a pathogenic role for the ligands during autoimmune 
development (257-261). Therefore, increase concentrating of BAFF in the serum could 
lead to over-reactive B cells, further lead to formation of tertiary follicles homing 
autoantibody production. Interestingly, our data shows factor B deficient mice had 
reduced levels in many of the B cell ligands, indicating protection from this hyper-
reactive B cell state. Factor B deficient mice had reduced follicles in the lungs along with 
reduced serum autoantibodies, demonstrating protecting from the pathogenic B cell 
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response following chronic cigarette smoke exposure. Furthermore, CXCL13, a key 
chemokine for TLO development and organization, showed no difference between the 
two experimental groups. Interestingly, CXCL13 remained elevated yet its receptor 
CXCR5 was reduced, suggesting possible a receptor mediated reduction or simply 
reduction of infiltrating B cells within the lungs. In a publication addressing the role of 
CXCL13 in emphysema progression, Litsiou et al shows increase expression of CXCL13 
in the lungs of patients when compared to non-smoke controls (262). Further, Brake et al 
attempts to delineate the role of CXCL13 in a mouse model by treating mice with anti-
CXCL13 during chronic cigarette smoke exposure. Data demonstrate anti-CXCL13 
treated mice were protected from follicle formations in the lungs, however due to an 
ongoing innate cell and T cell response in the lungs emphysema persisted (213). These 
data indicate a potential role of CXCL13 in emphysema progression, however also 
highlights the contributing role of the innate and T cell immune response, both that 
remained elevated in anti-CXCL13 treated mice, in lung tissue destruction. Investigating 
the therapeutic potential of anti-CXCL13 treatment following cigarette smoke exposure, 
may provide information on the potential clinical benefits of blocking lymphoid tissue 
formation. 
 
Interestingly, our data demonstrate that although factor B deficient mice have increased 
aggregates within the lungs they are protected from follicular formations, the site of 
potential autoantibody generation and auto-reactive T cell programing. Once again this 
could be due to a delayed inflammatory response with the complement deficiency and if 
	  
87	  
allowed enough time factor B deficient mice could develop similar. 
 
The pathogenic significance of these TLO structures and the specific antigens driving this 
adaptive immune response remain unknown, but groups have begun to investigate 
different potential candidate antigens. Given that B cell proliferation and TLO are 
associated with autoantibody production a number of groups have analyzed serum 
samples for the presence of specific autoantibodies in emphysema patients and rodent 
models. Brandsma et al. describes an autoantibodies response against extracellular matrix 
proteins following chronic cigarette smoke exposure (138), while others have looked into 
a protein modification process within the lungs, which could generate modified self-
proteins as a result of long-term cigarette smoke exposure (263, 264).  These newly 
modified proteins could be a stimulus for continued inflammation, through a loss of self-
tolerance, in the lungs after smoking cessation. Taken together these data suggest that 
there is evidence of an autoimmune response against both extracellular matrix proteins, 
as well as cigarette smoke modified proteins. Interestingly, here in our studies we clearly 
demonstrate the presence of autoantibodies against extracellular matrix proteins, and 
smoke modified proteins in our wild-type CS exposed animals, and that this autoimmune 
response was not seen in factor B deficient mice. This significant reduction in 
autoantibody response seen in factor B deficient mice may result because of a reduction 
in complement opsonization of auto-antigens, thus reducing the affinity of the B cell 
response, or maybe due to a dampening of the innate inflammatory response, thus 
reducing injury and potentially simply delaying the development of autoantibodies. If fB-
	  
88	  
/- mice were given a longer cigarette smoke exposure period they may eventually develop 
similar pathologies as wild type mice at 6 months. We, and others suggest that modified 
proteins within the lungs drive the underlying autoimmune component to emphysema 
progression, and the absence of alternative pathway activation provides protection by 
simply reducing the infiltrating immune cell burden, thus reducing the oxidative/smoke 
post translational modification of self proteins. An alternative hypothesis is that the 
reduction in complement activation could reduce B cell activation. Activation of the 
complement system generates opsonins (iC3b, C3d, C3dg), which are known to be a 
natural adjunct for antigens during antigen presentation to B cells.  Opsonin coated 
proteins lower the threshold for B cell recognition up to 10,000 fold when compared to 
non-coated proteins, demonstrating an essential role of complement in priming the 
humoral adaptive immune response (160, 188, 189, 265). Therefore in fB-/- were 
complement activation is reduced within the lungs; one could predict opsonization of 
antigens to be reduced.  
 
The pathogenic significance of autoantibodies is unclear, as is the reduction in 
autoantibody levels in fB-/-. Autoantibodies to a variety of extracellular matrix proteins, 
dsDNA, ANCA, and smoke modified proteins, have been demonstrated to increase in 
human and rodent studies, and to correlate with disease severity (158, 168, 177, 180, 240, 
242, 243, 246). Complement plays a key role in antibody effector functions, with 
antibody binding resulting in complement activation. We screened the serum of smoke 
exposed mice for autoantibodies using a panel of target specifies previously described in 
	  
89	  
the literature (168, 177, 180, 242). We demonstrate that smoke exposure increases 
circulating autoantibody levels in wild type animals, a feature that is not seen in fB-/- 
mice. The complement system is a major effector arm of the antibody response, but not 
all antibody isotypes activate the complement system. To more thoroughly interrogate the 
autoantibody response, we isotyped the main autoantibody specificities as seen in our 
cigarette smoke exposure model. In addition to elevated IgM antibodies, we were able to 
demonstrate that the major isotype elevated by smoke exposure in all tested specificities 
was IgG2a and 2b, both complement activating isotypes. Tissue antibody binding would 
lead to increased complement activation and complement mediated cell injury/death 
(266, 267). Therefore, the significant elevation in IgM, IgG2a and IgG2b in wild type 
demonstrates a potential mechanism by which the complement system participates in 
inflammation and injury in emphysema.  
 
In addition to B cell humoral responses recent novel studies have demonstrated a key role 
for complement in driving T cell responses. Local production of complement proteins at 
the cellular level by antigen presenting cells (APC) and T cells has been shown to 
promote T cell signaling, survival, and cytokine skewing. These novel studies 
demonstrate that C3a and C5a signaling promotes the proliferation of Th1 and Th17 
effector cells (6-8, 13, 194, 195, 268, 269). Inhibition of C3a and C5a signaling on the 
APC or the T cell can promote T regulatory cell expansion (6, 13, 194, 195). In 
emphysema a predominant Th1 and Th17 T cell response within the lungs of patients and 
experimental animals has been noted and associated with disease development, 
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progression and severity. Further, mice deficient, or depleted, of either of these T cell 
subsets, are protected from emphysema development (208, 209, 270). In our studies, we 
demonstrate reduced lung T cell infiltration and reduced splenic populations of CD4 and 
CD8 IFNy and IL-17 producing T cells in fB-/-, as compared to wild type smoke exposed 
mice. These findings are in keeping with a recent study that shows deficiency in C3-/- or 
C3aR-/- leads to reduced IFNy and IL-17 T cell responses in the lungs of smoke exposed 
mice (90). The authors suggest that C3a generated by cigarette smoke, elastases, and 
MMP12 acts in an autocrine fashion to stimulate the up regulation of C3aR on lung 
resident dendritic cells, the up regulation of which, promotes naïve T cell Th1 and Th17 
proliferation and differentiation (90). fB-/- may impair this autocrine stimulatory pathway 
via two potential mechanisms. Firstly, fB-/- significantly reduced expression of 
complement activation fragments in the lung microenvironment, which potentially would 
significantly reduce DC C3aR expression, leading to a reduction in DC/T cell interactions 
and Th1/Th17 T cell responses. Evidence for this comes from the reduced gene 
transcription levels for C3aR, IL-17 and IFNy levels in fB-/- smoke exposed mice and 
reduced overall T cell infiltrate. Secondly, the role of complement in APC and T cell 
interactions is thought to be directed, not only by local environmental concentrations of 
complement, but also from the production of complement components by APCs. 
Important to this local cell production of complement for co-stimulation of T cells is fB 
production. Therefore, the absence of fB in APCs in fB-/- animals may also impair APC/T 




Data presented here demonstrates a role for the complement system in cigarette smoke 
induced emphysema development. Mice with a sufficient complement system have 
increased complement protein transcription, along with complement deposition fragments 
on lung tissue signifying local activation. We demonstrate that mice, specifically the 
alternative pathway deficient, were protected from the overwhelming inflammatory 
response seen within the lungs following cigarette smoke exposure, resulting in a 
protection from lung tissue damage. Although our data provides information regarding 
the complement systems involvement in the development of emphysema, how 
complement protein deficiency specifically modulates the inflammatory responses to 
exert protection from lung damage and emphysema is difficult to dissect in these standard 
rodent emphysema model systems. The complement system bridges innate and adaptive 
immune responses, and can directly participate in each arm of the immune response 
independently of each other, and we have shown that fB-/- reduces factors of both arms 
(162). Whether the inhibition in T and B cell responses seen in fB-/- animals is due to a 
direct interaction with these systems or manifests as initial innate immune responses are 
dampened early after smoke exposure are unclear. Importantly, clinically patients seek 
therapy after emphysema has begun. The first clinical treatment for cigarette smoke 
induced emphysema is for the patient to quit smoking. Therefore a more clinically 
relevant study would be to address the role of the complement system following cigarette 
smoke cessation. Emphysema patients have ongoing inflammation and heighten oxidative 
stress within the lung following smoking cessation, indicating an ongoing continuous 
inflammatory response (244). Knowing that the complement system can modulate both 
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the innate and adaptive immune response during active smoking, investigating its role 
following smoking cessation could lead to potential therapeutic targets for a disease 
lacking therapeutic options, and is addressed in the subsequent chapters.  
 
One FDA approved complement therapeutic Eculizumab, a monoclonal antibody targeted 
to block C5 cleavage for the treatment of patients suffering from paroxysmal nocturnal 
hemoglobinuria (PNA) and atypical hemolytic uremic syndrome (aHUS) (271), is a 
potential therapeutic option. In the pathogenesis of these two inflammatory conditions 
there is an increase in complement activation without sufficient regulatory protein 
expression on red blood cells, leading to their lysis.  By blocking at the C5 point of the 
complement cascade, it protects patients from membrane attack complex (MAC) 
formation, thereby keeping RBCs intact (224, 272, 273). Given that we demonstrate C5 
and MAC blockade provides protection from emphysema, and that in particular C5a can 
shape adaptive immune responses the application of a clinically available inhibitor to 
emphysema patients could provide protection (225, 226). A second complement 
therapeutic is C1 esterase inhibitor (C1-INH). C1 inhibitor is a regulatory protein that 
complexes with classical pathway proteins C1, and cleared via the liver. Additionally, the 
inhibitory protein complexes with free C1 to prevent an autoreactive complement 
activation. Patients that have low levels or are completely deficient of C1-inhibitor are at 
increase risk to develop hereditary angioedema (HAE) is a genetic disorder in which 
patients lack functioning C1-INH, resulting in tissue swelling due to enhanced 
complement activation (272-274). Treatment options for these patients in reconstitution 
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with exogenous CI-inhibitor attempting to bring suboptimal levels back to normal (275). 
Since autoantibody production is one of the underlying mechanisms driving emphysema 
progression, utilizing C1-inhibitor may offer beneficial effects following chronic smoke 
exposure and could be investigated in future experimentations.   
 
With the successful application of Eculizumab clinically and the burgeoning knowledge 
of the role of complement in innate and adaptive immune responses the interest in the 
design, construction and delivery of complement therapeutics has never been greater. 
Here we demonstrated the important role that complement plays in emphysema 
development and in doing so identified another disease conditions that may benefit from 




DETERMINE THE EFFICACY OF COMPLEMENT THERAPEUTICS 




Emphysema is a growing health epidemic with a rising mortality rate. Current treatments 
for emphysema patients are aimed to alleviate symptoms rather than target the disease 
itself, which is due to its complex pathogenesis (155, 206, 276). Patients are prescribed 
bronchodilators to open up the airways when breathing becomes restricted and broad-
spectrum steroids to dampen the inflammatory response within the lungs (277). 
Unfortunately, there are a large percentage of patients that develop steroid resistance, 
making treatments ineffective (207, 278), and a recent American Thoracic Society report 
has questioned their use as best practices therapeutics. Over the past decade human and 
experimental data has identified key immune cells that infiltrate the lungs during disease 
onset and progression, and have tested strategies to therapeutically target these cell types 
to ameliorate disease. These collective studies have identified that cells of the innate 
immune system, neutrophils, monocytes and macrophages, invade the lungs during the 
early stages of disease development, with their numbers declining upon smoking 
cessation (129, 187, 204, 206, 246, 279-282). Despite the reduction in numbers, 
following smoking removal, the lungs still have a significantly elevated protease burden, 
which has also been targeted for treatment (244, 276, 283). In addition to innate immune 
cells, more recent studies have begun to demonstrate an increasingly important role for 
the adaptive immune system, not only in disease development, but also in disease 
progression post smoking cessation. Elegant studies by Tuder et al., and Motz et al., have 
shown that emphysema has an autoimmune component, with the presence of autoreactive 
T cells detected in human studies associated with disease severity, and adoptive transfer 
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of these T cells shown to induce emphysema in naïve animals (106, 248). Further, recent 
animal studies have shown the potential benefit of T cell depletion, either through anti-
CD4/8 or cyclosporine therapy (187). In these studies depletion of T cells prior to, 
during, or post smoking cessation leads to reduced disease in smoke exposed animals. 
While these approaches proved efficacious the broader application to human studies are 
not without risk. Broad spectrum T cell depletion in emphysema patients may have 
significant off target effects, such as increased infectious complication, loss of tumor 
immune surveillance, and increased incidence of acute exacerbations.  
 
Human histological studies have identified the presence of increased B cell aggregates in 
the lungs of emphysema patients, which increased organization and size with increasing 
severity of emphysema. These B cell aggregates form tertiary lymphoid organs (TLOs) 
predominantly around bronchiole or vascular structures in the lung (178). The 
pathophysiological significance of these structures is as yet unclear. It is hypothesized 
that these structures contribute to the local secretion of autoreactive antibodies, although 
animal studies, are yet to definitively confirm this. Emphysema patients often have 
elevated serum concentrations of autoreactive antibodies, with specificities identified 
against extracellular matrix proteins (elastin, collagen, decorin), smoke modified 
proteins, and anti-nuclear antigens (168, 180, 284, 285). In keeping with the B cell data 
the pathogenic significance of these antibodies is unclear, and is explored in chapter 5 of 
this thesis. Based on available data it is believed that TLOs and autoantibodies lead to 
inflammation, complement opsonization, and tissue injury (99, 178, 266, 267). Currently 
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no specific therapies have been employed to reduce B cell numbers and function in 
emphysema.  
 
Even though key innate immune cells have been identified in the pathogenesis of 
emphysema, targeting products of these cells, i.e. neutrophil elastase inhibitor, 
metalloproteinase inhibitor and/or IL-8 receptor antagonist, has shown little clinical 
benefits (178, 283). Therefore, identification of additional targets that reduces both innate 
and adaptive immune functions, while sparing host immune mechanisms are greatly 
needed.  
 
One immune system that can modify both the innate and adaptive arms of the 
inflammatory response is the complement system (162). As previously described, the 
complement system can be activated by one of three pathways, all of which lead to 
several potent pro-inflammatory effector functions. Complement’s anaphylatoxins, C3a 
and C5a, recruit and activate neutrophils and macrophages to sites of inflammation and 
also take part in enhancement of T cell-antigen presentation and antigen presenting cell 
(APC) signaling (6, 286). Moreover, numerous studies have demonstrated that the 
complement anaphylatoxins can skew T cell responses. C3a and C5a anaphylatoxins can 
enhanced the proliferation of Th1 effector cells, whereas anaphylatoxin receptor 
antagonism (C3aRA and C5aRA, blockade of C3a and C5a signaling) promotes 
regulatory T cell expansion, emphasizing that complement anaphylatoxin levels and 
expression can modulate T cell effector functions locally (194-196). 
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Initially, the complement system was known for its role in “complementing” the humoral 
immune response by acting as an effector system to augment antibody functions. In 
addition to aiding antibodies the complement system also improves B cell function. 
Following the cleavage of C3 into its fragments C3a and C3b, C3b associates with the 
target cell surface and is further degraded to its long-lived opsonization fragments (iC3b, 
C3d, C3dg). Antigens that are coated in complement opsonization fragments lower the 
threshold for B cell recognition by 1000 fold, acting as natural adjuvants for B cell 
recognition (160, 189). C3 deficient mice that were challenged with the influenza virus 
were unable to effectively clear the virus, as indicated by increased viral load, decreased 
viral specific antibodies, and reduced IFNγ production by T cells, indicating an 
ineffective T cell and B cell response within these mice (287). Without sufficient 
complement activation both the innate and adaptive immune responses have reduced 
efficacy in initiating a robust inflammatory response, making it an ideal system to target 
during a chronic inflammatory condition that is characterized by both T and B cell 
elements. The complement system is an ideal inflammatory cascade to target since its 
activation fragments can modulate both arms in the immune response.  
 
As we have previously discussed evidence of complements role in emphysema patients 
comes from bronchoalveolar lavage fluid samples that have increase cleavage fragment 
levels (C3a and C5a), decrease lung expression of the regulatory complement protein 
(CD46), increased plasma concentrations of C3 that are related to disease severity, and 
increase lung complement protein deposition (C3d). Taken together these data, and the 
	  
99	  
data presented in Chapter 3, indicate a role for the complement system in the 
pathogenesis of emphysema (98, 99, 166).  
 
Our in vivo data from aim 1 demonstrates that mice deficient in key complement 
proteins, C3, fB, C5, and C6, were protected from cigarette smoke-induced emphysema 
development. Mice that were deficient in the alternative pathway (factor B-/-) were 
protected from air space enlargement, pro-inflammatory cell recruitment, and enhanced 
pro-inflammatory cytokine burden within the lungs, further emphasizing a role for the 
complement cascade in the pathogenesis of emphysema. While these data support a role 
for complement activation in disease development it provides very little information 
about whether complement inhibition would be a suitable target for therapeutic 
intervention. Our data demonstrates that deficiency in key complement proteins provides 
protection from emphysema development. Given that complement can shape the innate 
and adaptive responses it is difficult to dissect where these complement deficiencies are 
halting disease or delaying onset. For instance, fB-/- would impair neutrophil infiltration, 
cytokine production, and reduce direct complement mediated lysis acutely, so the 
protection seen chronically could be a consequence of reduce early damage, and this is 
why we saw a reduction in T and B cell effector functions. Support for this assumption 
perhaps comes from our C1q/MBL data. We, and others have shown that autoantibody 
levels are increased in emphysema, and it is postulated that autoantibodies could drive 
disease development. Given these data we would have anticipated that the absence of 
C1q, which promotes complements response to bound antibody, would also have 
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provided protection. However, while C1q/MBL would inhibit classical and lectin 
pathway activation, they would have done nothing to impair alternative pathway 
activation, our protease mediated complement cleavage and activation. These data are not 
that dissimilar to that seen with T cell studies in emphysema. The role of T cells in 
emphysema were overlooked for many years based on the results that Rag1-/- and SCID-/- 
mice where not significantly protected from chronic smoke exposure induced emphysema 
(248, 249). The reality of these findings is that the development of disease is phasic with 
early innate immune mediated damage leading to the development of adaptive immune 
response, which are caused by the chronic inflammatory condition. Therefore, to address 
the clinical scenario, inflammation ideally post-smoking cessation, an animal model that 
more readily reflects the clinic is greatly needed. 
  
To address the clinical benefits for targeting the complement system during emphysema 
progression we developed a novel rodent cigarette cessation model. Mice were exposed 
to cigarette smoke, as described previously in chapter 2. In brief, mice were exposed for 6 
months to allow for emphysema to develop, and then underwent a 12-week smoking 
cessation period. Here we present data that this model recapitulates the features seen in 
human disease, with animals demonstrating robust T and B cells responses, increased 
pro-inflammatory cytokine levels, and increased complement activation as compared to 
never smoking controls. Following establishment of this smoking cessation model we 
sought to investigate the therapeutic potential of two complement inhibitory compounds, 
CR2-fH (blocks the alternative pathway, and amplification of the complement cascade) 
	  
101	  
or anti-C5 (blocks the generation of C5a and initiation of the terminal pathway).   
 
The targeted complement therapeutic, CR2-fH, was created and characterized in the 
laboratory of Dr. Tomlinson (231). The CR2-fH protein is composed of two regions, the 
CR2 region, which recognizes the deposition fragments iC3b, C3d and C3dg, therefore 
localizes to sites with heighten complement activation, i.e. the lung following chronic 
smoke exposure. The inhibitory region contains the complement regulatory protein factor 
H, which specifically blocks the alternative activation pathway. By utilizing an 
alternative pathway specific inhibitor, mice that are treated with CR2-fH remain to have a 
functioning classical and lectin activation pathway to protect from non-cigarette smoke 
related inflammation. Additionally, administering a targeted-therapeutic prevents the 
potential side effects of systemic complement inhibition (231).  Previous studies 
demonstrate the benefits of CR2-fH in several inflammatory conditions, including but not 
limited to, intestinal ischemia reperfusion injury, irritable bowl disease (IBD), stroke, 
systemic lupus erythematosus (SLE), and acute lung injury demonstrating the protective 
potential in our cigarette smoke model (253, 288-291).  
The second complement therapeutic that was utilized for our cigarette smoke cessation 
studies was anti-C5, also referred to as Eculizumab. Anti-C5 systemically blocks the 
cleavage of the C5 component into its cleavage fragments C5a and C5b, thereby blocking 
the generation of the C5a anaphylatoxin, and formation of the membrane attack complex, 
respectively (163). Several inflammatory conditions have shown beneficial effects 
following anti-C5 treatment, including collagen-induced arthritis, cardiac transplant, and 
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lupus (292-295). Furthermore, anti-C5 is a clinically available treatment for patients 
suffering from Paroxysmal nocturnal hemoglobinuria (PNH), and off label use in organ 






4.2.1 Complement Activation in the Lungs Following Smoking Cessation 
There is evidence of persistent complement activation in the lungs emphysema patients 
by the ongoing generation of the anaphylatoxins in the BAL fluid and deposition of 
opsonization fragments on the lung tissue (98, 99, 180). Whether or not continued 
complement activation is taking part in the pathogenesis of emphysema or due to the 
increased infection rate in patients led us to the investigation the role of the complement 
system in disease development. We demonstrate in the first specific aim that complement 
deficiency protects against emphysema development, indicating a role for the 
complement cascade in its pathogenesis. Next, we planned to determine if the 
complement system remains activate following the smoking cessation period in our 
mouse model. To do this we measured anaphylatoxin, C3a and C5a, levels in the lavage 
fluid of mice. We found that even after three months of smoking cessation both C3a and 
C5a levels remain significantly elevated when compared to age matched non-smoke 
controls (Figure 4-1a), demonstrating sustained complement activation within the lungs. 
We also evaluated gene transcription of complement proteins within lung following 
smoking cessation in mice treated with complement therapeutics compared to non-treated 
controls. The data demonstrates continued elevated expression of several key 
complement proteins, C3, C5 and factor B, following three months of smoking cessation. 
However, in mice treated with complement therapeutics gene transcription of these 
proteins were significantly reduced (Figure 4-1b). These data demonstrate that the 
complement system remains activate following smoking cessation and complement 
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Figure 4-1: Complement Protein Expression in the Lungs Following Smoking Cessation. (A) 
ELISA measure anaphylatoxin, C3a and C5a, in the bronchoalveolar lavage (BAL) fluid of mice 
following 3 months of smoking cessation. (B) RT-PCR analysis determines complement protein 
expression in lung tissue following smoking cessation, with or without, complement therapeutics. n=4, 

































































































































4.2.2 Complement Therapeutics Protect Against Emphysema Progression 
Unfortunately, emphysema patients may not seek clinical help until a significant amount 
of the lung is damaged. According to the National Heart, Lung and Blood Institute 
symptoms progress slowly, therefore patients may not know that they have emphysema 
until a significant amount of lung tissue is damaged 
(http://www.nhlbi.nih.gov/health/health-topics/topics/copd/).  Therefore, we developed a 
smoking cessation model to address a more clinically relevant problem, the benefit of 
complement therapeutics following smoking cessation. Our smoking cessation model is 
described in detail in chapter 2. In brief, mice were exposed to 6 months of cigarette 
smoke to ensure emphysema development. Mice were then housed under normal 
conditions for three months, which is referred to as our cessation period. During smoking 
cessation mice either received complement therapeutics, CR2-fH or anti-C5, or PBS via 
i.p. injection. After the three-month smoking cessation period lungs were harvested and 
evaluated for disease progression by mean linear intercept (MLI) analysis. Figure 4-2b 
demonstrates a significant increase in MLI levels indicating increased airspace 
enlargement in mice following 6 months of cigarette smoke exposure (6m CS) that 
remained elevated even after smoking cessation (Control). These data show ongoing lung 
tissue damage, even in the absence of activate cigarette smoke exposure. Interestingly, 
when mice were given complement therapeutics, CR2-fH or anti-C5, their MLI 
measurements were significantly reduced as compared to cigarette smoke cessation 







Figure 4-2: Complement Therapeutics Protect Against Emphysema Progression Following 
Chronic Smoke Cessation. (A) Representative images of H&E stained lung tissue from mice 
following the cigarette smoke cessation model. Images indicate significant airspace enlargement 
following cigarette smoke cessation, which was reduced in mice given complement therapeutics. 
Original magnification x20. (B) Quantification of lung tissue destruction, which was conducted by 
mean linear intercept (MLI) measurements, shows protection from ongoing destruction following 
smoking cessation in mice treated with complement therapeutics. n=8-15 data represented as mean ± 






4.2.3 Complement Therapeutics Protect From Lung Function Decline 
A key outcome analysis to determine disease status of COPD patients is based on lung 
function analysis.  Pulmonary function tests measure how quickly a patient can move air 
throughout the respiratory tract and identify respiratory damage (296). Clinical data show 
ongoing lung function decline in patients even after smoking cessation (245). To 
investigate the lung function in our mouse studies we utilized a double chamber 
plethysmograph system to investigate any changes in lung function during the smoking 
cessation period with or without complement therapeutics. Lung function analysis 
demonstrates a significant increase in PenH, an indicator of bronchoconstriction and 
inflammation, suggests enhanced inflammation within the lungs following 6 months of 
cigarette smoke exposure. Interestingly, following three months of smoking cessation 
there is a decline in PenH values, which was further decreased in mice given anti-C5 
therapy demonstrating by reducing the amount of inflammation in the lung following 
anti-C5 therapy the lungs are protected from ongoing lung function decline. Although 
there was no significant difference in Te and EEP values in mice treated with anti-C5 
when compared to cessation controls, there was a significant reduction in cessation 
controls when compared to 6 month cigarette smoke exposed. Therefore, when the 
continuous cigarette smoke exposure is taking away, such as during the cessation period, 
the innate immune response subsides, potentially allowing for respiratory recovery. These 
data further support the need to do multiple analyses in disease progression in a cessation 




Figure 4-3:Complement Therapeutics Protect From Lung Function Decline. Lung 
function measurements were taken at both 6 weeks and 12 weeks post smoking cessation to 
evaluate lung function decline through, enhanced pause (2), time of expiration (Te) and end 
expiratory pause (EEP) analysis. Data indicate a significant increase in all three parameters 
following 6 months of cigarette smoke exposure. Mice given anti-C5 therapy were protected 
from continued lung function decline when compared to cigarette smoke cessation controls. 
Data represented as mean ± SEM; n=4-6, p-value noted on graph 
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4.2.4 Complement Therapeutics Protect Against Immune Cell Infiltrates 
Mean linear intercept analysis demonstrate protection from emphysema progression in 
mice given complement therapeutics when compared to mice that did not receive therapy 
following cigarette smoke cessation. Studies show that following 6 months of cigarette 
smoke exposure there is a persistent inflammatory response within the lungs that 
continues after smoking cessation (129, 244). The persistence in inflammatory cells 
infiltrating the lungs after smoking cessation highlights a potential mechanism of 
continued lung tissue destruction. Therefore, we sought to investigate the immune cells 
within the lungs and key innate cytokines levels to determine if complement therapeutics 
had an impact on mechanistic features. RT-PCR analysis of innate immune cytokines 
demonstrates increased expression of multiple cytokines following 6 months of cigarette 
smoke exposure as we have shown in aim 1. All innate pro-inflammatory cytokine 
expression levels remained elevated following 3 months of smoking cessation. 
Interestingly, mice given CR2-fH showed decreased expression in several of the 
cytokine, including KC, MCP-1, MIP-2 and IL-6, when compared to cessation control 
(Figure 4-4a). Furthermore, mice given anti-C5 therapy had reduced levels in all the 
innate cytokines except TNF-α, indicating differential effects of the complement 
therapeutics on the innate immune response. Since several of these cytokines are 
responsible for innate immune cell recruitment, we next wanted to investigate the 
potential effects of complement therapeutics. Differential cell counts were conducted on 
BAL fluid cells. Figure 4-4b shows sustained elevation of macrophage and lymphocytes 
in the lungs following 3 months of smoking cessation, which were significantly 
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decreased in mice treated with complement therapeutics. Interestingly, neutrophil counts 
significantly dropped following 3 months of smoking cessation, demonstrating a 
persistence in the macrophage and lymphocytes cell populations infiltrating the lungs 
following a cigarette smoke cessation period. These data demonstrate that following 
complement therapeutic treatment there are reduced levels of both innate and adaptive 
immune cells within the lungs, next we sought to distinguish the lymphocyte subtypes 






Figure 4-4: Complement Therapeutics Protect from Ongoing Inflammation in the Lung 
Following Smoking Cessation. The innate immune response was evaluated in the lungs of mice 
following cigarette smoke cessation. (A) RT-PCR analysis indicates elevated innate cytokines 
transcription post smoking cessation. n=4 (B) Differential cells counts demonstrate persistence in 
infiltrating macrophage and lymphocytes following smoking cessation and in mice given complement 






































































































































4.2.5 Complement Therapeutics Skews the Persistent Th1 and Th17 Response in the Lung 
Following Cigarette Smoke Cessation 
Through histological analysis Hogg et al. characterized the lungs of patients with COPD 
and subdivided them by GOLD stage. Furthermore, we determined that as patients 
progressed into the later stages of COPD there is an increase in T cells and B cells within 
the lungs and follicular formations, indicating a potential developing autoimmune 
phenotype (178). Moreover, investigation into the T cell immune response within the 
lungs of COPD patients reveals both a Th1 and Th17 skewing. IL-17 producing CD4+ T 
cells have been associated with several autoimmune diseases, such as rheumatoid arthritis 
and psoriasis, further supporting a potential autoimmune component in the pathogenesis 
of emphysema (140, 209, 297, 298).  
 
In our mouse studies we wanted to determine the T cell population that persists following 
smoking cessation. The number of T cells within the lung is small and difficult to extract 
due to fibrosis and elastic tissue damage. Therefore, we sought to characterize the T cell 
cytokine milieu by RT-PCR. We found that following smoking cessation transcription 
levels of both IFN-γ and IL-17 were elevated, paralleling the mixed Th1 and Th17 
response found in COPD patients. Furthermore, we demonstrated while all T cell 
cytokines were analyzed, Il-17, IL-2 and IFN-γ remained elevated; IL-17 remained at 
levels consistent with active smoking. Interestingly, when mice were given complement 
therapeutics during the smoking cessation period, both IFN-γ and IL-17 expression was 
reduced in the lungs, demonstrating a potential T cell skewing following treatment 
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(Figure 4-5a). Recently publications indicate a role for complement proteins in Th1 and 
Th17 skewing of T cells (194). Strainic et al. revealed that by blocking anaphylatoxin 
signaling on T cells there is an enhanced population of regulatory T cells, suggesting a 
potential target to induce tolerance (195). However, when we measured IL-10 and TGF-β 
expression levels within the lungs of mice that underwent smoking cessation we found no 
significant differences between mice that were given complement therapeutics and 
cessation controls (Figure 4-5b). To confirm our RT-PCR findings we next wanted to 


































































Figure 4-5: Adaptive Immune Cytokine Gene Expression Levels Following Smoking Cessation. 
Th1 and Th17 gene expression was evaluated in the lungs of mice following smoking cessation through 
RT-PCR analysis. (A) Note a reduction in both Th1 and Th17 cytokine transcription levels, 
demonstrating potential complement mediated skewing of the T cell response within the lungs. (B) 
Analysis of regulatory cytokine gene expression demonstrated reduced expression compared to activate 





4.2.6 Complement Therapeutics Prevents the Generation of Auto-Reactive T cell in the 
Lungs Following Smoking Cessation 
Emphysema is a Th1 and Th17 skewed inflammatory response within the lungs as 
indicated by increased IFN-γ and IL-17 producing T cells within the lungs if COPD 
patients (177, 208, 209). Furthermore, when mice were given antibodies blocking CD4+ 
and/or CD8+ T cells they were protected from enhanced inflammation within the lungs 
following chronic cigarette smoke exposure (187). A publication by Lee et al. 
demonstrates an elastin mediated IFN-γ T cell response in peripheral blood T cells from 
COPD patients, suggesting autoreactive T cells as a source of ongoing inflammation in 
the lungs of COPD patients (177). Therefore we next wanted to investigate the T cell 
response in our smoking cessation model. Mouse splenocytes were cultured in the 
presence of mouse lung elastin peptides or cigarette smoke modified elastin peptides for 
36 hours. Following elastin stimulation cells were activated with PMA/Ionomysin and 
analyzed for IFN-γ production by measuring cytokines levels in the cell supernatant. Data 
demonstrates an increase in IFN-γ secretion in cells from the smoking cessation mice 
when cells were stimulated with cigarette smoke modified elastin peptides, which was 
absent in both complement therapeutic treated moues groups (Figure 4-6b). Interestingly, 
elastin peptides did not appear to elicit a response from mouse splenocytes in the 
smoking cessation groups (Figure 4-6a), suggesting that modification of self-proteins 





  A	  
B	  
Figure 4-6 Autoreactive T cells Splenocytes Following Cigarette Smoke Cessation. Mouse 
splenocytes were incubated with or without elastin or CSE-modified elastin peptides (30ug/mL) in IL-2 
(5U/mL) media for 36hrs. Following peptide stimulation, cells were activated with PMA/ionomysin in 
the presence of monensin for 5 hours. IFN-γ levels were measured from the supernatants by ELISA 
method. Data demonstrates increased IFN-γ production following smoking cessation in cells stimulated 
with CSE-modified elastin peptides, which was not evident in mice treated with complement 































































































































































































































































































4.2.7 Complement Therapeutics Modulates the B Cell Response within the Lung 
Following Cigarette Smoke Cessation 
We showed with our complement deficient mice a reduction in B cell activation, 
migration and follicles. RT-PCR analysis in our smoking cessation model demonstrates 
similar trends in our mice treated with complement therapeutics, a reduction in gene 
transcription in several of the B cell ligands, including APRIL, BAFF, SDF-1 and 
CXCR5 (Figure 4-7a). Interestingly, similar to our factor B deficient mice, there was 
ongoing transcription in CXCL13, which was down in smoking cessation mice. 
Lymphoid follicles are tertiary structures that comprise of potentially autoreactive T cells, 
B cells and dendritic cells. They have been characterized as pathogenic in several 
autoimmune disorders, such as SLE and RA (299). In a recent publication by Hogg et al. 
histological analysis of lung tissue sections from patients from each stage of COPD 
demonstrate increase frequency and density of these lymphoid structures as patients 
proceed into late stages of disease (178). It has been argued that patients suffering from 
COPD have an increased risk for bacterial or viral infections due to the compromised 
lung status as disease progresses. However it remains to be established what is the 
function of these immune cell reservoirs in the lung (159). In chapter 3 we show a 
decrease in the number and density of lymphoid follicles in our complement deficient 
mice when compared to wild type (Figure 4-7b). We first addressed the role of our 
follicular formations following smoking cessation with or without complement 
therapeutics by analyzing chemokines that assist in structural formation. We found that 
following 3 months of smoking cessation both APRIL and BAFF were reduced; however 
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SDF-1 remained elevated. In our mice given CR2-fH or anti-C5 there was a reduction in 
the transcription of all three B cell proliferating ligands. Analyzing two additional genes 
that are associated with lymphoid structure formation, CXCL13 and its receptor CXCR5, 
we found that reduced transcription following smoking cessation, however CXCL13 was 






















































































































Figure 4-7 B Cell Activation and Migration Factor Expression Following Cigarette Smoke 
Cessation. Mice were exposed to cigarette smoke for 6 months than allowed a 3 month smoking 
cessation period and B cell ligands were analyzed by RT-PCR. Data demonstrates a reduction in the 
transcription of key chemokines that play a role in lymphoid structure development. B cell activation 
factors are reduced following smoking cessation with or without complement therapy treatment n=4  
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4.2.8 Targeted Complement Therapy Protects Against Autoantibody Generation 
Following Smoking Cessation 
Data from chapter 3 shows a significant increase in autoantibody production following 
chronic cigarette smoke exposure that was significantly reduced in our complement 
deficient mice. Next we addressed if the autoantibody responses persist following 
smoking cessation, and if so, do complement therapeutics modify their effector functions. 
Data demonstrates that elevated anti-elastin IgM levels persist following 3 months of 
cigarette smoke cessation (Figure 4-8). In mice treated with complement therapeutics 
there were also elevated levels of anti-elastin IgM autoantibodies. We found no 
difference in total anti-elastin IgG levels in our smoking cessation mice. Therefore we 
analyzed specific IgG isotypes to determine if any differences in sub-types were present 
(Figure 4-9). There was no significant increase in any of the anti-elastin IgG isotypes 
following smoking cessation period, which begs the question, could a modified proteins 
be driving the autoantibody response following smoking cessation.  
 
The next serum antibodies evaluated were cigarette smoke modified mouse lung elastin 
peptides. We found that following smoking cessation anti-CSE modified elastin IgM and 
IgG levels remained elevated when compared to non-smoke controls, however, mice 
given complement therapeutics also had elevated levels (Figure 4-10). When evaluating 
the IgG isotypes for CSE-modified elastin antibodies we found that following cigarette 
smoke cessation there were elevated levels of IgG2a, and IgG2b which are complement 
activating antibodies highlighting a potential complement mediated mechanism. 
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Surprisingly, All four isotypes were elevated in our CR2-fH treated mice and IgG2a were 
also significantly increased in anti-C5 treated mice (Figure 4-11). Even though 
complement treated mice have increased serum autoantibody levels they were protected 
from emphysema development, which led us to investigate complement mediated 




















































































Figure 4-8 Anti-Elastin Serum Autoantibodies Persist Post Smoking Cessation. ELISAs measured 
serum anti-elastin autoantibody levels in mice following 6 months of cigarette smoke, after 3 months of 
smoking cessation with or without complement therapeutics. Data demonstrates elevated anti-elastin 
IgM autoantibody levels following 3 months of cigarette smoke cessation. There were no apparent 
alterations in IgG levels, however there was a trend towards reduced IgG elastin in anti-C5 therapy. 
















































































































































































































































































































Figure 4-9 Anti-Elastin IgG Isotypes in the Serum Following Cigarette Smoke Cessation. Anti-
elastin IgG isotypes were measured in the serum of mice that underwent the cigarette smoke cessation 
model and was compared to 6 month cigarette smoke exposure. Interestingly, in mice given 
complement therapeutics, anti-C5 therapy suppressed isotype switching whereas CR2-fH did not appear 




































































































Figure 4-10 Anti-Cigarette Smoke Modified Elastin Autoantibodies in the Serum Following 
Cigarette Smoke Cessation. Following chronic cigarette smoke exposure there was a significant 
increase in anti-CSE-modified elastin autoantibodies in mice following cigarette smoke cessation. Anti-
C5 treated mice had a significant reduction in anti-CSE-elastin IgM levels when compared to cessation 





























































































































































































Figure 4-11 Anti-Cigarette Smoke Modified Elastin IgG Isotypes in the Serum Following 
Cigarette Smoke Cessation. Following chronic cigarette smoke exposure there was a significant 
increase in anti-CSE- modified elastin IgG2b antibody levels. However, although the levels were 
elevated at 6 months they did not reach significance. Interestingly, there was a significant increase in 
IgG2a levels following smoking cessation, a complement activating isotype. Complement inhibitory 
strategies had no significant impact on circulating IgG2b or IgG2a levels. Treatment with CR2-fH lead 
to significant increase in non-complement activating IgG isotypes, IgG1 and IgG3.  n=8-12, data 
represented as mean ± SD p-value noted on graph. 
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4.2.9 Complement Therapeutics Protect Against Antibody Mediated Complement 
Activation 
Complement inhibition during cigarette smoke cessation leads to reduced lung damage 
and immune cell infiltration, however, unlike our deficiency strains, inhibition has no 
significant impact on serum autoantibody levels. Similar findings were discovered in 
mice treated with anti-C5 in a model of collagen-induced arthritis. Mice were protected 
from clinical symptoms such as paw thickness and joint swelling; yet their antibodies 
levels remained elevated (292). The paper concluded the anti-C5 therapy was modulating 
the inflammatory response downstream of antibody binding; therefore we evaluated co-
localization of immunoglobulin and complement deposition fragment C3d within the 
lungs of mice. Representative images of immunofluorescent staining shows significant 
increase of IgM and C3d deposition in the lungs of mice following smoking cessation. In 
mice treated with CR2-fH and anti-C5 there was IgM deposition within the lungs with a 
significant difference noted in anti-C5 treated mice. However there was a significant 
reduction in C3d deposition. These data indicate that our complement therapeutics 
modulate antibodies induced inflammation post immunoglobulin deposition (Figure 4-
12).  
 
Immunostaining for IgG within the lungs we found no significant difference in mice 
following 3 months of smoking cessation when compared to non-smoke controls. 
However, there were elevated levels of IgG in both groups of mice given complement 
therapeutics. Increased IgG levels within the lungs could indicate the presence of 
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immunomodulatory IgGs following complement therapy especially insight of the 
increase IgG3 levels noted in CR2-fH treated mice. These IgGs could be inhibiting 
binding of pathogenic IgGs and/or taking part in the anti-inflammatory response by 
inducing inhibitory FcγR expression within the lungs in treated mice (300, 301) Future 
experiments are needed to investigate the specific IgG isotypes deposited in the lungs of 
mice following complement therapy. While binding of antibodies was not significantly 
altered in complement inhibited mice, the level of C3d deposition was significantly 
reduced in both treatment groups. Further, BAL C3a and C5a concentrations were 
significantly reduced, demonstrating that complement inhibition leads to reduced lung 
complement activation. Both inhibitors significantly reduced C5 and C5a levels. C5/C5a 
were not abolished by anti-C5 therapy suggesting local lung production of C5 as 






Figure 4-12 Co-localization of IgM and Complement Deposition Fragments in the Lung 
Following Smoking Cessation. Representative images demonstrate IgM-FITC (green) and C3d-Alexa 
555 (red) co-localizing in the lungs following cigarette smoke cessation, suggesting antibody-mediated 
complement activation. Mice given CR2-fH or anti-C5 have reduced C3d within the lungs, signifying a 
potential protective mechanism from complement-mediated inflammation. n=4, original magnification 











Figure 4-13 Co-localization of IgG and Complement Deposition Fragments in the Lung Following 
Smoking Cessation. Representative images show the IgG-FITC (green) and C3d-Alexa 555 (red) co-
localizing in the lungs following cigarette smoke cessation, demonstrating antibody-mediated 
complement activation. Mice given CR2-fH or anti-C5 have reduced C3d within the lungs, indicating 









   
Figure 4-14 Quantification of IgM, IgG and C3d Deposition Within Lung Tissue From Cessation 
Groups. Computerized image analysis of (A) IgM (B) IgG (C) C3d following smoking cessation. Note 
that complement inhibition reduced IgM binding and C3d deposition. Measurement of complement 
anaphylatoxin levels as an indicator of complement activation shows that CR2-fH and anti-C5 
significantly reduce (D) C3a and (E) C5a concentrations. Data represented as mean ± SEM, n=4 
*p<0.05, **p<0.01, ***p<0.001 
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4.2.10 Complement Regulatory Protein Expression in the Lungs of Mice Treated With 
Complement Inhibitory Proteins 
IgM and IgG autoantibody serum and tissue levels were not significantly reduced by our 
anti-complement therapies. However, despite this lack of antibody modulation we 
demonstrate that the main effector mechanism of antibody binding, complement 
activation was significantly reduced as evidenced by complement deposition, activation 
and gene transcription. Complement activation is regulated on host cells by membrane 
bound complement regulatory protein expression. A recent article demonstrated that 
CD46 expression, a C3 convertase inhibitor, levels showed a correlation between reduced 
CD46 levels with increased clinical emphysema scores (166). Expression of complement 
regulators is impacted by the local inflammatory milieu, with a recent literature 
highlighting an IL-17-C3a axis regulating membrane complement regulatory protein 
expression (302). These data suggest that increased local C3a concentrations stimulate 
the release of IL-17, which in turn drives down complement regulatory protein 
expression, leading to comprised host anti-complement defenses and tissue injury. Our 
RT-PCR data demonstrates a reduction in IL-17 gene expression in the lungs following 
smoking cessation in complement therapy treated mice, and further shown reduction in 
BAL complement anaphylatoxin levels. Taken together the reduction in complement 
activation in treated mice despite autoantibody deposition may be impacted by host cell 
expression of membrane complement inhibitors. To investigate this we performed RT-
PCR analysis measuring complement regulatory protein expression (Crry and CD59) 
from the lungs of our experimental groups. We demonstrate that therapeutic complement 
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inhibition results in an increase in complement regulatory protein expression in treated 
mice, highlighting an additional anti-inflammatory mechanism by which the lungs of 
complement inhibited animals are protected.   
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Figure 4-15 Complement Regulatory Proteins Expression in the Lungs in Mice Treated with 
Complement Therapeutics. RT-PCR was utilized to analyze gene transcription of complement 
regulatory proteins Crry and CD59 from lung tissue. Note that CR2-fH or anti-C5 treated mice have 
increase complement regulatory protein expression in the lungs. Data signifies fold change from 




COPD is a growing health concern and according to the American Lung Association 
2010 hospitalization cost rose to 49.9 billion dollars, emphasizing the necessity of finding 
effective therapeutics (50). Targeting the innate immune system utilizing protease 
inhibitors and/or antibody depletion of innate cytokines has shown little efficacy in 
stopping disease progression (205, 283, 303). Even though the innate immune response is 
predominate in the lungs during disease development and remains elevated even after 
patients quit smoking. As emphysema progresses, adaptive immune cells, begin to 
infiltrate into the lungs, further complicating an already unclear pathogenesis (178). 
Groups have postulated the shift from an innate driven immune response to an adaptive 
one as an indicator for a developing autoimmune component to the disease.  
 
Data from specific aim 1 demonstrates that several of our complement deficient strains of 
mice (C3-/-, factor B-/-, C6-/- and mice treated with anti-C5 monoclonal antibody) were 
protected from emphysema development as analyzed by mean linear intercept analysis. 
We also demonstrate that by just targeting one arm of the complement system, the 
alternative activation pathway, we protected mice from emphysema development and 
keep the remaining pathways in tact to protect the lung from non-cigarette smoke related 
inflammation. From our initial studies we demonstrate a significant role of the 
complement system in propagating cigarette smoke mediated inflammation, in this aim 
we wanted to address the potential of complement therapeutics following cigarette smoke 
cessation, for a more clinically relevant model. 
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Initial treatment for cigarette smoke related disease is smoking cessation, attempting to 
delay damage of the remaining healthy lung tissue. Unfortunately, even after a patient 
quits smoking there is a continuous influx of immune cells into the lungs and oxidative 
stress levels remain elevated, leaving the lungs in a highly inflamed state (57, 159, 178). 
Here we present data demonstrating the development of a clinically relevant mouse 
model for the investigation of therapeutic strategies to reduce lung damage post smoking 
cessation. Mice were exposed to cigarette smoke for 6 months as described in detail in 
the methods chapter and following emphysema development they were allowed a 3 
month cessation period. Following the 3 month cessation period macrophages and 
lymphocytes remained significantly elevated in the lungs as compared to non-smoke age 
matched controls, similar to what is seen in patients. Additionally, Th1 and Th17 pro-
inflammatory cytokines expression remained elevated and autoantibodies persisted, 
demonstrating an ongoing adaptive immune response within the lungs even after the 
rapid innate response subsided. We demonstrate several similarities in our smoking 
cessation mice to what is reported in patient lungs, indicating an appropriate emphysema 
model for therapeutic studies (159, 211) 
 
Initial studies were to determine whether the complement system remains active 
following cigarette smoke cessation. Bronchoalveolar lavage fluid analysis indicates 
increase concentrations of anaphylatoxin C3a and C5a, and lung tissue shows increased 
gene expression of complement proteins following smoking cessation. Protein and RNA 
data indicate continued complement activation within the lungs demonstrating a potential 
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system to target for emphysema therapy. Therefore here we investigated the potential 
therapeutic efficacy of complement inhibition for modulation of disease progression.  
 
Our data from chapter 3 shows that by blocking the alternative activation pathway, mice 
were protected from both the innate and adaptive immune response, characteristically 
seen in chronic cigarette smoke induced inflammation. To address the role of the 
alternative pathways in our smoking cessation model we utilized an alternative pathway 
targeted complement therapeutic, CR2-fH. Additionally, for clinical significance we 
utilized FDA approved systemic inhibitory protein anti-C5, which blocks C5a generation 
and MAC formation, which is used for PNH therapy.  
 
CR2-fH is an inhibitor protein with two regions, targeting region (CR2), which 
recognizes activation fragments iC3b, C3d and C3dg and therefore will target to sites of 
heighten complement activation (i.e. the lungs). The second region is the inhibitor 
molecule; factor H (fH), a regulatory protein that inhibits the alternative activation 
pathway. CR2-fH is an ideal treatment since the molecule locates to sites of complement 
activation, yet does not block systemically complement activity (151). Furthermore, by 
utilizing inhibitory proteins of just the alternative pathway is leaves the classical and 
lectin pathways in tact, which may be crucial for emphysema patients since that are 
highly susceptible to respiratory infections (88, 250).  As mentioned previously, by 
targeting the alternative pathways CR2-fH treated mice blocks stabilization of the C3 





In addition to CR2-fH, we also investigated the effect of anti-C5 therapy during the 
smoking cessation period. In specific aim 1, mean linear intercept analysis shows that 
mice given anti-C5 throughout the course of the 6 month cigarette smoke exposure were 
protected from airspace enlargement when compared to wild type controls. Therefore we 
wanted to address the potential of anti-C5 in our smoking cessation model. Moreover, 
anti-C5 is currently a clinically available therapy for paroxysmal nocturnal 
hemoglobinuria (PNH), which is also a complement driven disease, and has shown to be 
beneficial in several inflammatory conditions, such as RA, SLE and transplantation (239, 
272, 292, 293, 295, 304). In mice given anti-C5 monoclonal antibody, C5 cleavage is 
blocked which prevents generation of its fragments C5a and C5b. By attenuating C5a 
concentration within the lungs, it could potentially reduce immune cell recruitment and 
activation as well as dampen Th1 and Th17 cell skewing that follows chronic cigarette 
smoke exposure. Additionally, blocking C5b will prevent membrane attack complement 
formation and will protect the mice from complement-mediated lysis or MAC mediated 
inflammation. 
 
In complement therapy treated mice, RT-PCR data demonstrates reduced expression of 
several complement proteins, including C3, C5 and factor B, when compared to smoking 
cessation mice, indicating complement inhibitions reduces in situ complement protein 
transcription. Mice given complement therapeutics were also comparably protected from 
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lung tissue destruction as indicated by reduced mean linear intercept values, the main 
histopathological analysis for emphysema that quantifies the amount of airspace 
enlargement in the lungs as compared to untreated controls. Additional analysis assessing 
lung tissue destruction was conducted by lung function analysis utilizing a double 
chamber plethysmography machine. Unfortunately, we were unable to collect lung 
function data for our CR2-fH treated mice. However, data from our anti-C5 treated mice 
demonstrate a significant reduction in PenH, a marker of bronchoconstriction indicating 
inflammation in the airways, when compared to smoking cessation controls. All these 
data taken together demonstrate the potential benefit of complement therapeutics for 
amelioration of cigarette smoke induced continuing lung damage. These data led us to 
evaluate the mechanisms by which these inhibitors induced protection.  
 
Investigating the immune profile within the lungs following smoking cessation data 
demonstrates a continued infiltration of predominantly macrophages and lymphocytes, 
similar to what is seen in emphysema patients. Interestingly, RNA data demonstrates 
reduced cytokine expression of several innate cytokines, such as KC, MCP-1, MIP-2 and 
IL-6, in both therapy treated groups when compared to non-treated controls. IL-1β 
expression was reduced in mice given anti-C5, yet there was no effect in those given 
CR2-fH. Interestingly, both therapies had no effect on elevated TNF-α levels, which 
could be beneficial for COPD patients for the cytokines role in fighting respiratory 
infections (52). Furthermore, differential cell counts from the lavage fluid show a 
significant reduction in infiltrating cells, demonstrating complement therapeutics 
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prevented immune cell recruitment into the lungs during smoking cessation. These data 
demonstrate that each complement therapeutic weakens the innate immune response 
within the lung, protecting lung tissues from ongoing destruction. 
 
As a bridge between the innate and adaptive immune response the complement system is 
an ideal target for chronic inflammatory conditions. Investigations into the effect of 
complement therapeutics on the adaptive immune response post smoking cessation 
demonstrates a dampening of Th1 and Th17 response within the lungs. Our RT-PCR 
analysis from lung tissues shows that T cell cytokine levels persist post-smoking 
cessation. While the level of gene transcription is evaluated for IFNγ and IL-2 as 
compared to controls it is reduced in smoking cessation as compared to acute smoking. 
IL-17 levels remain elevated at levels consistent to active smoking, perhaps suggesting 
that the IL-17 response plays a more prominent role in mediated T cell injury post 
smoking cessation.  
 
The influence of the complement system on the T cell response has recently become a 
central topic in the literature (6, 13). The identification of anaphylatoxin receptors on 
dendritic cells and T cells led to investigators analyzing the impact of the innate 
chemotactic peptides on the T cell fate. These studies lead to the novel hypothesis 
whereby APC produced complement facilitates T cell proliferation, skewing and function 
(6). Heeger et al. showed a predominate IFNγ response in DAF-/- mice following APC-T 
cell interactions that was ameliorated by anti-C5 treatment (7). Moreover, Strainic et al 
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demonstrated that complement anaphylatoxin signaling on naïve CD4+ T cells skews to 
the IFNγ producing Th1 cells where as in anaphylatoxin receptor deficient mice, had 
heighten FoxP3+ regulatory T cells (194, 195) Furthermore, Hashimoto et al shows that 
mice deficient in C5aR had a suppressed CD4+IL-17 response in a model of autoimmune 
arthritis, further emphasizing the impact of complement proteins on the T cells response. 
(269). With our complement therapeutics, by modulating complement activation in the 
lung microenvironment we potentially block availability of anaphylatoxins to associate 
with their receptors, which could be the protective mechanism reducing the Th1 and 
Th17 T cell responses, thereby protecting lung tissue from T cell mediated destruction.  
 
We sought to address the T cell populations seen in our model and to investigate if there 
was an antigen specific immune response. Clinical data demonstrates a correlation 
between elastin specific IFNγ producing T cell and disease severity in COPD patients, 
indicating a potential autoreactive T cell response in the lungs as disease progresses 
(208). Mouse splenocytes were simulated with or without elastin peptides or cigarette 
smoke modified elastin peptides. ELISAs were utilized to measure IFNγ production in 
the supernatant of splenocytes following CSE-modified elastin simulation within the 
spleen of mice following smoking cessation, indicating an antigen specific T cell 
response to a cigarette smoke modified proteins. Furthermore, in splenocytes from CR2-
fH or anti-C5 treated this CSE-elastin specific T cell response was suppressed, indicating 
disruption of the complement-IFNγ axis. By blocking complement activation we 
potentially could be blocking autoreactive T cells generation that response to alter self-
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proteins, such as elastin peptides and CSE-modified elastin peptides. These data 
demonstrate that by utilizing complement inhibitor proteins we are potentially protecting 
mice from this autoimmune feature for emphysema progression. 
 
We also anticipate modulation of the B cell response by complement therapeutics during 
cigarette smoke cessation since there was a reduction in follicular formations in our 
complement deficient mice following chronic smoke exposure and serum autoantibody 
levels. RT-PCR analyses of B cell activation (BAFF), proliferation (APRIL) and 
migration (CXCL12, CXCL13) ligands were evaluated during acute smoking. 
Interestingly, the only ligand that remained elevated following smoking cessation was 
stromal derived factor-1 (SDF-1), which is also a ligand for progenitor cells indicating a 
possible fibrotic mechanism during the cessation period. Little is known about the factors 
that promote lung regeneration, or whether regeneration is possible following chronic 
smoke induced injury. However, given the increase in SDF-1 and improve lung function 
investigations into stem cell recruitment, lung regeneration and lung remodeling may be 
interesting in this novel model system. Complement therapeutics did appear to reduce 
most of the B cell ligands, however mice given anti-C5 have increased expression of 
APRIL and both complement treated groups have increase expression of CXCL13, a 
chemotactic ligand for B cells. CXCL13 is a chemoattractant for B cells released from 
stromal cells and dendritic cells that assists in follicle formation. In follicle rich lung 
tissue samples from COPD patients there is increase expression of CXCL13 and its 
receptor CXCR5 (262). Furthermore, Bracke et al. demonstrates that in vivo blockade of 
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CXCL13 during chronic cigarette smoke exposure let to a reduction of B cell follicles 
within the lungs of mice, however this did not fully protect mice from CS induced 
inflammation (213). Morissette et al. addressed the role of tertiary lymphoid tissue 
persistence in the lung following 60-120 days of smoking cessation, demonstrating 
increased accumulation of these structures throughout the lungs (246). Conclusions from 
this paper suggest that the innate immune response subsides during cessation, however 
the increase growth of follicles home autoantibodies, which perpetuates disease. 
Although we demonstrate continued ligand expression to support lymphoid structure 
formation in our complement therapeutic group there is decreased expression of its 
receptor, CXCR5, indicating a possible receptor down regulatory as the protective 
mechanism. Another explanation of reduced CXCR5 expression could simply be from a 
reduction of infiltrating B cells in the lung due to the dampened inflammatory response 
following complement therapy. RT-PCR data demonstrates differential effects of 
complement therapeutics on B cell migration and proliferation. Futures studies are 
needed to delineate the effect of treatment follicle formation and the pathogenic 
significance of tertiary lymphoid tissue.  
 
It remains debated whether or not these lymphoid structures and their products, 
autoantibodies, are helpful or harmful in the lungs following chronic smoke exposure. 
Our complement deficient data demonstrates a reduction in follicles, although not 
aggregates, in the lungs of factor B deficient mice, and no significant increase in any 
autoantibodies measured. Therefore we investigated the autoantibody response in our 
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smoking cessation mice treated with complement therapeutics, and examined the elastin 
autoantibody response, We opted to focus our studies of elastin antibodies given that 
elastin peptides have been shown to drive cigarette smoke induced emphysema in mice, 
and clinical studies demonstrating evidence of anti-elastin T and B cell responses in 
human emphysematous patients (177, 208, 305). In addition to investigating an elastin 
response, we also modified elastin peptides with cigarette smoke to address the potential 
of an altered form of self-antigen driving disease. In the anti-elastin response we did see a 
continued elevated levels of anti-elastin IgM following smoking cessation, however 
complement treated mice also had elevated levels. There was also no significant 
difference between anti-elastin IgG. Evaluating the different IgG isotypes we found no 
significant increase following smoking cessation, even though levels were elevated at 6 
months in IgG2b and IgG3. There was a significant increase in CR2-fH IgG2a levels 
when compared to cessation mice, yet no significant difference when compared to non-
smoke controls. Interestingly, all IgG isotypes were suppressed in mice given anti-C5 
therapy, indicating a potential role of C5a and/or MAC in influencing antibody 
generation. Even though CR2-fH treated mice block at the alternative pathway C5 can be 
independently cleaved by other sources, such as thrombin, therefore MAC may be 
playing a significant role in emphysema progression (230).  
 
Kirkham et al. highlights the potential of a carbonyl-modification process in the lungs 
that could oxidatively modified self proteins leading to alter forms of self antigen driving 
disease progression (180). To address a potential modified epitope driving disease we 
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modified elastin peptides with cigarette smoke extract and measured autoantibodies in the 
serum of mice following smoking cessation with or without complement treatments. Data 
demonstrates elevated anti-CSE modified elastin IgM and IgG levels following smoking 
cessation, however once again our CR2-fH treated mice also had increased levels. Anti-
C5 mice trended upward, but did not reach significance, when compared to non-smoke 
controls. Investigating the different IgG isotypes there was only an elevated IgG2a 
response following smoking cessation. IgG2a is a potent activator of the complement 
system, suggesting a potential complement mediated antibody response in the lungs. 
Surprisingly, all of the anti-CSE modified elastin IgG isotypes were significantly 
increased in mice treated with CR2-fH and only IgG2a in anti-C5 treated mice. The CR2 
region of the inhibitory proteins recognizes complement opsonins iC3b, C3d and C3dg, 
targeting the sites of complement activation, but also would theoretically block 
association of complement-coated proteins with CR2 on B cells, therefore one would 
postulate reduced antibody production simply by blocking recognition from B cells, 
which was not seen in our data. Previous studies investigating the benefit of targeted 
complement therapy (CR2-fH and CR2-Crry) in lupus nephritis models demonstrates a 
reduction in anti-nuclear antibodies levels and reduced clinical scores, highlighting 
complement therapeutics modulation of the autoantibody response. Although we saw 
increased levels of antibodies in our CR2-fH treated mice, all of the IgG isotypes are 
elevated, even those responsible for immunomodulatory functions, IgG1 and IgG3. 
Increased serum antibody levels may not correlate with functional consequences. The 
reduced levels of autoantibodies seen in untreated smoking cessation mice may suggest 
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that autoantibodies were localizing in the target tissue (i.e. the lung). 
 
Whether or not these autoantibodies are truly playing a pathogenic role remains open to 
debate, in a previous publication utilizing anti-C5 therapy for collagen-induced arthritic 
mice, mice were protected from disease, yet antibody levels remained increased. The 
authors hypothesized that anti-C5 treatment was affecting the inflammatory response 
following antibody deposition, at the complement deposition point (292). Therefore we 
investigated co-localization of deposition fragment C3d with IgM and IgG in the lungs. 
Immunofluorescent staining showed a significant increase in IgM deposition in the lungs 
of mice following smoking cessation, which was reduced, not to significance, in CR2-fH 
treated mice and significantly reduced in mice given anti-C5. Interestingly, there was no 
significant difference in IgG following smoking cessation rather an increase in mice 
given complement therapeutics, further supporting a possible IgG modulatory mechanism 
within the lungs. Isotyping the IgG that are deposited in the lungs will provide 
mechanistic details of how complement therapeutics could be modulating the IgG 
response in our smoking cessation model. We have so far been unable to optimize 
immunostaining for the specific IgG isotypes. Although antibody levels were not 
completely ameliorated in the lungs, there was a significant reduction in complement 
deposition, similar to what has been shown previously (231, 288, 290, 291). Therefore, if 
antibodies are in fact driving disease progression in our smoking cessation model, 
treating mice with complement therapeutics likely provides protection from complement 




An alternative possibility for seeing beneficial effects of complement therapeutics even 
though antibody level remains high could be increased expression of complement 
regulatory proteins in the lungs. Our data demonstrates increase of complement 
regulatory proteins Crry and CD59 in mice given complement therapeutics when 
compared to smoking cessation mice. This increase in autoantibody binding in addition to 
increased complement regulation may induce conditional tolerance to the autoantibody 
response, much like that observed in transplant biology (302).  
 
Each complement therapy offers protection from ongoing lung tissue destruction, innate 
and adaptive inflammation and complement mediated cytotoxicity. While both provide 
many beneficial aspects, CR2-fH targets to the lungs rather than systemically blocking 
complement activation, where as anti-C5 is clinically available, so FDA approval for 
treatment may be accelerated. In a recent publication Yuan et al demonstrates a dendritic 
cell-C3a/C3aR-IL-17 T cell axis driving emphysema progression, suggesting blocking at 
any point of this axis, in the case of this paper utilizing C3aR-/- mice, protects from 
disease. The paper concludes that cigarette smoke increases production of C3, which 
following C3 cleavage led to the association of C3a with its receptor C3aR on dendritic 
cells. The complement activated DC induced an IL-17 T cell response driving 
emphysema development (90). Blocking at any point of this signaling mechanism would 
protect from cigarette smoke induced emphysema, which was achieved with CR2-fH 
treatment. Taking together here we propose that inhibition of complement activation in 
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lungs of ex-smokers reduces the activation of complement effector molecules. The 
reduction in C3a, C5a and C3 deposition promotes the decrease in complement mediated 
tissue damage and reduced T cell activation via interference of C3aR and C5aR signaling 
on T cells and APC, given the data generated by Yuan et al. (90). In addition to 
modulating inflammation diversely, complement inhibition reduces effector functions of 
autoantibodies by preventing local C3 accumulation and activation, which in turn reduces 
C3a mediated IL-17 up-regulation, thereby reducing IL-17 mediated suppression of 
complement regulatory protein expression. The decrease in local complement activation 
restores, or enhances Crry and CD59 expression thereby providing other protection from 
autoantibody mediated lung injury. 
 
Due to the diverse role of the complement system in the post cessation inflammatory 
milieu complement inhibitors are promising therapeutic approaches. Currently there are 
two complement-targeted treatments available, as previously mentioned anti-C5 for 
paroxysmal nocturnal hemoglobinuria (PNH) and C1 esterase inhibitor for hereditary 
angioedema (274). Both of these conditions results from unregulated complement 
activation, which is corrected by blocking C5 functions and classical pathway activation, 
respectively. Although these conditions are rare clinically, the therapeutic benefits 
demonstrate the potential for complement-based therapy.  
 
Recently a clinical trial using the modified form of Compstatin, a complement 
therapeutic that blocks C3 and its activation fragments, has gone into clinical trials for 
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COPD patients (Patent number WO2013036778A2). The goal of the COPD Compstatin 
clinical trial is to investigate how blocking the complement system effects the pathogenic 
Th1 and Th17 responses and provides a disease targeting therapy to prevent emphysema 
progression. Our data shows that by utilizing CR2-fH or anti-C5 in mice following 
smoking cessation, Th1, Th17 and autoantibody response can be ameliorated. Taken 
together these rodent data provide a solid foundation for implementation of this novel 
clinical trial.  
CHAPTER FIVE 
 




Emphysema is a complex inflammatory conduction in the lungs that leads to irreversible 
lung tissue destruction. Although its pathogenesis remains unclear, one of the leading risk 
factors is known, cigarette smoke exposure (50). Current hypotheses describing 
emphysema progression focus on the protease/anti-protease and oxidative/anti-oxidant 
responses, which are not sufficiently regulated in disease state, thus result in lung tissue 
destruction. The postulated mechanisms focus predominantly on cells of the innate 
immune response; however, recently groups have begun to address the contributions of 
the adaptive immune response (53, 57, 306, 307). 
 
Clinically, as emphysema progresses into later stage disease there is evidence of adaptive 
immune cells infiltrating into the lungs, suggesting the potential for a memory response, 
which persists following smoking cessation. Further, when characterizing the 
inflammatory response, there is evidence of infiltrating T cells, B cells and dendritic cells 
along with the presence of tertiary lymphoid structures and elevated autoantibodies 
against lung proteins (99, 159, 177, 178, 208, 209, 211, 242). Moreover, emphysema 
patients are shown to have auto-reactive T cells against lung elastin peptides, further 
supporting an autoimmune component to the disease (208). In agreement with human 
data, mouse models of chronic cigarette smoke exposure demonstrate elevated 
autoantibodies along with follicular formations, indicating parallel pathologies in mice 
and humans (168, 180, 246). Further, B cell deficient mice were protected from 
emphysema following chronic cigarette smoke exposure, indicating a pathogenic role for 
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B cells in disease development (308). However, the role of these autoimmune features are 
playing remains unclear and as well as the antigen(s) driving this autoreactive state.  
 
Although clinically there is evidence of an autoimmune response in emphysema patients, 
there are currently limited in vivo studies addressing the mechanistic role of the 
autoimmune component in emphysema development and progression. This could be 
largely due to the fact that current animal models investigating emphysema development 
vary in disease severity (309). The two leading mouse models utilized to investigate 
emphysema include porcine pancreatic elastase treatment (PPE) and secondly, long-term 
cigarette smoke exposure (310). Although each model system offers different key aspects 
of the disease pathogenesis, each provides varying degrees of disease severity. Since 
autoantibodies become evident at late stage disease, when patients present with lymphoid 
follicles in the lungs, disease status is key for investigating the contributing role of 
autoantibodies in emphysema (178).  
 
For the elastase mouse model, the degree of emphysema is dependent on the dose of 
elastase given, ranging from moderate to severe, as early as 28 days. The elastase model 
is ideal for two reasons: 1) provides an extensive amount of elastolytic induced lung 
damage and 2) offers an ideal timeline. One disadvantage for the elastase model is it 
lacks the added oxidative burden provided by cigarette smoke exposure, which is 
prevalent in the patient population (305, 311). In the second mouse model, chronic 
cigarette smoke exposure, even after 6 months of cigarette smoke exposure mice only 
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develop mild emphysema, lacking the extensive lung tissue destruction. Although each 
model has its own limitations combining both may be ideal for emphysema research 
(309, 312).  
 
In regards to the current clinical evidence and limited murine work, we hypothesis that 
autoantibodies against lung components play a significant role in cigarette smoke induced 
emphysema development. Further, following chronic cigarette smoke exposure; lung 
tissue breakdown fragments serve as antigens driving autoantibody production, thus 
resulting in an autoimmune phenotype to develop within the lungs. To test this hypothesis 
we utilized a three mouse models to investigate the role of autoantibodies. Through the 
use of immunization, we induced autoantibodies production against lung specific 
antigens in mice and following cigarette smoke exposure and/or elastase treatment we 
determined if autoantibodies are pathogenic and driving emphysema development. 







Figure 5-1 Immunization Model. Outlines the groups utilized for the cigarette smoke 





5.2.1 Histological Characterization of a Novel Mouse Model For Emphysema 
Development 
Clinical data indicate that autoantibodies against lung specific proteins are significantly 
elevated in late stage emphysema patients. However, it remains debated whether these 
lung autoantibodies are pathogenic or biomarkers of disease. To investigate the role of 
autoantibodies in the pathogenesis of emphysema we utilized three mouse models of 
representing three different stages of emphysema development. Representative H&E 
stained lung tissue sections in figure 2 demonstrate the severity of emphysema in each 
mouse model: 1. Mice that were exposed to 12 weeks of cigarette smoke represented a 
mild for of emphysema (Figure 5-2) 2. Mice given low dose elastase developed a 
moderate form of emphysema (Figure 5-3) 3. Lastly, mice given low dose elastase and 
exposed to 12 weeks of cigarette smoke exposure developed severe emphysema (Figure 
5-4).  
 
To address whether or not autoantibodies contribute to disease development mice were 
immunized with either mouse lung elastin peptides or cigarette smoke modified elastin 
peptides. A recent publication from Kirkham et al investigates the potential for 
oxidatively modified self-proteins as the antigenic source for pathogenic autoantibodies 
driving emphysema progression (180). Therefore for our studies we oxidatively modified 
our mouse lung elastin peptides to address the role of modified proteins in our mouse 
models. Previous studies evaluating morphological changes in the mouse lung during 
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chronic smoke exposure show that an effective exposure time takes at least four months 
to generate significant emphysematous changes in the mouse lung. Therefore the limited 
tissue destruction following only three months of cigarette smoke exposure was not 
surprising in our model. Interestingly, mice that were immunized with cigarette smoke 
modified elastin peptides had exacerbated disease compared to cigarette smoke controls 
and also elastin immunized mice (Figure 5-2b), suggesting that modification of lung 
proteins resulting from chronic cigarette smoke exposure could source pathogenic 
autoantibodies. 
 
Evaluating the other two-mouse models, data demonstrates that when mice were give low 
dose elastase autoantibodies exacerbated disease. Further, in mice given low dose 
elastase and exposed to cigarette smoke for 12 weeks, representing the most severe form 
of emphysema, also have exacerbated disease with immunization. Taken together, these 
data indicate a role for autoantibodies in emphysema development.  In both the elastase 
and combined model there appeared to be not significant difference between immunizing 
with elastin peptides or cigarette smoke modified elastin peptides, indication both 
antigens could source pathogenic antibodies (Figure 5-3 and 5-4). However, histological 
analysis demonstrates extensive damage to lung tissue in the moderate and severe 
emphysema mouse models in immunized mice. Future studies utilizing the immunization 
model could harvest representative mice at different time points to evaluate disease 
progression within the lungs, which would provide information on the role of 
autoantibodies in a combined model.  
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Cigarette Smoke Exposure Model 
 
  
Figure 5-2 Immunization Mice Exposed to Cigarette Smoke. Following immunization with 
elastin or CSE-elastin peptides mice were exposed to cigarette smoke for 12 weeks. (A) 
Representative H&E stained lung sections from each group. Original magnification 20x. (B) 
Airspace enlargement was quantified from 10 random field H&E stained tissue sections via mean 





Elastase Treated Model 
  
Figure 5-3 Immunization Mice Treated with 
Elastase. Prior to immunization with elastin or 
CSE-elastin peptides porcine pancreatic elastase 
(PPE) was administered to mice intra-tracheally 
(A) Representative H&E stained lung sections 
from each group. Original magnification 20x. (B) 
Airspace enlargement was quantified from 10 
random field H&E stained tissue sections via 
mean linear intercept (MLI) analysis. Data 
represented as mean ± SEM, n=5-9, p-values 







Figure 5-4 Immunization Mice Treated with 
Elastase and Exposed to Cigarette Smoke. 
Prior to immunization with elastin or CSE-elastin 
peptides porcine pancreatic elastase (PPE) was 
administered to mice intra-tracheally then were 
exposed to cigarette smoke for 12 weeks. (A) 
Representative H&E stained lung sections from 
each group. Original magnification 20x. (B) 
Airspace enlargement was quantified from 10 
random field H&E stained tissue sections via 
mean linear intercept (MLI) analysis. Data 
represented as mean ± SEM, n=5-9, p-values 





5.2.2 Lung Function Decline In Immunization Mouse Model 
Pulmonary function tests are key diagnostic tools to predict the degree of emphysema in 
the lungs of patients. For our mouse models lung function analysis was conduced utilized 
a restrained double chamber plethysmograph system. One of the major outcome 
measurements from the plethysmograph system is the enhanced pause (2) parameter. 
Enhanced pause is referred to as a marker for bronchoconstriction and an indicator for 
inflammation in the airways. In both the cigarette smoke alone group and elastase 
treatment alone group we found no significant difference in PenH following the 12-week 
exposure period compared to their controls. However, in mice that were immunized with 
elastin peptides or cigarette smoke modified elastin peptides there was a significant 
increase in PenH in both the cigarette smoke and elastase models (Figure 5-5b and b), 
indicating a role for these lung specific autoantibodies in enhancing inflammation within 
the lungs. Data demonstrates no additive effect of immunization in mice that were treated 
with lose dose elastase and exposed to cigarette smoke for 12 weeks (Figure 5-5c). These 
data indicate that autoantibodies could contribute to enhance inflammation in the airways 
leading to bronchoconstriction, lung tissue destruction ultimately resulting in a decline in 
















































































































































Figure 5-5 Lung Function Analyses From Three Mouse Models of Emphysema Development. 
Throughout the 12-week exposure lung function measurements from mice were taken utilizing a 
restrained double chamber plethysmograph system. Enhanced paused (2) was analyzed from each of 
the three models, (A) 12 weeks of cigarette smoke, (B) elastase treated mice or (C) elastase treated 
and cigarette smoke exposed mice. Note in both the cigarette smoke model and elastase model when 
mice are immunized there is a decline in lung function when compared to non-immunized controls. 





5.2.3 Autoantibodies Against Cigarette Smoke Modified Elastin Peptides Exacerbate 
Disease 
We found that following immunization with either elastin peptides or cigarette smoke 
modified elastin peptides mice developed exacerbated disease in all three models. 
Therefore, results support the hypothesis that autoantibodies are significantly contributing 
to emphysema development, so we next wanted to determine which immunoglobulin 
classes were elevated in each model.  
 
ELISAs were utilized to measure serum levels of autoantibodies against immunized 
peptides. Data demonstrates that mice exposed to cigarette smoke for 12 weeks had a 
significant increase in anti-elastin IgM levels following elastin immunization compared 
to non-smoke and cigarette smoke controls, however there was no significant difference 
in anti-elastin IgG, signifying a lack of class switching (Figure 5-6a and c). Interestingly, 
in both immunization groups had a significant increase in anti-cigarette smoke modified 
elastin IgM and IgG levels when compared to non-smoke and cigarette smoke controls, 
indicating classes switching to long lived IgGs (Figure 5-6b and d). We further wanted to 
isotype the IgG antibodies to determine of a specific isotype was predominant. ELISA 
data shows a significant increase in anti-CSE-elastin IgG2a levels, which is important to 
note that IgG2a is a pro-inflammatory isotype that can strongly activate the complement 
system (Figure 5-7b). 
 
Similar to the cigarette smoke exposure model, there was a significant increase in anti-
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elastin IgM levels in elastase treated mice that were immunized with elastin or CSE-
modified elastin peptides (Figure 5-8a and b). However, in the elastase model we also 
observed an anti-elastin IgG response, which could be due to the different destructive 
mechanisms and inflammatory processes involved in disease progression for each model 
(Figure 5-8c). Evaluating the anti-CSE-modified elastin response, we found similar 
results as seen in the cigarette smoke exposure model, mice treated with low dose 
elastase had a significant increase in anti-CSE-modified elastin IgM and IgG levels 
(Figure 5-8b and d). Further, we detected an anti-CSE-modified elastin IgG2a and IgG2b 
response, two isotypes that can strongly activate the complement system (Figure 5-9b). 
Data from these two emphysema mouse models further supports a role for modified self-
proteins as the antigen source for generating pathogenic autoantibodies in emphysema 
development.  
 
Lastly, in the combined model, there appeared to be no anti-elastin IgM or IgG response 
in this group of mice, however there were elevated levels of anti-CSE-modified elastin 
IgM and IgG, indicating a modification process was driving autoantibody production in 
these mice (Figure 5-10). Similar to the other two emphysema mouse models, IgG 
isotype data reveals an IgG2a response in combined treated mice that were immunized 
(Figure 5-11b); further supporting modified self-proteins generating pathogenic 
autoantibodies. All these data taken together demonstrate antibody-mediated 
inflammatory response is resulting in antibody class switching to complement activating 


































































































































































































































Figure 5-6 Autoantibody Levels Against Elastin Peptides and CSE-Modified Elastin Peptides in 
The Cigarette Smoke Exposure Model. IgM and IgG autoantibody levels were measured in the 
serum of mice following 12 weeks of cigarette smoke exposure to evaluate possible class switching 
due to immunization. ELISAs were utilized to measure anti-elastin IgM (A), anti-elastin IgG (C), 
anti-cigarette smoke modified elastin IgM (B) and anti-CSE-elastin IgG levels (D). Note that only 
CSE-modified elastin led to class switching following 12 weeks with or without cigarette smoke 
exposure, which was absent for the elastin response in immunized mice. Data represented as mean ± 




















































































































































































































































Figure 5-7 IgG Isotypes Against Cigarette Smoke Modified Elastin in The Cigarette Smoke 
Exposure Model. ELISAs measured Serum autoantibody IgG isotypes, IgG1 (A), IgG2a (B), IgG2b 
(C) and IgG3 (D) against CSE-modified elastin peptides in mice following 12 weeks of cigarette 
smoke exposure. Note that following immunization there was a differential response between mice 
immunized with elastin peptides and mice immunized with CSE-modified elastin peptides. Data 













































































































































































































































































Figure 5-8 Autoantibody Levels Against Elastin Peptides and CSE-Modified Elastin Peptides in 
The Elastase Model. IgM and IgG autoantibody levels were measured in the serum of mice 12 
weeks after an initial elastase treatment to evaluate possible class switching due to immunization. 
ELISAs were utilized to measure anti-elastin IgM (A), anti-elastin IgG (C), anti-cigarette smoke 
modified elastin IgM (B) and anti-CSE-elastin IgG levels (D). Note that in the elastase model there is 
an IgG response against elastin and CSE-modified elastin (C and D) with immunization. Data 

























































































































































































































































































Figure 5-9 IgG Isotypes Against Cigarette Smoke Modified Elastin in The Elastase Model. 
ELISAs measured serum autoantibody IgG isotypes, IgG1 (A), IgG2a (B), IgG2b (C) and IgG3 (D) 
against CSE-modified elastin peptides in mice 12 weeks after an initial elastase treatment. Note that 
following immunization there was a differential response between mice immunized with elastin 
peptides and mice immunized with CSE-modified elastin peptides. Data represented as mean ± SD, 

































































































































































































































































Figure 5-10 Autoantibody Levels Against Elastin Peptides and CSE-Modified Elastin Peptides 
in The Combined Model. IgM and IgG autoantibody levels were measured in the serum of mice 
after an initial elastase treatment and 12 weeks of cigarette smoke exposure to evaluate possible class 
switching due to immunization. ELISAs were utilized to measure anti-elastin IgM (A), anti-elastin 
IgG (C), anti-cigarette smoke modified elastin IgM (B) and anti-CSE-elastin IgG levels (D). Note that 
in the combined model there appears to only be a CSE-modified elastin IgG response (C and D) for 














































































































































































































































































Figure 5-11 IgG Isotypes Against Cigarette Smoke Modified Elastin in The Combined Model. 
ELISAs measured serum autoantibody IgG isotypes, IgG1 (A), IgG2a (B), IgG2b (C) and IgG3 (D) 
against CSE-modified elastin peptides in mice after an initial elastase treatment and 12 weeks of 
cigarette smoke exposure. Note that in the combined model there is only an IgG2a (B) response 






5.2.4 Anti-C5 Therapy Protects Against Autoantibody Mediated Lung Tissue Destruction 
Data from autoantibody ELISAs demonstrates elevated complement activating IgG 
isotypes in all three emphysema mouse models. Therefore, we next wanted to investigate 
the potential benefit for complement therapeutics in autoantibody induced emphysema 
development. For complement therapeutic studies we chose to treat mice that had 
underwent the combined model with anti-C5 therapy for several reasons: 1) Mice 
developed the most severe form of emphysema, 2) The combined model provided two of 
the main pathologies seen in patients, the significant elastolytic damage (elastase) and 
enhanced oxidative burden (cigarette smoke exposure) and lastly, 3) Clinically, patients 
present with elevated autoantibody levels in late stage disease. For clinical relevance, 
mice began anti-C5 treatment following the initial elastase treatment and after 3 weeks 
into the cigarette smoke exposure.  
 
Evaluating morphological changes in the lung through mean linear intercept 
measurement data shows that mice given anti-C5 therapy were protected from 
exacerbated disease generated by autoantibodies. In elastin peptides and cigarette smoke 
modified elastin peptide immunized mice; both groups had a significant reduction in lung 
tissue destruction, indicating that complement therapeutics may be a potential option for 





Figure 5-12 Complement Therapeutics Protect Mice from Autoantibody-Mediated Lung Tissue 
Destruction. Four weeks after the initial elastase challenge and three weeks into the cigarette smoke 
exposure, mice were given 800ug of anti-C5 i.p. twice a week for the remainder of the experiment. 
Mean linear intercept analysis was utilized to determine the protective effect of complement 
therapeutics in the combined model. Note that in immunized mice treated with anti-C5 they have 
reduced MLI scores than untreated, demonstrating anti-C5 therapy is protecting mice from 
autoantibody induced lung tissue destruction. Data represented as mean ± SEM, n=5-9, p-values 
notes on graph. 
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5.2.5 Anti-C5 Therapy Protects Immunized Mice from Lung Function Decline 
Morphological data demonstrates that mice treated with anti-C5 therapy had a significant 
reduction in airspace enlargement when compared to untreated immunized mice, 
suggesting that complement therapeutics protect against antibody-mediated 
inflammation. Throughout the course of the experiment we also monitored disease 
progression by lung function analysis through the use of a restrained double chamber 
plethysmograph system to investigate the protective effects of anti-C5 therapy. Enhanced 
pause (2) data shows an increase in PenH in mice that were given a lose dose of elastase 
and exposed to cigarette smoke for 12 weeks. Lung function further declined mice that 
were immunized with elastin peptides at 12 weeks signified by an increase in PenH. 
Interestingly, in elastin-immunized mice that were treated with anti-C5 they had a 
decrease in PenH, further supporting protection with complement therapy from antibody-
mediated lung inflammation (Figure 5-13a). 
 
Evaluating the results from mice immunized with cigarette smoke modified elastin 
peptides show that at 10 weeks PenH is increased compared to non-immunized mice, 
however by 12 weeks levels between immunized and non-immunized mice were similar. 
Additional, CSE-modified elastin immunized mice treated with anti-C5 demonstrated 
elevated levels of PenH compared to non-treated controls (Figure 5-13b). Although these 
data do not reflect the morphological measurements, it further emphasized the need for 
multiple analyses to determine the status of emphysema in the lungs. Due to the 
resilience of the lungs, clinically pulmonary function tests can sometimes underestimate 
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the extent of disease in the lungs, therefore with the use of CT scans it allows for 
additional diagnostic tools to determine the stage of emphysema within the lungs of 














































































Figure 5-13 Lung Function Analysis of Mice Treated With Anti-C5 Therapy. Lung function was 
analyzed throughout the course of the 12 weeks experiment in mice immunized with elastin peptides (A) 
and CSE-modified elastin peptides (B). Enhanced paused (2) is the designated marker for 
bronchoconstriction and inflammation in the airways. Note anti-C5 protected from elastin induced lung 
function decline but not CSE-modified elastin. Data represented as mean ± SEM, n=5-9, *p<0.05 






5.2.6 Autoantibody Levels in Mice Treated with Complement Therapeutics 
Data thus far demonstrates that autoantibodies against lung elastin proteins exacerbate 
disease in multiple mouse models of emphysema. We show that pathogenic 
autoantibodies are of the complement activating IgG isotypes, suggesting a mechanism 
for lung tissue destruction. We also show that mice treated with complement therapeutics 
are protected from the additive destructive effects of autoantibodies in the combined 
elastase and cigarette smoke exposure mouse model. Next, we wanted to determine if 
complement therapy was having a direct effect on the autoantibody response or 
modulating the inflammatory response through another mechanism of protection. To 
address this question we determined the antibody phenotype against elastin peptides or 
cigarette smoke modified elastin peptides.  
 
Analysis of both lung antigens demonstrates that anti-C5 therapy appeared to have no 
effect of anti-elastin or anti-CSE-modified elastin antibody levels (Figures 5-14 through 
Figure 5-17). Furthermore, complement activating isotype IgG2a remains elevated in 
anti-C5 treated mice from both immunized groups (Figure 5-15 and Figure 5-17), 
indicating that complement therapeutics appear to have no effect of autoantibody 
production. Although therapy does not appear to modulate circulating antibody levels, 
anti-C5 may be having a local effect in protecting the lungs from emphysema progression 
in these mice, since data does show protected from lung tissue destruction in treated 
mice. Mouse models utilizing anti-C5 for a treatment in of Rheumatoid arthritis (RA) 
demonstrate similar results that mice treated with anti-C5 continued to have elevated 
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autoantibody levels, yet were protected from RA symptoms, suggesting that the 









































































































































































































































































































































































































































































































































































































Figure 5-14 Elastin and CSE-Modified Elastin Autoantibody Levels in Anti-C5 Treated Mice 
From the Combined Model. IgM and IgG autoantibody levels were measured in the serum of mice 
after an initial elastase treatment and 12 weeks of cigarette smoke exposure to evaluate possible class 
switching due to elastin immunization. A group of mice were also given the complement therapeutic 
anti-C5 starting 4 weeks into the exposure. ELISAs were utilized to measure anti-elastin IgM (A), 
anti-elastin IgG (C), anti-cigarette smoke modified elastin IgM (B) and anti-CSE-elastin IgG levels 
(D). Note that anti-C5 treatment appears to have no protective effect on autoantibody levels. Data 





















































































































































































































































































































Figure 5-15 IgG Isotypes Against Cigarette Smoke Modified Elastin in Anti-C5 Treated Mice 
From the Combined Model. ELISAs measured serum autoantibody IgG isotypes, IgG1 (A), IgG2a 
(B), IgG2b (C) and IgG3 (D) against CSE-modified elastin peptides in elastin immunized mice 
following an initial elastase treatment and 12 weeks of cigarette smoke exposure . Note that anti-C5 











































































































































































































































































































































































































































































































































































































































Figure 5-16 Elastin and CSE-Modified Elastin Autoantibody Levels in Anti-C5 Treated Mice 
From the Combined Model. IgM and IgG autoantibody levels were measured in the serum of mice 
after an initial elastase treatment and 12 weeks of cigarette smoke exposure to evaluate possible class 
switching due to cigarette smoke-modified elastin immunization. A group of mice were also given the 
complement therapeutic anti-C5 starting 4 weeks into the exposure. ELISAs were utilized to measure 
anti-elastin IgM (A), anti-elastin IgG (C), anti-CSE elastin IgM (B) and anti-CSE-elastin IgG levels 
(D). Note that anti-C5 treatment appears to have no protective effect on autoantibody levels. Data 




































































































































































































































































































































Figure 5-17 IgG Isotypes Against Cigarette Smoke Modified Elastin in Anti-C5 Treated Mice 
From the Combined Model. ELISAs measured serum autoantibody IgG isotypes, IgG1 (A), IgG2a 
(B), IgG2b (C) and IgG3 (D) against CSE-modified elastin peptides in cigarette smoke modified 
elastin immunized mice following an initial elastase treatment and 12 weeks of cigarette smoke 
exposure. Note that anti-C5 treatment does not affect IgG2a levels (B). Data represented as mean ± 












5.3 DISCUSSION  
Chronic obstructive pulmonary disease is complex inflammatory condition with an 
unclear pathogenesis (181, 206). The role of the innate immune response in COPD 
progression has been extensively studied, yet the contribution of the adaptive immune 
response remains unknown. It has recently been postulated that the autoimmune 
component drives the continuing inflammatory response as the disease progresses. The 
role of autoantibodies in emphysema development remains to be a controversial topic 
within the literature. It has been suggested that lung specific autoantibodies are 
pathogenic and contribute to emphysema progression, whereas other have argued they are 
merely biomarkers of disease (159, 211, 241, 284). Infiltrating adaptive immune cells 
increase within the lungs as patients progress into the later stages of disease (GOLD 
stages III-IV) (178). Clinical data has identified anti-elastin autoantibodies along with 
autoreactive T cells against lung elastin peptides in patients, further supporting an 
autoimmune component to disease development (99, 177, 208, 242, 243). Even though 
these data strongly suggest an autoimmune phenotype contributing to emphysema 
progression, mechanistic details are lacking. 
 
To address the role of autoantibodies in emphysema development and progression we 
utilized three different mouse models, each varying in disease severity. Data 
demonstrates that in each mouse model, autoantibodies against lung elastin peptides or 
CSE-modified elastin peptides exacerbate disease. Further, following 12 weeks of 
cigarette smoke exposure, a time point known to show minimal lung tissue destruction in 
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C75BL/6 mice, the mice that were immunized with cigarette smoke modified elastin 
peptides had a significant increase in airspace enlargement when compared to non-
immunized controls (167). These data support the possibility that a modification of self-
tissue due to oxidative stress, resulting from chronic cigarette smoke exposure, could be 
the antigenic source for autoantibodies in emphysema patients.  
 
We chose to utilize several different mouse models for emphysema to investigate the role 
of autoantibodies in disease pathogenesis. In each model the degree of disease varied to 
allow investigation into several stages of emphysema progression. For in vivo studies, the 
two main model systems used in emphysema research are the porcine pancreatic elastase 
(PPE) induced model and the chronic cigarette smoke exposure model (309). Each model 
system offers different features that are prevalent in emphysematous lungs. For the 
elastase model there is an extensive amount of lung tissue destruction whereas in the 
cigarette smoke model there is enhanced oxidative stress (167, 310, 312).  
 
While each model offers its own advantages and disadvantages for emphysema research 
we chose to used both and also combined the models to determine the role of 
autoantibodies in several stages of emphysema development. Mice were immunized with 
mouse lung elastin peptides or elastin peptides that were oxidatively modified by 
cigarette smoke extract (168, 180). Following 12 weeks of cigarette smoke exposure 
(mild disease) or low dose elastase treatment (moderate disease) or elastase treatment and 
cigarette smoke exposure (severe disease) the degree of emphysema in the lungs was 
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quantified to determine the contribution of autoantibodies to disease development. Mean 
linear intercept data demonstrate that autoantibodies exacerbate emphysema in all 
experimental mouse models. Further, lung function analysis indicates that autoantibodies 
accelerate lung function decline and the predominant IgG isotype responsible for the lung 
tissue destruction is IgG2a, indicating a potential complement-activating mechanism 
driving inflammation. 
 
Currently there is limited literature addressing the role of autoantibodies in emphysema 
development and progression. Clinical data demonstrate elevated autoantibodies against 
lung epithelial cells, endothelial cells, extracellular matrix proteins and oxidatively 
modified proteins in emphysema patients when compared to non-disease controls (99, 
158, 168, 177, 180, 240, 242). However, whether or not these autoantibodies are 
contributing the disease progression or are biomarkers for disease state remains debated 
(211, 284). There is evidence of elevated autoantibody levels in mice following 6 months 
of cigarette smoke exposure (168). Further, Kirkham et al demonstrates an antibody 
response in mice against oxidatively modified self-proteins, further supporting an 
autoimmune component to disease progression (180).  
 
Conversely, in a recent publication from Brandsma et al. mice were immunized with 
extracellular matrix proteins, collagen, decorin and elastin and exposed to cigarette 
smoke for 6 months. Results suggested that autoantibodies against these extracellular 
matrix proteins did not exacerbate disease, however in mice exposed to cigarette smoke 
	  
185	  
for 6 months did not develop emphysematous changes. Since the exposure method did 
not establish emphysema in the mice, it is difficult to interpret whether or not 
autoantibodies contribute to emphysema development (168). Nonetheless, there are 
several reports indicating a pathogenic role for elastin peptides in emphysema 
development. Houghton et al demonstrates in a PPE-induced emphysema mouse model, 
mice treated with an elastin peptide antagonist were protected from lung tissue 
destruction (305). Furthermore, there is evidence of anti-elastin autoantibodies in patients 
along with autoreactive T cells against elastin fragments (177, 208, 242). Although 
Brandsma et al. dispute the role of autoantibodies in emphysema development their 
ineffective smoking exposure model weaken the impact of their conclusion. Therefore, 
we chose to investigate the role of anti-elastin autoantibodies in our three mouse models 
and also address the hypothesis that neo-epitopes generated from a modification to self-
proteins drive pathogenic autoantibodies production. We found that autoantibodies 
against elastin peptides and CSE-modified elastin peptides exacerbate disease, supporting 
the hypothesis that autoantibodies play a significant role in emphysema progression.  
 
Interestingly, when investigating the autoantibody response following immunization, all 
experimental mouse models demonstrated IgG class switching in the anti-CSE-modified 
elastin response, however not in the anti-elastin response. Further IgG isotyping 
demonstrated elevated anti-CSE-modified elastin IgG2a for all experimental mouse 
models, which is a complement activating isotype. Therefore we chose to treat a group of 
mice with the complement therapy anti-C5. Anti-C5 is an antibody that recognizes 
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complement component C5 and blocks its cleavage thereby preventing generation of the 
anaphylatoxin C5a and initiation of the terminal complement pathway (293, 295). Anti-
C5 has been show to be beneficial in other inflammatory conditions, such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) and transplantation (292-295).  
 
For complement therapeutic studies we chose to utilize the combined model. There were 
several reasons why we chose the combined model, the mice developed severe disease, 
they pathological features of enhanced elastolytic damage (elastase) and increased 
oxidative burden (cigarette smoke exposure) are both present and lastly, clinically 
autoantibodies appear to play a significant role in late stage disease (178, 180). Mean 
linear intercept analysis from anti-C5 treated mice demonstrate protection from 
autoantibody-mediated lung tissue destruction. Further, lung function analysis indicates 
that in elastin immunized mice anti-C5 therapy protects from lung function decline, 
identifying a potential therapeutic option for emphysema patients. Evaluating the 
autoantibody data from anti-C5 treated mice demonstrate no modulation of autoantibody 
production. Similar findings were reported in a mouse model of collagen-induced 
rheumatoid arthritis (RA). Anti-C5 treated mice were protected from RA symptoms, such 
as paw thickness and arthritis score, yet continued to have elevated autoantibody levels. It 
was concluded from the paper that anti-C5 therapy might be modulating the 
inflammatory response downward of antibody binding (292). Our results indicate that 
anti-C5 may too be protecting from inflammatory mechanism downstream of antibody 
binding. Additionally, investigating the autoantibody response within the lungs may be 
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more telling of the protective effect of the anti-C5 therapy.  
 
The major finding from this paper strongly supports a role for autoantibodies in 
emphysema progression. Data demonstrate that elastin or CSE-modified elastin 
immunized mice have exacerbated disease in three different mouse models of 
emphysema. Further, immunized mice have elevated anti-CSE-modified elastin IG2a 
levels, suggesting a complement activating mechanism. Our complement therapeutic 
studies indicate that anti-C5 therapy protects mice from autoantibody induced lung tissue 
destruction, indicating a potential therapeutic treatment for emphysema patients.  
CHAPTER SIX 
 
SUMMARY AND FUTURE DIRECTIONS 
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6.1 SUMMARY AND FUTURE DIRECTIONS   
Currently there is limited literature on the role of the complement system in emphysema 
development. Clinical samples show decreased complement proteins in the serum and 
increase complement cleavage fragments in the bronchoalveolar lavage fluid of 
emphysema patients, indicating activation of the complement system (98, 197, 313). 
Furthermore, there is decreased complement regulatory protein expression on lung tissue, 
demonstrating an ideal microenvironment for complement-mediated inflammation (99). 
Although some have suggested activation of the complement system is potentially due to 
infection status, since emphysema patients are at increase risk for infection, the role of 
complement proteins in disease mechanisms have yet to be fully elucidated (159). 
Therefore, the work in this dissertation sought to understand the role of complement 
system in emphysema development and progression, furthermore, to investigate a 
potential system to target for therapeutic intervention. 
 
Our findings indicate that several different complement pathways/effector molecules are 
taking part in emphysema development. Mean linear intercept, the key analysis to 
determine the degree of emphysema within the lungs of mice, demonstrates many 
different complement deficient strains were protected from lung tissue destruction, C3-/-, 
factor B-/-, C6-/- and anti-C5 mAb treated. Although each deficiency needs further 
exploration, we chose to focus on our factor B-/- mice, since blocking specially at the 
alternative pathway will protect mice from emphysema development and allow the 
remaining complement activation pathways to remain intact for non-cigarette smoke 
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related inflammation. Additionally, by blocking at the alternative pathway, we target the 
point of amplification of the complement system. Our findings show that fB-/- mice have 
a dampened innate and adaptive immune response in the lungs following 6 months of 
cigarette smoke exposure, signifying protection from both arms of the immune response. 
These findings offer convincing evidence that the complement system is playing a role in 
the pathogenesis of emphysema, indicating a specific target point for therapy.  
 
Interestingly, C1q/MBL-/- mice were not protected from emphysema development. 
C1q/MBL-/- mice exhibited similar levels of lung tissue destruction as wild type mice. 
One of the recognized hypotheses attempting to explain emphysema progression 
addresses a potential underlying autoimmune component taking part in its pathogenesis 
through autoantibody generation against lung specific epitopes (314). The classical 
activation pathway is initiated by recognition protein C1q identifying immune 
complexes, a mechanism that C1q/MBL-/- mice lack (25). Therefore, one could postulate 
that C1q/MBL-/- mice, which are protected from antibody mediated complement 
dependent cytotoxicity, would be protected from emphysema development, however this 
was not seen. Although these mice are deficient in a major antibody mediated 
inflammatory mechanism, they continue to have a functioning innate immune response, 
therefore, neutrophils and macrophages can still infiltrate to the lung during chronic 
cigarette smoke exposure and produce tissues destroying proteases and reactive oxygen 
species (52, 57, 178, 279). Moreover, autoantibody production has been suggested to 
result from chronic cigarette smoke exposure (279). An immune response against matrix 
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protein autoantibodies could develop as a result of the ongoing lung tissue destruction, 
triggered by an increase in ECM fragments within the lungs, which occurs with a 
significant amount of lung tissue destruction (168, 177, 209). The increase in ECM 
proteins in the lungs could over-stimulate the adaptive immune response, resulting in an 
auto-reactive state. Furthermore, it has been postulated that modification of self-proteins 
by oxidative stress could be the antigens driving autoantibody production (180). 
Therefore, targeting the classical activation pathways could be beneficial to patients with 
established emphysema, whom also have evidence of an autoimmune component. 
Characterizing the role of the classical and lectin pathway in emphysema development 
and investigating its role in emphysema progression will provide additional information 
of complement effector functions in disease pathogenesis. Since we show autoantibodies 
can drive disease progression, targeting the classical pathway after established disease 
may provide an additional target for therapy. Evaluating autoantibody development 
throughout the course of the cigarette smoke exposure would offer insight of when the 
autoantibody response begins. Additionally, treating mice at different time points 
throughout the 6 month smoke exposure period would provide mechanistic information 
of when blocking the classical pathway is beneficial.  
 
Our findings indicate that by blocking the alternative pathway we reduce the innate 
immune response in the lungs following chronic cigarette smoke exposure. Furthermore, 
analysis from mouse splenocytes demonstrates an increase in CD4+IL-17+ and CD8+IL-
17+ T cells following 6 months of cigarette smoke exposure. These IL-17 producing T 
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cells were significantly reduced in factor B-/- mice when compared to wild type cigarette 
smoke exposed. Recently groups have begun to fully appreciate the effects of 
complement proteins on the T cell response. Initial studies challenging complement 
deficient mice (C3-/-) with influenza virus show a suppressed IFNγ T cells response and a 
reduction in viral clearance, demonstrating the requirement for complement proteins in T 
cell activation and proliferation (287). Recently, investigations into the mechanistic 
relationship between complement proteins and naive T cells indicate anaphylatoxin 
receptor (C3aR and C5aR) signaling is needed to generate an IFNγ+CD4+ response (194). 
Further, blocking anaphylatoxin signal results in naive CD4+ T cells to proliferate into 
regulatory FoxP3+ phenotype, promoting a tolerant state (195). Clinical data investigating 
the T cell profile in emphysema patients indicates IFNγ and IL-17 T cells correlate with 
disease severity, indicating an autoreactive T cell population in patients (208). 
Additionally, T cells from emphysema patients demonstrate increased IFNγ production 
following elastin peptides stimulation, further supporting an autoimmune response (177, 
209). These data taken together, in regards to our findings, suggest that by skewing the T 
cell response in our complement deficient mice we could be protecting the lungs from 
autoreactive T cell generation following chronic cigarette smoke exposure. A recent 
publication by Yuan et al. addresses the role of C3a-C3aR signaling in emphysema 
development. Data suggests that C3aR signaling on dendritic cells activate self-reactive 
IFNγ and/or IL-17 producing T cells to infiltrate into the lungs leading to lung tissue 
destruction (90). Therefor, blocking the anaphylatoxin signaling mechanism, mice were 
protected from emphysema development. Our results demonstrate that blocking at the 
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alternative pathway we block amplification of complement activation, thereby preventing 
anaphylatoxin signaling, which could be the protective mechanism in T cell skewing. 
 
One of the major obstacles following cigarette smoke cessation is understanding and 
modulating the continued inflammatory response within the lungs. There is clinical 
evidence of autoreactive anti-elastin IFNγ and IL-17 producing T cells in the lungs of 
emphysema patients that correlate with disease severity (208). Our data shows that by 
blocking complement activation we protect mice from increased CD4+IL-17+ and 
CD8+IL-17+ T cell generation, which could be the key T cell subset driving the 
autoimmune response, a cytokine that has been associated with several other autoimmune 
diseases. These data show we are having an effect on the T cells response with 
complement inhibition, but we wanted to further address this mechanism in a more 
clinically relevant model and investigate complement inhibition during smoking 
cessation. 
 
The first treatment plan for emphysema patients is cigarette smoke cessation, attempting 
to slow down disease progression. Unfortunately, even after the daily insult of cigarette 
smoke exposure is gone there is ongoing inflammation in the lungs, which results in 
continued lung function decline (206). In order to investigate the role of the complement 
system in a more clinically relevant model we developed and characterized a cigarette 
smoke cessation rodent model in our lab. C57BL/6 mice were exposed to cigarette smoke 
for 6 months followed by a 3 month smoking cessation period. Data from our cessation 
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model showed similar pathologies as seen in human patients, persistent macrophage and 
lymphocytes infiltrating the lungs, continued lung tissue destruction and increase in 
autoantibody levels (52, 178, 279). These data indicate our cessation model is an 
appropriate mouse model for therapeutic studies. Our findings show increased 
complement anaphylatoxin levels in the bronchoalveolar lavage fluid when compared to 
non-smoke controls, indicating continued activation of the complement system in the 
lungs following smoking cessation, therefore a valid target for therapy. The complement 
therapeutics that were chosen for our cessation studies included CR2-fH, a targeted 
complement inhibitor that blocks at the alternative pathway, and Anti-C5, a systemic 
complement inhibitory antibody (231, 239).  
 
As anticipated, mice treated with complement therapeutics had a dampened innate 
immune response in the lungs, since the complement system is one of the major 
components for orchestrating innate cell recruitment and activation (4, 5). Furthermore, 
complement therapeutics also reduced mean linear intercept measurements, indicating 
protection from emphysema progression. Additionally, we wanted to address the effect of 
blocking complement activity in our smoking cessation model on the adaptive immune 
response. Interestingly, mice given complement inhibitory proteins had suppressed 
transcription of IFNγ and IL-17, two cytokines that have been suggested to drive 
autoreactive conditions in the lungs of emphysema patients (208, 209, 270, 315). To 
further investigate the potential of an autoreactive T cell response in our smoking 
cessation model, we stimulated mouse splenocytes with elastin peptides, an antigen 
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previously described to activate autoreactive T cells in emphysema patients, and cigarette 
smoke modified elastin peptides, to investigate if oxidatively modified self-proteins are 
the antigenic stimulant (177, 208, 209). Our ELISA data demonstrate a significant 
increase of IFNγ in the supernatants of splenocytes from smoking cessation mice 
following CSE-elastin stimulation, which was absent in elastin-stimulated cells. 
Interestingly, in splenocytes from mice treated with CR2-fH or anti-C5 there was no 
significant increase in IFNγ in the supernatant following elastin or CSE-elastin 
stimulation, suggesting protection from autoreactive T cell generation.  
 
Recent findings demonstrate a relationship between the APC-T cell complex and 
complement activation. For a T cell to be activated three signals must occur: 1. Antigen 
recognition via the MHC-TCR interaction, 2. Co-stimulatory molecule signaling and 3. 
Cytokine release supporting T cell differentiation and proliferation (316). Following the 
APC-TCR interaction there is evidence of increase complement alternative pathway 
protein secretion (C3, fB and C5) and decrease complement regulatory protein expression 
(285), allowing for C3 convertase assembly thus amplifying complement activation (6, 
7). Work utilizing complement deficient mice (C3-/-, C3aR-/-, C5aR-/-, C3aR/C5aR-/-) 
demonstrates a reduction in effector T cell activation and proliferation in the absence of 
complement anaphylatoxin signaling, highlighting the co-stimulatory (signal 2) 
requirement of complement proteins (90, 194, 195). Yuan et al addresses this APC-TCR-
complement protein axis in emphysema development and data shows C3aR signaling via 
the APC (dendritic cell) is required for IFNγ T cell production, further supporting a role 
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for the complement system in T cell skewing (90). All these data taken together with 
regards to our findings, by blocking complement activation in the lungs following 
smoking cessation we could be changing the T cell phenotype and protecting the lungs 
from autoreactive T cell generation. Our RT-PCR data shows reduced IFNγ and IL-17 
gene expression in the lungs, and our splenocytes data indicates reduced circulating 
CD4+IFNγ+ T cells, suggesting modulation of the T cell response following therapy. 
However, complement inhibition locally may differ form what is seen systemically. We 
see a reduction in CD4+IL-17+ T cells in the spleen of mice following smoking cessation, 
which could be due to localization of the T cells population in the lungs, therefore 
determining the T cell phenotype in the lung is needed. Future experiments identifying 
the T cell population in the lungs following smoking cessation with or without 
complement therapeutics will enhance our understanding of how inhibition of the 
complement system effects the T cell response and determine local verse systemic effects 
during emphysema progression. 
 
In addition to the T cell response, we also investigate the B cell response in emphysema 
by investigating the autoantibody response in these mice. Currently the role of 
autoantibodies in emphysema is unclear. Whether or not these autoantibodies are driving 
disease progression or simply biomarkers for disease status remains debated (211). In 
chapter 5 of this dissertation we attempt to answer the question of whether or not these 
autoantibodies are pathogenic. Our findings suggest autoantibodies contribute to disease 
progression and a modification of self proteins are the source of the antigen, since mice 
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immunized with CSE-modified elastin peptides developed emphysema as early as 12 
weeks, whereas those given unmodified elastin peptides were not significantly different 
from their non-immunized cigarette smoke exposed controls. In chapter 4 we do address 
the autoantibody response in our smoking cessation model, we see increased anti-elastin 
IgM levels and anti-CSE modified elastin IgM and IgG levels following smoking 
cessation, indicating class switching for antibodies against oxidatively modified self-
proteins. Moreover, elevating the IgG isotypes revealed increase anti-CSE-modified 
elastin IgG2a, a complement activating isotype indicating a potential complement driven 
mechanism for antibody mediated inflammation. Surprisingly, mice treated with targeted 
complement inhibitory proteins CR2-fH had elevated levels of above-mentioned 
antibodies along significant increase levels of all anti-CSE modified elastin IgG isotypes. 
These data were surprising since in a lupus mouse model, mice treated with CR2-fH had 
reduced levels of anti-dsDNA antibodies when compared to non-treated controls. 
Moreover, mice treated with soluble CR2 also have reduced levels, indicating by 
blocking at the opsonin-B cells axis mice were protected from autoantibodies generation 
(291). Since all IgG isotypes were elevated in CR2-fH treated mice, it could indicate a 
potential immunomodulatory effect of the IgG subsets. Additionally, our experiments 
evaluated autoantibodies in the serum, investigating a systemic marker. It may be more 
telling to evaluate the autoantibody response in the lungs to distinguish systemic verse 
local inflammation.  
 
Our data did show differential effects on the antibody response between the two 
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complement inhibitory treatments. Anti-C5 did have suppressed anti-CSE modified 
elastin IgM although no significant difference in IgG levels. Interestingly, the only IgG 
isotype that was significantly increased in the anti-C5 treated mice was anti-CSE 
modified elastin IgG2a, a complement activating isotype. In a paper investigating the 
anti-C5 as a potential treatment for collagen induced arthritis, mice treated with anti-C5 
were protected from clinical symptoms of arthritis yet remained to have antibody 
deposition in the joints. The paper concluded that anti-C5 treatment suppressed the 
inflammatory response despite antibody deposition (292). These results led to the 
question, could we be modulation the antibody mediated inflammatory response 
downward of antibody deposition? Therefore, to address this question we utilized 
immunofluorescent staining to determine if there was co-localization of complement 
deposition fragments and immunoglobulin. Our data demonstrates increased IgM 
deposition following cigarette smoke cessation, which was reduced but not to 
significance in CR2-fH treated mice and was significantly reduced in anti-C5 treated 
mice. Interestingly, there was no significant different in IgG deposition levels following 
smoking cessation, however there were elevated levels in mice treated with CR2-fH, 
which once again could be due to the immunomodulatory IgG response in the lungs. 
Despite IgM and IgG deposition levels, data shows a significant increase in C3d 
deposition in the lungs following smoking cessation, which was significantly reduced in 
both complement therapeutic mice, indicating that our therapy is taking effect following 
antibody deposition to dampen the inflammatory response. Therefore, complement 
therapeutics proves to be beneficial even in established disease, signifying that the 
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treatments are ideal for clinical therapy.  
 
Although this dissertation does address several of the initial questions asked, there are 
several remaining questions that need to be further explored. Our findings demonstrate 
that the complement system is playing a role in emphysema development and 
progression; blocking several of its activation fragments protects mice from lung tissue 
destruction. Analysis of the inflammatory response indicates that by blocking the 
complement system mice are protected from both the innate and adaptive arm of the 
immune response, and we appear to be modulating the autoreactive immune response that 
persists following cigarette smoke cessation. Even though we demonstrate autoantibodies 
against extracellular matrix proteins as well as proteins that have been oxidatively 
modified, the specific antigen(s) driving the autoimmune response in the lungs remain 
unknown. Data demonstrates a response against mouse lung elastin peptides and CSE-
modified lung elastin peptides, however additional proteins could be taking part in 
disease propagation. Further exploration into additional antigens could provide additional 
information of pathogenic autoantibodies that home to the lung following smoking 
cessation. A recent publication from Daffa et al. investigates autoantibodies against panel 
of lung specific proteins from tissue homogenates and serum samples from COPD 
patients, similar experiments could be done in our mouse models (285). Expanding our 
antigen panel may give further insight into the specific protein driving disease 
progression. Our immunization model suggests oxidatively modified portion of the 
proteins was driving disease progression, however utilizing the same models with another 
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modified proteins, i.e. CSE modified collagen, could help further determine the epitope 
the autoantibodies are recognizing. Moreover, similar to the B cell response, determine 
the antigen driving the T cell response, whether it is the same or different, is yet to be 
known. We show similar results in the T cell assay, exaggerated response with CSE-
modified elastin when compared to elastin, but we do not know the specific epitope 
stimulating the T cell response.  
 
Our investigations also focus on the T cell population and how its phenotype changes 
following complement inhibition. In the Yuan et al. paper data strongly suggests the 
dendritic cell as the site of complement signaling needed for T cell differentiation (90). 
Future investigations could determine the antigen specific APCs in the lung driving the 
autoreactive state and how complement inhibition is effecting the immune cell 
population. IL-17 stimulates CCL20 secretion, a chemoattractant for dendritic cells (315). 
Our data indicates a reduction in IL-17 gene expression in the lungs in CR2-fH and anti-
C5 treated mice. Therefore, we may be modulating the DC population in the lung via 
suppression of IL-17, a mechanism that needs further investigation. 
 
There is currently a phase I clinical trial in the United Kingdom investigating 
complement inhibition in COPD patients by utilizing an analog of Compstatin, AP-1 
(Patent number 20140371133). AP-1 is a complement inhibitory protein that binds to the 
C3c portion of the C3 molecules, preventing C3 convertase assembly (274). Drug 
delivery for AP-1 will be tested by nebulization, inhibiting complement activation locally 
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in the lung attempting to reduce the inflammatory response and alter the T cell phenotype 
in COPD patients (http://apellis.com/portfolio-item/copd-and-severe-asthma/). Our data 
supports the ability of complement inhibition modulating the T cell response in the lungs, 
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